Data reduction methods to study cancer susceptibility by Santaolalla Revenga, Aida
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 
















Data reduction methods to 




Thesis presented in accordance with the requirements for the 














Translational Oncology and Urology Research (TOUR) 
School of Cancer and Pharmaceutical Sciences 










The copyright of this thesis rests with the author and no quotation from it or 











When I started my journey in science, I was deeply intrigued about biology and its 
systemic level functioning and mathematics. This enthusiasm has driven years 
working in health sciences, first in bioinformatics, then health informatics and 
computational biology and finally in cancer epidemiology and biostatistics. This 
adventure somehow guided me into cancer epidemiology and biostatistics, 
disciplines that I am truly passionate about. In 2011 I was fortunate to join Prof Lars 
Holmberg’s KCL team and afterwards Dr Mieke Van Hemelrijck’s KCL team, where I 
immersed myself into a dynamic, translational and challenging environment where 
I learned about cancer, epidemiology and biostatistics. Dr Mieke Van Hemelrijck 
with her passion and her amazing work ethos encouraged me to pursue a PhD in 
Cancer Epidemiology, while working as a data manager for the group. She inspired 
me to continue learning and accept new challenges over the years that we have 
been working together. Therefore, I would like to thank her for her wonderful 
support and dedication during all these years.  
 
I would also like to thank my second supervisor Dr Anita Grigoriadis for all her help 
and guidance with the Thesis projects and my third supervisor Prof Ton Coolen for 
his great support with the mathematical methods and the Terahertz project. 
 
I would also like to thank Prof Lars Holmberg, a true role model for a data scientist 
through his global vision and his critical approach to science.  I also have to say a big 
thank you to the all the members of the TOUR group for their help, their support 
and their dynamic, joyful and inspiring work – in particular Dr Hans Garmo for his 
advice with the statistical methods. 
 
I also want to acknowledge the Swedish collaborators, the AMORIS team (Ingmar 
Jungner, Niklas Hammar, and Göran Walldius) for giving me the opportunity to work 




My friends and family deserve a special thank you. They have been always there 
supporting and comforting me during this amazing journey and specially in this last 
period where a second journey has started with our first child coming in April. My 
friends at KCL, Fara, Virginia, Erika and Salpie, for the nice lunches and laughs and 
my friends in Spain, Pepe, Sara, Berta, Kris, Olga, Adri and Patri, who always stayed 
in touch. My parents, Carmen and Angel, have always encouraged me to follow my 
instinct and pursue my dreams, and showed me that perseverance and curiosity are 
driving forces in live. My sister Bea, my niece Mariana and Rui for their love and 
support during this adventure and my dog Mipa who kept me company every 
evening whilst writing this thesis. My grandmother, Lucinia, who is looking out for 
me every day. 
 
My beloved Manuel deserves a very special acknowledgment. Without his help, and 
especially in this last period whilst also being pregnant, this thesis could not have 






Background and Aims 
Cancer burden continues to increase in an aging population and hence cancer data 
has evolved into complex and multidimensional datasets with the advent of the 
OMICs sciences. Pathogenesis varies between patients and presents an intricate 
gene-environment interplay, which is reflected by the multifactorial character of the 
population susceptibility to cancer.   
The current thesis, therefore, aims to comprehend population susceptibility to 
cancer and heterogeneity of the disease by investigating new statistical approaches 
using multidimensional cancer datasets to ultimately develop effective stratification 




The thesis is divided into two main areas of study: Population susceptibility to 
disease and Individuals’ susceptibility to disease. 
1. Population susceptibility to disease. 
The following projects utilised data from the Apolipoprotein MOrtality RISk 
(AMORIS) study:  
a. The Blood exposome 
A subset of the internal-external blood exposome components were evaluated by 
exploring the reciprocity of 21 standard serum markers and 4 external factors 
following a four-step statistical analysis: correlation analysis, hierarchical clustering, 
principal component analysis and multivariable analysis of the variance 
(n=154,207). 
b. Metabolic profiles to assess cancer risk and mortality 
To identify metabolic profiles linked to carcinogenesis and mortality and their 
intrinsic associations, latent class analyses followed by multivariate Cox regression 




standard blood biomarker measurements to reflect population heterogeneity 
(n=13,615). 
2. Individuals’ susceptibility to disease. 
c. Discrimination of breast cancer tissue 
Imaging data generated by scanning 44 ex vivo breast tissue samples, utilising a 
terahertz probe (n=257), was evaluated using a two-step statistical approach 
(Gaussian deconvolution processing followed by a Naïve Bayes Classifier) to 
distinguish malignant and benign breast tissue, with the ultimate aim to identify 




a) The subset of the blood exposome analysis in AMORIS showed a tight 
interaction between internal markers of related pathways such as iron 
markers, whilst less well-known correlations also appeared (Albumin and 
Calcium). External markers showed that males and lower education were 
associated with serum biomarker levels that might be indicative of worse 
health outcomes. The variability of the data was distributed among all the 
markers studied. 
b) The metabolic profiles analysis in AMORIS identified four LCA metabolic 
profiles within the population: (1) normal values for all markers (63% of 
population); (2) abnormal values for lipids (22%); (3) abnormal values for 
liver functioning (9%); (4) abnormal values for iron and inflammation 
metabolism (6%). All metabolic profiles (classes 2-4) increased risk of cancer 
and mortality, compared to class 1 (e.g. HR for overall death was 1.26 
(95%CI: 1.16 - 1.37), 1.67 (95%CI: 1.47 - 1.90), and 1.21 (95%CI: 1.05 - 1.41) 
for class 2, 3, and 4, respectively). 
c) The Bayesian classifier for tumour tissue discrimination performed using the 
combined Gaussian derivatives, obtained the following values: 69%, 89%, 
53%, 60%, 86%, for accuracy, sensitivity, specificity, positive predictive value 




correctly in more than 89% of the cases with an accuracy of 0.7 and 
sensitivity of 0.9. 
 
Conclusion  
The subset of the blood exposome studied presented a complex synergy between 
the internal-external components, which demonstrates the need of systemic 
approaches involving multiple markers capable of evaluating the internal biological 
and external environment when assessing health outcomes.  Moreover, the LCA 
analysis indicated that internal blood markers, when assembled into meaningful 
metabolic profiles by optimised statistical methods, could help stratify the 
population for cancer risk and mortality and provide insight in cancer susceptibility 
and aetiology. Finally, the Bayesian classifier effectively discriminated malignant 
from benign breast tissue using TPI imaging data, however presenting moderate 
specificity, which suggests the potential clinical applicability of this method to 
improve the adequate excision of the margins in BCS surgery, if the specificity can 
be optimised. 
 
Overall, the projects in this thesis demonstrate the capability of data reduction 
methods to explore cancer susceptibility and develop potentially effective 
stratification models, and highlight the importance of data driven approaches in the 
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Chapter I. Introduction and research objectives 
 
Cancer development involves multiple biological pathways and includes diverse 
genetic, molecular and clinical events, with pathogenesis varying between patients 
(1, 2). It is critical to identify which biomarkers are linked to carcinogenesis, as well 
as their associations, to get a better understanding of the complexity of cancer, 
specifically its causes and evolution (3, 4).  This could improve cancer assessment 
and lead to early clinical interventions, better treatment options and improved 
patient outcomes (5).   
 
Cancer data has been generated by the latest technologies, resulting in highly 
complex, shared multiple types of data and huge volumes of information. For 
instance, advances in ‘omics’ technologies have created many candidate markers 
with potential clinical value for cancer diagnosis and prognosis, but so far relatively 
few have made it into clinical practice (6, 7). Thus, more systematic-based 
approaches are needed to replace single biomarker analysis with multiple testing 
(multiple biomarkers) in large datasets (5, 8, 9). This will enhance the shift from a 
classic hypothesis driven (exposure to outcome) to a data driven approach (multiple 
exposures to an outcome), accelerating the discovery of biological mechanism links 
with disease and with population susceptibility to disease (10). 
 
Several different data reductions methods have been used to explore the relation 
between biomarkers and disease in health sciences (11). Data reduction methods 
are defined as mathematical algorithms that decrease data dimensionality to help 
its exploration. Clustering is one such data exploratory tool that has been used in 
many areas such as clinical information, genomics and proteomics (12). The main 
idea is to group objects into meaningful classes that will describe the data. Related 
samples are clustered according to similarity coefficients. Another technique less 
used in cancer studies is Latent Class Analysis (LCA), a classification method to 
explore the underlying relationships between biomarkers, which groups subjects 




analysis techniques reduce data to a manageable size allowing easier identification 
of associations, as described in Figure 1. The figure illustrates the concept behind 
the statistical approach used in this thesis. 
 
Figure 1. Schematic representation of the concept followed in the statistical methodology. The 
methodology can be applied in different biomedical settings: clinical, imaging or genomics. A big 
cancer dataset contains a large amount of cancer data structured in a data matrix with multiple 
observations and variables that define these observations. The analysis aims to reduce the dimension 




With the overall goal of investigating statistical methods to stratify individuals based 
on their underlying risk of cancer whilst using multiple biomarkers, this thesis aimed 
to explore cancer susceptibility using data reduction methods in different 
biomedical settings. More specifically, this thesis comprises of the following two 
approaches to explore cancer susceptibility: 
 
1. To investigate population susceptibility to cancer in a clinical setting, I 
explored whether data driven approaches could develop effective cancer 





a. Project A: I investigated a subset of the blood exposome by (1) 
evaluating interactions in routinely assessed health biomarkers and 
(2) assessing how the external environment influences these 
interactions. 
b. Project B: I evaluated how metabolic profiles can assess risk of cancer 
and mortality.  
 
2. To investigate individual susceptibility to cancer in an imaging setting, I 
explored individuals’ heterogeneity in an imaging diagnostic setting to 
improve breast cancer tissue discrimination intraoperatively, using material 
from King’s Health Partners’ Breast Cancer Biobank:  
a. Project C: I evaluated how imaging data produced by a terahertz 
probe can discriminate between different breast tissue samples, with 
the ultimate aim of using this probe intraoperatively in breast-
conserving surgery to predict positive margins. 
 
Overall, this thesis aimed to enhance our understanding of the use of data reduction 
methods in different biomedical settings and comprehend how to implement these 
methods to assess cancer susceptibility more efficiently to ultimately develop 
effective cancer risk stratification tools.  
 
The next chapter provides an overview of the current state of the art with respect 
to cancer epidemiology and current approaches to cancer risk assessment. Chapter 
III explores methods to reduce data dimensionality and optimize prediction – with 
a specific focus on the methods used in the three projects described above. The 
methods and results of the studies in the Swedish AMORIS database are described 
in Chapter IV, whereas Chapter V describes the findings of the imaging project. 
Finally, chapter VI is the concluding chapter, which interprets the results and 







Chapter II. Background on cancer heterogeneity 
 
I. Cancer Epidemiology 
a. Global burden of cancer  
Cancer continues to be one of the major causes of death worldwide. The  burden of 
cancer is increasing due to the aging of a growing population and the adoption of 
health risk behaviours, mainly in the developed countries (14). 
 
 In 2015, 17.5 million cancer cases and 8.7 million cancer deaths were estimated 
worldwide using the Global Burden of Disease methodology (GBS), establishing 
cancer as the second leading cause of death, following cardiovascular disease (CVD) 
(15).  
 
Since 2005, incident cancer cases have increased by 33% and this number is 
expected to continue raising over the following years, with breast cancer (BC) being 
the most common cause of cancer accounting for around 2.4 million cases in 2015 
(15). During the same period, cancer deaths have decreased in many countries, 
however the opposite trend is seen some countries, such as in the Sub-Saharan 
Africa region (Figure 2). Cancer survival tend to be worse in developing countries, 
mainly because of the lack of screening policies and the limited access to treatments 
(16). 
 
In men, prostate cancer (PCa) is the most common cancer worldwide with tracheal, 
bronchus, and lung cancer being the main causes of cancer death, while in women 
breast cancer remains the leading cause of cancer and cancer death (Figure 3) (15).  
 
To meet the cancer challenge, personalized medicine has explored novel treatment 
approaches, such as T-cell engineering in Immunotherapy (17), improving life 
expectancy in patients in high income countries. In contrast, low income countries 




options for the population (14). Cancer prevention, early diagnosis and adequate 
treatments are thus key to fight cancer. 
 
Figure 2. Relative Changes in Age-Standardized Cancer Incidence Rates (A) and Mortality Rates (B) in 
Both Sexes for All Cancers in 195 Countries or Territories from 2005 to 2015. Figure taken from the 











Figure 3. Age-Specific Global Contributions of Cancer Types to Total Cancer Incidence and Mortality 















b. Carcinogenesis and hallmarks of cancer 
Cancer is a multi-pathway disease, assembled as a heterogeneous and hierarchically 
organized system (3).  
 
From a molecular perspective, the processes that drive the evolution from a normal 
cell to a cancer cell involve the sequential acquisition of alterations that damage the 
cell DNA. The arise of mutations can occur due to endogenous mechanisms  such as 
errors during the replication of the genetic material, due to the chemical instability 
of the genetic material, or due to the interactions with free radicals produced during 
the metabolic routes. Likewise, exogenous agents as radiation and chemical 
carcinogens can be also responsible for damaging the DNA material (18). 
 
A more complex picture emerges when exploring the biological pathways and 
networks involved in carcinogenesis (19). From a protein level, multiple oncoprotein 
pathways are implicated in oncogenesis, such as the Receptor Protein-Tyrosine 
Kinases (PTKs) (20, 21), the Wnt/Wingless Pathway (22, 23), Cadherins cell receptor 
and Catenin (24, 25), Rho and Ras protein family (26, 27) or the MAP Kinase 
Pathways (28).   
 
With respect to these pathways, the hallmarks of cancer publication established a 
new paradigm to understand the development of human tumours (3, 4). Six 
biological capabilities, upgraded to eight in the more recent publication, were 
defined as essential when rationalising the complexity of cancer disease. These 
capabilities comprised, as cited by the authors, the following: proliferating 
signalling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, activating invasion and metastasis, 
reprogramming of energy metabolism and evading immune destruction. This 







Figure 4.  Therapeutic Targeting of the Hallmarks of Cancer. The figure presents the six capabilities 
defined in the 2000 publication together with the emerging hallmarks and enabling capabilities and 






In 2016, this schema was translated into biochemical pathways by Pavlova and 
Thompson (29). The hallmarks were deciphered in terms of maintaining the oxygen 
and nutrients needed to facilitate tumour growth, proliferation and dissemination. 
The biochemical hallmarks defined were: deregulated uptake of glucose and amino 
acids, the use of opportunistic modes of nutrient acquisition, the use of 
glycolysis/TCA cycle intermediates for biosynthesis and NADPH production, the 
increased demand for nitrogen, the alterations in metabolite-driven gene 
regulation, and finally, the sophisticated metabolic interactions with the 






Figure 5.  Hallmarks of Cancer Metabolism. The figure presents the mechanisms utilised by cancer 
cells to acquire nutrients to ensure cancer cells proliferation and interactions with the 





This comprehensive framework, comprising molecular, biological and biochemical 
pathways, illustrates the complexity of the biology of cancer. Defining cancer as a 
multilayer disease that implies the involvement of diverse biological pathways at 
different biological levels, including distinct genetic, molecular and clinical events, 





c. Cancer heterogeneity 
i. Characterisation of the disease 
As early as in 1977, the presence of multiple subpopulations in a single mouse 
mammary tumour was reported. The authors hypothesised that heterogeneity was 
a general fact in cancer and maybe important for treatment strategies (30). 
 
Heterogeneity is a dissolute term that can describe diverse biological phenomena 
when applied to cancer. For example, heterogeneity already plays a role in 
neoplasia, where multiple routes, through the accumulation of genetic and 
epigenetics alterations, could lead to its differentiation into tumour tissue. 
However,  cancer variation is mainly used to expressed heterogeneity on genetic 
and phenotypic changes between tumours with different organ and cell origin or 
between individuals with the  same histopathological tumour type,  as displayed in 
Figure 6 (31).  
 
Intertumoral variability, defining heterogeneity between same histopathological 
tumour types, is highly dependent of patient’s characteristics, as age, sex and 
hormonal or immunological status, therefore population heterogeneity also plays a 
part in cancer variation. Different phenotypes can occur in hosts with similar 
characteristics, therefore each patient’s tumour may be considered unique while 
sharing many common features (1). For example, breast cancer (BC) that is highly 
heterogeneous, may present different morphology, behaviour and clinical 
implications in patients (32). 
 
Moreover, it is now established that solid tumours can contain different 
subpopulations of cells with diverse genomic mutations originated from the same 
primary tumour. This variation within a tumour is identified as intratumoural 







Figure 6. Intertumour and intratumour heterogeneity. Figure taken from the causes and 




Given all the previously mentioned elements of disparity, each histopathological 
tumour type may be considered as a collection of multiple diseases that consist of 
diverse subtypes. These subclasses that can be defined using different approaches 
and techniques.  The utilisation of immunohistochemistry (ICH) markers, together 
with clinic-pathological tumour characteristics as morphology, tumour size, volume 
or grade, has been the classical approach to a clinically relevant cancer molecular 
characterisation (32, 34). These biomarkers are widely used in standard clinical 
practice to assess cancer diagnosis, prognosis and treatment selection, but have 
proven not to be enough to explain all cancer heterogeneity and variation on clinical 
outcomes (35). Focusing on BC, in the last decades predictive IHC markers including 
estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth 
factor receptor 2 (HER2) have been extensively used for biological breast tumour 
subtyping and have been useful to treat highly endocrine responsive tumours but 
not to treat non-endocrine active tumours that lack of targeted therapies for 
patients leading to poor prognosis (32, 35).  
 
Therefore, in the last decade with the focus on personalised medicine and the 
advanced molecular technologies, multiple efforts have been made to reveal a 
comprehensive molecular characterisation of the disease able to clinically profile 




In BC, multiple studies have attempted to molecularly classify the disease.  In 2000, 
C. Perou published a new classification for the breast cancers, using DNA 
microarrays and patterns of gene expression. Moreover, in 2012 Curtis et al. 
presented a comprehensive molecular portrait of human BC using 2000 samples 
(36-38) .   
 
Consequently, heterogeneity should be considered as an inherent characteristic of 
cancer and unravelling its variation by molecular profiling the disease, could further 
drive a development in targeted therapeutics interventions and biomarker 
discovery. 
 
ii. Characterisation of the population: Cancer susceptibility 
After exploring the insights of diversity in carcinogenesis, the next step is to 
understand the heterogeneity that occurs at population level.  
 
Each individual’s susceptibility to cancer can be explained as a result of 
heterogeneity in the following elements: a biological component modulated by 
genetics, life-style behaviour aspects and environmental factors (39). 
 
Focusing first on the internal or biological component, variation in human genetics 
is vast.  The human genome differs in 0.5% between two individuals; a small 
difference which still implies millions of differences in the DNA (40). The 
mechanisms responsible for this genetic drift between individuals start with the 
exchange of genetic material in the sexual reproduction where two haploid cells, 
formed during meiosis, produce a diploid zygote (41) . At a molecular level, different 
mutational events arise in genes during a human live. At a population level, natural 
selection creates positive selective pressure in individuals with a genetic dotation 
that represents an advantage in the environment adaptation (42).  
 
Most of the genes can present different variants in the population known as genetic 




nucleotide position such as single nucleotides polymorphism (SNPs), then small 
insertions or deletions are next type of variation, followed by larger structural 
alterations (chromosomal rearrangements) and copy number variations in the 
genome. The Human Genome project, the International HapMap project and the 
Human Variome project have widely explored genetic variation and identified 10 
million of frequent DNA variants, mainly SNPs, in a set of human samples (43-46). 
 
Based on this inherited variation, an individual will have a predisposition to certain 
cancers due to specific cancer susceptibility gene alterations. Mechanisms of 
inheritance of cancer susceptibility are the consequence of alterations in different 
types of genes divided in two main classes, genes that preserve the integrity of the 
genome called caretakers and genes that control the proliferation cycle or 
gatekeepers, which completely regulate the tumour growth by suppression of the 
proliferation or by promoting cell death (47).  These two groups of genes include 
alterations in  tumour oncogenes as APC gene, defects on the tumour repair genes  
as the gatekeepers BRCA1 and BRCA2 mutations  associated with susceptibility to 
breast cancer, colon cancer, ovarian and prostate cancer (47, 48) and others 
alterations as in the genes that are involved in the stimulation of the vascularisation 
of tissue (49).  
 
A small proportion of many cancers is due to inherited mutations in above 
mentioned genes, which results in a high risk of developing specific cancer. 
Moreover, genes present different penetrance, meaning that the extent of 
expression of the genes varies in the individuals that carry them. When exploring 
genetic variations associated with complex diseases, high penetrance genes directly 
related with disease that confer high risk on the carriers are rare, for example BRCA1 
and BRCA2 BC susceptibility genes account for 16-25% of inherited risk of BC. 
However, lower penetrant genes that are more common polymorphic variants, 
confer only small risk of disease, which  might confirm the hypothesis that the 
combination of effects of the less penetrant variants together with environmental 




confirmed by Yang et al. who estimated that the number of genes needed to 
account for complex disease susceptibility in the population, are between 20 to 50 
variants, which would explain only half of the burden of a common disease (51). 
 
Ethnicity also plays an important role in cancer susceptibility. Due to natural 
selection, populations that are geographically and ancestrally distant tend to differ 
in their genomic variation expressing diverse polymorphism frequencies (43). This 
implies that different ethnicities may inherit diverse susceptibility to cancer because 
of their specific genetic content (52, 53). African-American men have the highest 
incidence rates for PCa while Japanese men have the lowest (54) . However, the 
difference of these incidence rates may also be influenced by disparity in cultural, 
socio-economic, and environmental factors (55-57).  
 
Gender is a well-established factors of cancer susceptibility in the field of cancer 
epidemiology. Different studies have shown that cancer incidence is higher in men 
than women, particularly in haematological cancers, sarcoma, lip and larynx (58). 
Survival rates and mortality rates follow the same pattern for many cancer (59). 
 
Age has been extensively studied as one of the main risk factors for cancer, given 
that it is considered as an age-related disease with incidence increasing after 
midlife.  Aging biological processes might be responsible for this association given 
the accumulation of genetic and epigenetic mutations over time, along with the 
aggregation of environmental exposures, such as chemicals and radiation and the 
adoption of health risk-behaviours, such as tobacco use, lack of physical activity, 
poor nutrition or excessive alcohol consumption (60). Ultimately, age can be 
considered as a cancer susceptibility risk factor modulated by genetics, social and 
environmental agents. Moreover, these health risk behaviours are also influenced 
by one individual’s gender (61, 62). 
 
Hence, the following section describes population susceptibility to cancer as a result 




To understand the proportion of attributable risk to behavioural, environmental and 
metabolic factors, I explored the Global Burden of Disease, Injuries, and Risk Factor 
study 2013. The study concluded that 50% of global mortality and more than 30% 
of attributable deaths, years of life lost, years lived with disability, and disability-
adjusted life-years (DALYs) can be explained by behavioural, environmental and 
metabolic factors, with high BMI being one of the leading risk factors (Figure 7). 
 
Moreover, environmental exposures such as air pollution, tobacco smoking and 
alcohol use are factors that have accounted for about 12.6 million deaths, more than 
20% of the global mortality, as reported by the WHO in 2012. 
 
Figure 7. Proportion of global all-cause DALYs attributable to behavioural, environmental, and 






Moreover, in 2002 C. Willett indicated that non-genetic factors can account for up 
to 80%-90% of the risk for diseases responsible for high mortality in Western 
countries, concluding that the most common cancers in developed countries are 
due to environmental factors (63).  He investigated migration studies together with 
twin studies and estimated that the genetic component of BC was 27%, whereas 




Furthermore, lifestyle factors such as smoking, obesity, unbalanced diet, alcohol 
consumption and lack of exercise, were confirmed major risk factors for cancer (65, 
66).  
 
Smoking increased the risk of lung cancer with a relative risk of 4.4 for men and 2.8 
for women, when comparing current smokers with never smokers as presented in a 
systematic review of the Japanese population (67). Similar results have been 
observed for cancer of the lower urinary tract in a Germany population (65). 
Moreover, over 70% of colon cancer has been found to be accountable to smoking 
habits (63, 68).  
 
Obesity or high BMI have also been associated with various cancers risk such as BC, 
PCa and colon cancer, probably because an interaction with hormonal pathways (66, 
69). In 2012, Renahan et al. reported that 3·6% of all new cancer cases in adults 
were attributable to high BMI, indicating that excess of body weight can be one of 
the most important preventable causes of cancer, particularly in high-income 
countries (70-73). High meat intake and high fat diets have also been broadly 
reported as associated with an increased risk of cancer (68, 74-77). For example, an 
American prospective study showed elevated risks for multiple cancers (78), on the 
contrary high intake of fruit and vegetables has been shown to have a protective 
effect for colorectal cancer (79, 80). 
 
Alcohol intake has recently been confirmed as a definitive risk factor for cancer, 
accounting for 5%-6% of new cancers and cancer deaths worldwide (81).  
 
Socioeconomic and cultural background are essential when trying to understand 
the variability of all the above mentioned behavioural lifestyle factors in individuals. 
For example, lower socioeconomic circumstances are associated with health-risk 
behaviours and poor cancer outcomes (57, 82, 83). Danai et al. presented the 
leading cancer mortality risk factors for low-middle-income countries versus high 




low fruit and vegetable intake appeared in low-and-middle-income and overweight 
and obesity were significant in high income countries (84). Ethnicity can be 
responsible for lifestyle behaviours that may explain differences in cancer risk in 
different races. For example, it has been shown that the lower BC rates for south 
Asian and black women in England may be explained by differences in lifestyle and 
reproductive behaviour (85). Healthy lifestyle behaviours as a balance diet, weight 
management, regular physical activity and cessation in smoking and alcohol will 
reduce cancer risk in the population (66). 
 
The environmental factors, sometimes measured as occupational factors (e.g. air 
pollution, heavy metals and various endocrine disrupting chemicals) are also an 
important component of population cancer susceptibility (63, 86). Rappaport 
pointed out that given the fact that environmental causes are mainly responsible 
for chronic diseases such as cancer, the causal agents are still insufficiently 
characterised (87). The environmental exposures that have been more extensively 
studied are air pollution, chemicals and radiation. 
 
Environmental chemicals are substances commonly detectable in every day 
products such as drinking water, foods, dental amalgams and pesticides. These 
chemicals include heavy metals such as cadmium, mercury and lead, allergens and 
organic chemicals, for which duration in the environment and body is fluctuating. 
The mechanisms of action of these toxics in the body varies, with oxidative stress, 
DNA damage, endocrine and immune disruption, being the main processes 
associated with cancer disease (88-90). For example, Bladder cancer is a tumour 
well-known for its environmental component. Risk of bladder cancer is associated 
with smoking fumes, arsenic in drinking water and occupational exposure to 
aromatic amines (2-naphthylamine, 4-aminobiphenyl and benzidine) and 4,4'-
methylenebis (2-chloroaniline) as a result of chemical dye exposure, rubber and 





Moreover, exposition to radiation even in low doses induces ionization in the body 
which causes DNA damage at various levels as damage to single, bases, single-strand 
breaks, double-strand breaks and multiply-damaged sites. Radiation exposure has 
been widely associated with BC, established mainly through studies of patients 
exposed to therapeutic radiation and studies investigating the Japanese bomb 
survivors (66).  
 
Given all the above-mentioned factors of variability in the population, including the 
genetic - environmental axis, characterisation of the population can be proven 
difficult and to fully understand population cancer susceptibility the interplay of all 
the above-mentioned factors needs to be taken into consideration. 
 
II. Cancer Assessment: Biomarkers & Exposome 
Given the above described heterogeneity in cancer susceptibility, the next challenge 
is to explore different approaches to assess the risk to disease. 
 
Cancer development is a multistep pathway that begins with one individual 
exposure to an agent that might activate a biological response. This biological 
process might present early effects in the body that will derivate in the later 
development of the disease. Therefore, carcinogenesis can be considered a 
continuum of molecular and genetic alterations leading to disease, as shown in 
Figure 8. In each stage of the pathway, the susceptibility to disease will depend on 
different factors in different proportions and consequently, the approach to 
evaluate the disease will vary along the disease pathway (93-95). For example, in 
the exposure and biological response stage, exposomics can be an adequate 
approach to assess disease development, whereas at the disease stage, 
translational research will be preferable to evaluate disease. 
The projects described in this thesis, will consider cancer assessment at the stage of 






Figure 8.  Schematic representation of the disease pathway. At different stages of the disease, the 
susceptibility can be attributable to different factors and the approach to assess the disease will be 
different. Figure adapted from Molecular Epidemiology of Chronic Diseases and the Exposome 
Lecture from R. Vermeulen. 
                 
 
 
a. Biomarkers in cancer  
As explored in the previous sections, cancer development involves multiple 
biological pathways and includes diverse genetic, molecular and clinical events (1, 
2). The pathogenesis varies between patients given the broad spectrum of cancer 
heterogeneity as described above. Therefore, it is critical to identify robust 
biomarkers that are precisely linked to carcinogenesis to get a better understanding 
of the complexity of cancer, its causes and evolution, to ultimately improve cancer 
diagnosis and prognosis (10, 93).  
 
A cancer biomarker or a cancer biological marker, is any measurement taken from 
a biological sample at any systemic level such as biochemical, molecular, 
immunological or psychological, that can be monitored and utilised as an accurate 
indicator of a biological or pathological process or of a therapeutic response in 
cancer patients (5, 96).   
 
The utility of cancer biomarkers is diverse and encompass the whole spectrum of 
the disease. Their applicability comprises all disease stages, from the early 
evaluation of the exposure or causes of disease, the identification of subclinical 




meaningful classification of disease,  to the identification of individuals susceptible 
to disease for early diagnosis and individuals with high probability of therapeutic 
response for better prognosis (97).  
 
Perera et al. classified biomarkers following the disease pathway (Figure 9).  This 
classification can be summarised in three main groups: markers of exposure and  
dose utilise in risk prediction and exposure assessment, markers of effect 
appropriate for screening, diagnosis and prognosis and markers of susceptibility 
employ in population stratification and risk assessment (94). 
 
 
Figure 9. The continuum of biomarkers with representative examples within each category. Figure 





Nevertheless, biomarkers’ clinical relevance will depend on the following 




reproducibility, validity, and in the patients and physician’s perception about the 
use and benefits of the marker (98). 
 
To establish the clinical utility of a biological marker, sensitivity, specificity, positive 
predictive value (PPV) and negative predictive value (NPV) are measured. Sensitivity 
and specificity account for the number of true positive cases and true negative cases 
detected by the marker. The PPV is the proportion of individuals who tested positive 
and are true cases and on the contrary, NPV is the proportion of individuals who 
tested negative and are negative cases. Receiver operating characteristic (ROC) 
curves are commonly used to the assess the prediction capabilities of a marker by 
plotting sensitivity values versus 1 - specificity values of the marker in comparison 
with the values of standard prediction marker commonly stated as “the gold 
standard” (93, 99). Based on these measurements of performance, a good 
predictive marker will have high sensitivity and specificity. However, some 
characteristics might be more desirable depending of the specific used of the 
marker, for example a diagnostic marker will require a high sensitivity while in a 
screening marker, both sensitivity and specificity are crucial to avoid the detection 
of a high number of false positives.   
 
Moreover, to implement a new marker into clinical practice, a careful assessment 
of the utility of the marker is required. Variability of the measurements 
compromises the reliability of the marker causing failure of the validation process. 
Errors in study design and execution of the validation trials, failures on 
standardisation of the preparation (e.g. specimens’ collection, handling and storage 
of the samples), variation due to intra-interindividual variability and temporal and 
seasonal variation of the markers are some of the pitfalls in the biomarker validation 
(93, 97, 100). 
 
Hence, several of the biomarkers that have been studied today in relation with 
cancer presented poor usability, e.g. CD44, telomerase, mucin 1 (MUC1), mucin 2 




Prostate specific antigen (PSA) in PCa, though its efficacy is being questioned, given 
the low specificity of the marker and that screening programmes have not shown 
an effective decrease in mortality rates (98). 
 
During the last decades, advances in imaging technologies together with the new 
high-throughput ‘omics’ technology (e.g.: genomics or proteomics) have created 
many new candidate markers with potential clinical value for cancer diagnosis and 
prognosis (96, 101) . However, very few of these identified biomarkers have been 
integrated into clinical practice and their superiority over the “standard” biomarkers 
such as prostate specific antigen (PSA) or oestrogen receptor (ER), have yet to be 
proven (96, 98, 102). 
 
This discrepancy can also be seen in data published by the US Food and Drug 
Administration (FDA) in 2002. The number of publications on cancer biomarkers has 
rapidly increased, while FDA-approved plasma-protein tests has decreased over the 
same period of time (96, 103). Furthermore, a report published in Nature in 2011 
suggested that high-throughput ‘omics’ technology has produced more than 
150,000 scientific publications on putative biomarkers, leading to only about 100 
biomarkers clinically validated (100) . 
 
Thus, despite this increase in data on biomarkers, their translation from bench to 
clinic has proven to be difficult (100). Moreover, molecular markers often show low 
values for specificity and sensitivity (5, 8, 9, 96, 104).  
 
Nevertheless, the challenge of developing cancer signatures through new robust 
biomarkers is a new exciting research area, given the vast amount of information 
produced with the rapid advances in omics and imaging technologies. Hence, new 
approaches to biomarker development have now shifted to systematic-based 
approaches, replacing single biomarker-based detection by multiple profiling testing 
simultaneously, which may provide new avenues for biomarker development for 





With the advent of genomics, there has been increasing interest in unravelling the 
environmental exposure given that the environmental contribution to complex 
diseases can account for 80 or 90% of the attributable risks (63). Moreover, 
following the change of paradigm in biomarker discovery for complex diseases, the 
drift from exploring single markers to more systematic approaches utilising multiple 
markers concurrently, Professor Christopher Wild introduced the concept of the 
Exposome in the field of cancer epidemiology in 2005. He defined the concept as 
”Exposome is the science of the impact of the environment on health and disease” 
and refers to the “totality of exposures  an individual is subjected to from conception 
to death” (Figure 10) (106). 
 
Due to the lack of characterisation of the environmental component of disease, 
further attempts to implement the theoretical concept of the exposome into 
practice were made. Two main approaches to describe the exposome of an 
individual during different stages in life were defined: a “bottom-up” concept 
measuring all the chemicals in each exposure at each time point and a “top-down” 

















Figure 10.  Characterising the exposome. The exposome comprises every exposure to which an 





Moreover, the exposome can be represented by three main components that 
summarise the different exposures that a person may be subject to in different 
stages of their life: internal, general external and specific external. The internal 
exposome is represented by the metabolism, endogenous circulating hormones, 
body morphology, physical activity, gut microbiota, inflammation, and aging; the 
specific external exposome comprise radiation, infections, chemical contaminants 
and pollutants, diet, lifestyle factors, occupation and medical interventions and 
finally the general external exposome accounts for social capital, education, 






Given the broad spectrum of exposures described above, no one single technology 
can estimate the entire exposome, a wide range of tools (and statistical techniques) 
will be necessary to characterise the exposome (Figure 11). 
 
Figure 11.  Characterisation of the different component of the Exposome (left) and different 
technologies available to evaluate each of the components (right). Figure taken from Molecular 





In 2010, Patel et al. conducted a pilot Environmental-Wide Association Study 
(EWAS) exploring 266 unique environmental factors in relation with Type 2- 
Diabetes (110). Currently, there are many studies calling on epidemiological 
research to assess the exposome, with some studies currently collecting data for 
exposome analysis such as the HELIX project and the EXPOSOMIC consortium (111-
117).  
 
i. Blood exposome and metabolites  
Rappaport et al proposed a top-down approach to estimate the exposome based on 
the inherent capacity of the blood samples of characterising the exposome. Blood 
transports chemicals to and from tissues and represents a reservoir of all 
endogenous and exogenous chemicals in the body at a given time, and exposures 




and exogenous origin. Rappaport explored 1,561 chemicals (including metabolites, 
food chemicals, pollutants, drugs) from human samples without finding any order 
of distinction between endogenous and exogenous chemicals, food and drugs  
(117). 
Therefore, the blood exposome offers an accessible route interrogating all 
biologically-relevant exposures to identify intermediate or endpoints that can be 
early biological markers in the causal pathway that links exposure to an etiologic 
agent for the onset or outcome of disease as suggested by “meet-in-the-middle” 
approach introduced by Paolo Vineis and Frederica Perera in 2007 (95). These 
markers can be useful to identify subclinical disease and identify susceptible 
individuals by measuring susceptibility in metabolites for disease stratification (108, 
118). 
 
Moreover, metabolites are modulated by genetics and environmental factors, 
which make them ideal candidates to assess internal and external exposure (108, 
119). Holmes et al. explored the concept of metabolic phenotypes as a product of 
interactions among a variety of factors- lifestyle/environmental, gut microbial and 
genetics, and demonstrated that metabolites discriminate populations for coronary 
heart disease and stroke based on blood pressure (112). 
 
Figure 12 provides an overview of how the blood exposome encompasses the above 
described susceptibility factors, establishing blood metabolites as ideal candidates 
to assess health and disease. The current thesis uses approaches similar to the 
above-explained concept of the exposome, but specifically focused on a subset of 






Figure 12. Metabolic profiling and the Exposome. The interplay between the different disease 









Chapter III. Background on statistical methods used to assess 
disease heterogeneity  
 
This section covers the methods generally employed in cancer studies and 
specifically focuses on those methods used in the different projects presented in 
this thesis.  
  
Due to the complexity of cancer disease, the extensive population heterogeneity, 
and the newly emerged cancer data and demand for high-sensitivity and high-
specificity biomarkers, significant sample sizes are required for multiple testing 
validation. As a result, sophisticated mathematical, statistical and computational 
multivariate approaches are essential to extract the biological and clinical relevant 
information related to disease outcome (10, 100).  
 
Therefore, new bioinformatics tools and computation algorithms are being 
developed to extract meaningful patterns able to predict phenotypic traits and 
outcome to improve our understanding of cancer biology and ultimately to enhance 
cancer care (120, 121). 
 
I. Cancer Data 
Cancer data is a broad concept that covers information of a wide nature. This data 
comes in a variety of formats, including numeric and codified values, signals and 
images, reports, summaries, multivariate time series and concentrations of 
biological molecules (120).  
 
With the onset of the high throughput technologies following the human genome 
sequence, Omics data have been produced in vast amounts together with 
environmental and behavioural population data (45). From the exposome spectrum, 
cancer external and specific external data contains demographics, environmental, 
life-style and behavioural factors, while internal data include clinical and OMICS 




structural features of molecules involved in important biological processes, such as 
metabolism and its regulation. The OMICs data follow the central dogma of 
molecular biology that explains how the biological information flows, where DNA is 
transcribed to RNA that then is subsequently translated to Proteins (122). OMICS 
information includes Genomics (DNA material), Epigenomics (DNA) and 
Transcriptomics (RNA) measuring gene expression and its regulation, Proteomics 
(Protein) and finally Metabolomics (Metabolites) that characterise the whole 
cellular activity, including the internal response to external stresses. Ultimately, all 
these complex interactions among molecular factors, including environmental and 
behavioural components, will result in the phenotype  (121). 
 
Cancer datasets are commonly structured in large data matrices with N observations 
(e.g. individuals, tissue samples, patients, etc…) and M variables or attributes of 
each observation (e.g. exposures as clinical biomarkers, imaging characteristics, 
genes, proteins or other features). Since the utilisation of the high-throughput 
technologies, M is usually many times bigger than N (Figure 13). When exploring 
outcome information, a response matrix will be associated with the cancer dataset 
and a spatial component will be included for longitudinal approaches, increasing the 
level of complexity of the analysis.  
 





Cancer data is characterised by different elements: (i) the variability of the 
dimension of the datasets, going from hundreds to millions (proteins to genes), (ii) 
the variety of the nature of the variables studied which can be continuous, binary, 
categorical, counts, etc.., (iii) the noise or error due to experimental conditions and 
finally, (iv) the heterogeneity of the data given its biological nature. An extra layer 
of complexity is provided by the underlying correlations that frequently exist 
between the different features studied. Therefore, the inherent complexity and 
multidimensionality observed in cancer data requires a flexible statistical 
framework able to extract meaningful information, whilst identifying the correct 
associations to predict cancer outcomes (121). 
 
Consequently, different methodologies are required for the exploration and analysis 
of the data, including data visualisation, information analysis and data mining. 
Methods like data mining are currently being integrated into clinical practice, while 
other data reduction methods such as classification and regression models need to 
be investigated further (120, 123) . Furthermore, these data reduction methods 
have been broadly used in bioinformatics and computational biology, but there is a 
lack of integration of biological and clinical data. 
 
II. Methods to reduce data dimension and optimize prediction 
Given the dimension of the cancer datasets and the increasing numbers of instances 
where there are more features that can be predictors of outcome than 
observations, most of the approaches to analyse this type data aim to reduce the 
dimension of the datasets, while exploring and extracting the substantial 
information. 
 
Common avenues for the analysis of the cancer data are different classes of 
regression-type analysis such as univariate approaches and multivariate approaches 
that include dimension reduction, feature selection approaches for variable 




a. Univariate analysis 
Univariate analysis explores each of the potential predictors independently in 
relation with the disease outcome. The relation between the N observations from 
individuals and the independent predictor in a study  can be formulated using a 
generalised linear model provided that the outcome is a real-valued observation 
(Figure 14) (127). 
 
Figure 14.  Linear model for an observation i and a predictor j. It estimates the association between 




Based on generalised linear models, a variety of methods can be utilised to estimate 
the association between the predictor and the outcome depending on the nature of 
the outcome.  
 
There are six possible scenarios: 
 If the outcome is a continuous variable, we could utilise a linear regression 
or an ANOVA to estimate an association between the predictor and 
outcome. For example: association of meat or alcohol intake and glucose 
levels in blood. 
 If the outcome is a categorical variable, we could utilise a multinomial logistic 
regression, ANOVA or X2 test to estimate an association between the 
predictor and outcome. For example: association of meat or alcohol intake 




 If the outcome is a binary variable, we could utilise a logistic regression, T-
test or X2 test to estimate an association between the predictor and 
outcome. For example, presence of glucose levels in blood and death of 
bladder cancer. 
 If the outcome is a count variable, we could utilise a Poisson regression to 
estimate an association between the predictor and outcome. For example, 
glucose measurements in blood and risk of bladder cancer over a period of 
time. 
 If the outcome is a time, we could utilise a survival model to estimate an 
association between the predictors and outcome. For example: glucose 
levels in blood and time to bladder cancer-specific death.  
 
The different methodologies mentioned above, estimate the relation between the 
predictor and outcome following different approaches:  
 Linear, logistic, multinomial, Poisson regression and survival analyses 
model the relationship between respectively, a scalar, binary, categorical 
or time outcome variables and one or more explanatory variables (or 
independent variables) (127, 128). 
 T test and chi-squared test X2 test explore the sampling distribution and 
determine if two or more sets of continuous data or frequencies are 
significantly different from each other (129, 130). 
 ANOVA analyses the variance or differences among different group 
means (129, 131, 132). 
 
This univariate approach estimates each feature of the observation as an 
independent predictor of the outcome studied, which implies multiple testing to 
identify true associations with disease outcome. The significance of the association 
between the predictor and outcome is measured by comparing the result of the 
chosen test to the (1-)th percentile of the distribution of the statistic under the null 
hypothesis that implies no association. Type I error defines  the chance of 




positive error will increase with the number of tests taken to test the hypothesis in 
the dataset; hence, correcting for multiple testing needs to be considered when 
performing multiple univariate analyses in a dataset.  
 
There are several approaches to assess multiple testing, for instance by controlling 
for the Family-Wise Error Rate (FWER) or by regulating the False Discovery Rate 
(FDR). Based on these two routes, there are multiple methods available such as 
Benjamini-Hochberg,  Bonferroni, Holm’s and Šidák corrections that can be 
employed for multiple testing correction (133). 
 
Mixed models, allow for a greater flexibility to model the association between 
exposure and outcome given that both linear and non-linear models can be mixed 
together. This can be advantageous when prior biological knowledge about the 
association exists, allowing to account for random effects due to the variance of 
observations (134, 135). 
 
Another standard univariate approach commonly used is correlation analysis. To 
understand the possible interactions between the two continuous features in the 
cancer dataset, correlation coefficients are usually performed (136).  There are two 
main type of tests available to measure the possible two-way association between 
two continuous features which use depends on the underlying distribution:   
 Pearson’s correlation coefficient which quantifies to which extent there is a 
linear relationship between the variables.   
 Spearman’s correlation coefficient which quantifies to which extent there is 
a monotonic relationship between the variables (not necessarily of a linear 
nature) which one variable can rise or drop while the other increase. 
 
To interpret the direction and intensity of the interaction, the r coefficient is used. r 
coefficient is dimensionless and it can range from +1 to -1. The r coefficient can be 




 r = ± 1 indicates a perfect linear (Pearson) or monotonic (Spearman) 
association. 
 r = 0 indicates no relationship. 
 r < 0 indicates a negative relationship. The more negative the coefficient, the 
stronger the association. 
 r > 0 indicates a positive relationship. The more positive the coefficient, the 
stronger the association. 
 
As explored previously, univariate approaches are computationally efficient and 
adaptable to different outcomes, although the potential of simultaneous predictive 
effect between different predictors and the outcome is ignored, lacking of a 
systemic approach to the disease studied (137). 
 
b. Multivariate Analysis 
Multiple factors interplay in biological disease mechanism, clinical outcomes or 
population risk stratification, as explored in previous sections. Therefore, 
multivariate analysis appears to be the adequate approach to study cancer risk. 
Multivariate approaches will explore multiple potential predictors and their 
correlations in relation to disease simultaneously, given that different predictors 
may explain diverse interactions with the outcome of study. 
 
The two main avenues for multivariate analysis, while reducing the dimension of the 
cancer multidimensional data matrix, consists of either grouping the N observations 
or the M features into a number of G clusters or selecting a number of features that 
contain the main variance of the data in relation with the outcome of study. 
Dimension reduction techniques, feature selection approaches for variable 
selection, and classification/clustering techniques are the standard methodologies 
performed for this type of analysis. Data reduction methods can thus be defined as 
mathematical algorithms that decrease the data dimensionality to help its 
exploration, by summarising the information into a smaller number of components 




Dimension reduction techniques 
These methods reduce the number of features or variables in the multidimensional 
matrix into a set of variables of lower dimensionality by applying (usually linear) 
transformation to the data. The new variables or components are linear 
combinations of the original features that produce a reduced representation of the 
original data. The linear combinations are computed to capture the variability of the 
original data by optimising a specific measure of the mathematical distance 
between the original and transformed feature values (138).  These methods can be 
categorised as feature extraction methods. 
 
Moreover, these methods can be unsupervised (where no prior information of the 
data structure is known) or supervised (where information of the structure and 
correlation with the outcome of interest is considered). Principal component 
analysis (PCA) is a well-established unsupervised method that reduces data by 
identifying directions based on the dominant eigenvectors of the data covariance 
matrix,  called principal components, projecting the data onto the dominant 
eigenvectors ensures that the variation of the original features is maximal (139, 
140). It has been broadly employed in clinical diagnosis, such as 
radiopharmaceutical assays to evaluate organ function (141) and to weigh up the 
expression of genes in tumour samples (142).  
 
Another similar technique is Factor analysis (FA) which also models the observed 
variables as linear combinations of potential factors that will define the different 
classes available in the data. However, this technique considers random errors in 
the measurements, optimises the common variance of the data and assumes that 
the  observed variables were the linear combinations of a smaller number of 
underlying and unique factors (143-145). Factor analysis can either be supervised 
(termed confirmatory analysis) or unsupervised (termed exploratory analysis). In 
confirmatory factor analysis, a hypothesised factor structure is tested using the data 
whereas exploratory factor analysis does not require any prior information about 




cluster biomarkers to explore their associations with cardiovascular disease (146) 
and confirmatory factor analysis has been utilised to confirm the hypothesis that 
the components of the metabolic syndrome are manifestations of a single common 
factor (147, 148). 
 
Another technique widely used in biological studies is the Partial Least Square 
regression approach (PLS) (149).  This supervised method explores latent variables 
that are capable of constructing the outcome variables, so that correlation with the 
outcome is explored in this method. This regression approach implies an a priori 
assumption of the number of latent variables that will define the data. This method 
has been used in cancer research, for example to discriminate between benign and 
cancer samples based on gene expression profiles (150).  
 
The above-mentioned dimension reduction methods have proven to be useful to 
reduce the dimension of the data, aiding in the exploration and analysis of the data, 
however sometimes the latent components are difficult to interpret from a 
biological perspective. 
 
Feature Selection methods 
To overcome the limitations of the above methods, alternative variable selection 
techniques have been explored to reduce the number of features by selecting a 
combination of predictors in a cancer dataset that best define the outcome. These 
approaches are developed mostly for linear and nonlinear regression models in 
which the impact of the predictors is mediated strictly via a linear combination as in 
the model of Figure 14. They all involve modifying maximum likelihood estimators 
of the regression coefficients by adding penalty terms (that favour null regression 
coefficients).  
The two-main variable-selection techniques via penalty terms are LASSO regression 
and the Elastic net. All these methods are regressions applied to analyse multiple 





To account for more complex variability in the associations between exposures and 
outcome, more general Bayesian approaches of these methods have been 
developed. 
 
c. Data reduction methods applied in this Thesis 
This section provides more background about the data reduction methods 
employed in the projects of this thesis which belong to the clustering/classification 
methodologies. 
 
Latent-class analysis, a specific type of cluster analysis  
Latent-class cluster analysis (LCA) is a specific type of model-based clustering and is 
the method selected for one of the projects performed in this thesis. Clustering is a 
data reduction tool that has been widely used in the context of big data. Related 
samples are clustered according to similarity or dissimilarity coefficients. Hence, 
clustering reduces data to a manageable size allowing easier identification of 
associations and patterns. Similar to variable selection approaches, these methods 
are considered feature selection methods. 
 
Classification or clustering methods also play an important role in medicine. Patients 
can be classified based on some variables, which can be symptoms, clinical or 
physical measurements, or response to treatments such as surgery. Classification of 
patients can be useful for statistical diagnosis, medical prognosis and prediction of 
cancer outcomes (151). As a result, the classification problem in medicine has been 
approached from different angles, resulting in a wide variety of methods available 
and are commonly used in bioinformatics. It can be applied to cluster genes or 
samples with similar expression patterns. Many clustering algorithms exists such as 
K-means, density-based algorithms, general type-2 fuzzy sets and probabilistic 
clustering (152, 153).  
 
Overall, clustering is a classification of observations into groups on the basis of some 




classification without making use of a priori knowledge of any group structure (even 
when such information is available). Here, determining the optimal number of 
clusters required to fit the data is a difficult task. In contrast, in supervised clustering 
one knows and uses a priori information on the class membership of each sample, 
and the task is to extract from this information a protocol for assigning as yet 
unclassified samples reliably to their classes. This is also called discriminant analysis. 
Each observation belongs to one of the specific groups, of which the number is by 
definition known. This a priori knowledge of the number of groups reduces the 
complexity of the cluster analysis.  
 
There are many types of clustering algorithms available, each with their own specific 
features, based on the different assumptions made to evaluate the groups that 
represent the data and on the (implicit or explicit) measures used to quantify 
similarity. For example, the classical methods, hierarchical and partitioning 
clustering, are heuristic methodologies, where classification is based on the nature 
of the data (e.g. similarity, dissimilarity between variables).  This implies that the 
class structure is not known beforehand, which makes the choice for a final cluster 
approach ad-hoc and subjective.  In contrast, model-based clustering algorithms 
are probabilistic by nature, based on an assumed generative model for the 
population, offering an alternative to the heuristic algorithms. In the model-based 
approach, the problem of determining the number of clusters is replaced by the 
challenge of choosing the right generative model for the data.  This method has 
been tested in comparison with the established heuristics algorithms in gene 
expression studies, showing a superior performance, consistently selecting the 
correct model and number of clusters (154). 
 
Latent Class Cluster Analysis (LCA) is a specific type of model-based clustering and 
is the method selected for project B in this thesis. This clustering method is 
commonly used in social sciences (13, 155). The goal of this analysis is to use a 
representative community sample rather than one individual sample to characterise 




have used LCA to explore underlying relationships between biomarkers and disease 
outcomes. This method differs from the clustering algorithms listed above in that 
instead of grouping biomarkers, it groups subjects according to the latent class 
under which they are categorised (156). 
 
LCA is a statistical method for the analysis of multivariate data. It was developed to 
handle only categorical data types (156), but later on improvements were made to 
allow use of continuous data and mixed data types (157).  The aim of this algorithm 
is to stratify the observed (manifested) variables by an unobserved “latent” variable 
that eliminates the confounding between those variables which are assumed to be 
mutually independent. The model will group each observation from the dataset 
probabilistically into a “latent class”, which could explain how that observation will 
respond to the manifested variables. The relationship between the manifested 
variables can thus be explained in terms of a latent variable (156) . This idea is 
illustrated in Figure 15, where X1: Xj manifested variables are explained by the latent 
variable C that can be associated with an outcome of interest Z.  
 
Figure 15.  Schematic representation of Latent Class Cluster Analysis. Manifested variables of a 







In mathematical terms, LCA is a statistical model for a sampled population. This 
model assumes that a heterogeneous population comprises multiple homogeneous 
subpopulations (named as classes, groups or clusters) with a different multivariate 
probability distribution function. Therefore, the final model will be a finite mixture 
of distributions (158).  More specifically, LCA is a form of model-based clustering, 
which assumes that the data is generated by a finite mixture of underlying 
probability distributions such as multivariate normal distributions or Gaussian 
mixture (159). Therefore, the clustering problem becomes a matter of estimating 
the model parameters of the different distributions. 
Firstly, we can define the basic latent class cluster model by the following formula: 
 
  Figure 16.  Formal mathematical formulation of the Latent Class Analysis. 
 
where Yn is the nth observation of the manifest variables, S is the number of classes, 
and πj is the prior probability of membership in class j. Pj (Yn | j) is the class-specific 
probability of Yn given the class specific parameters j. Pj is a probability mass 
function when the manifest variables are discrete and a density function when the 
manifest variables are continuous. For continuous data, the cluster specific 
parameters to be estimated are therefore the mean and variances (156, 160). 
 
Figure 17. Schematic representation of the fitting of the data into a mixture of Gaussian distributions 
followed by the LCA method. The LCA analysis fits the data into a finite mixture of underlying 
probability distributions such as multivariate Gaussian distributions represented in different colours 











Thus, when using the LCA model one needs to estimate of all the above probabilistic 
parameters of the class-dependent Gaussian mixture models, which is 
computationally nontrivial (Figure 17). This is usually done via the Maximum A 
Posteriori Probability (MAP) protocol, using the Expectation-Maximization (EM) 
algorithm and Newton-Raphson (RM) based search algorithms to find the most 
probable point. The algorithms iterate until convergence to a maximum global 
optimum, whereby the MAP estimates of the model parameters (mean, covariance 
and latent class mixing proportions) and a class-specific prior probability can be 
obtained. Once these parameters are estimated, one has to decide on the best 
possible LCA model and the optimal number of latent classes.  Ideally, one chooses 
a model that is complex enough to fit of the data, but avoids overfitting. The 
Bayesian Information Criterion (BCI), the Akaike’s Information Criterion and the Chi-
squared (X2) are broadly used statistical tools for evaluating a set of competing LCA 
models; these criteria penalise on the number of model parameters to avoid 
overfitting of the data (158, 159). 
 
Overall, the LCA model has multiple benefits in comparison to other clustering 
methods. It has the flexibility and possibility to handle very complicated 
distributional forms, provides a less arbitrary estimation of the number of clusters, 
and there is a formal criterion to make a decision about the number of clusters and 
parameters to include. It also avoids the unnecessary scaling of the observed values 
when the distribution is not normal and it has the possibility of using different data 
types. Finally, LCA  is a probabilistic approach, such that it also takes into account 
the uncertainty about the object class membership,  which can be very useful when 
interpreting the results (161).  
 
Given the complexity of LCA as a model-based clustering method, several statistical 
software packages have been developed to estimate its parameters. For the 
projects B, I have used statistical packages developed for SAS and R. PROC LCA  was 




using categorical data (162). poLCA and MCLUST are R software packages (163, 164). 
poLCA performs a latent class analysis using categorical variables, whereas MCLUST 
estimates density functions that permit the use of continuous variables (157, 165). 
MCLUST automatically estimates the best mixture model according to different 
covariance structures and different numbers of clusters. It can carry out 
unsupervised and supervised clustering (Figure 18). 
 
Naïve Bayes Classifier 
Another method based on model-based probabilistic approach is the Naïve Bayes 
Classifier, which is used in project C of this Thesis. The Naïve Bayes Classifier 
performs discriminant analysis in high-dimensional data that can be useful to predict 
clinical outcome for future patients (Figure 18). This method is an optimisation of 
the LCA method and it was developed to overcome the heavy computational 
demand of the Bayesian probabilistic approaches whilst avoiding overfitting.  
This Bayesian latent class regression enables reliable extraction of individualized 
predictive patterns from cancer data with much larger dimensions and increased 
accuracy, compared to what is feasible with standard regression and machine 
learning tools, enabling the identification of statistically significant disease or host 
heterogeneity in multivariate associations  (166). 
 









Chapter IV. Population susceptibility to Disease.  
 
To meet the cancer challenge, understanding the insights of disease and population 
heterogeneity will be fundamental pieces on the cancer puzzle, specifically towards 
the pursuit of personalised medicine. Comprehending all sources of variability will 
allow for an accurate and effective stratified medicine. 
 
As highlighted in the previous chapters, cancer datasets have grown extensively in 
the last decades, due to high throughput technologies and to the need of big 
samples sizes to establish new biomarkers. Moreover, single biomarkers or single 
clinical symptoms seem insufficient to capture patients’ heterogeneity and tailor 
treatments, therefore more systematic efforts exploring multiple markers with 
advance statistical methods are necessary to improve early diagnostic tools in 
cancer disease. However, to build efficient stratification models for diagnosis, the 
unnecessary information that increases complexity and noise should be discarded 
by reducing the dimension in the phenotype space to its predictive components. 
 
Thus, this chapter aims to explore multiple standard of care serum markers in 
relation to cancer diagnosis following a two-step approach: Firstly, understanding 
the role of these markers as a subset of the blood exposome and secondly, 
characterising the potential of these standard of care established markers as 
markers of cancer susceptibility. The molecules studied in this chapter, blood 
metabolites, both modulated by environment and genetics, are considered 
adequate markers to investigate a subset of the exposome and its association with 
cancer disease and mortality. 
 
Hence, in this chapter I investigated population susceptibility to cancer in a clinical 
setting, exploring whether data-driven approaches could develop effective cancer 
risk stratification tools using the Swedish Apolipoprotein MOrtality RISk study 






a. Project A: Blood exposome in AMORIS: 
I considered the study of a subset of the blood exposome by (1) 
evaluating interactions, as correlations, in routinely assessed health 
biomarkers and (2) assessing how the external environment influences 
these interactions. 
b. Project B: Metabolic profiles as risk factors in AMORIS: 
I evaluated how multiple markers of blood exposome, when reduced to 
metabolic profiles, can assess risk of cancer and mortality in a given 
population. 
 
The projects covered in this chapter are based on data available from the Swedish 
AMORIS database, so that the first section of this chapter describes this valuable 
data resource in more detail. The second section of this chapter outlines the health 
serum markers studied as exposures in both projects. Next, each specific project is 
explained in more detail.  
 
I. Data Source: AMORIS 
The Swedish Apolipoprotein MOrtality RISk study (AMORIS) is one of the largest 
prospective cohort studies worldwide with detailed information on serum 
biomarkers. Between 1985 and 1996, the Central Automation Laboratory (CALAB) 
processed fresh blood and urine samples from 812,073 individuals on a diverse 
number of markers, comprising 49% men and 51% women. CALAB, a leading centre 
for collection and analyses of blood and urine samples in the Stockholm county, 
processed analysis from individuals who were either healthy individuals referred for 
clinical laboratory testing as part of a general health check-up through occupational 
health care or outpatients. The results from those analyses were donated in 2002 
to the Karolinska Institutet, Stockholm, Sweden, for research purposes. The AMORIS 
cohort was initially set up to study apolipoproteins and the risk of fatal stroke and 
infarction. This database with information on more than 500 biomarkers, has been 




the Patient Register, the Cause of Death Register, the consecutive Swedish Censuses 
during 1970-1990, and the National Register of Total Population by using the 
Swedish 10-digit personal identity number (Figure 19A, 19B). These linkages provide 
detailed information on demographics, lifestyle, socio-economic status, vital status, 
cancer diagnosis, comorbidities and emigration. Data from the National Cancer 
Register provides information about cancer diagnosis prior to assessment of blood 
biomarkers in CALAB (index date) as well as incident cancer after this index date. 
AMORIS has been updated with extended follow-up until 31st December 2012 and 
enriched with clinical cancer information from the detailed Swedish Breast, 
Prostate, and Colorectal Cancer Clinical Quality Registers. Up to 31st December 
2012, 153,820 deaths (18.9%) and 144,533 incident cases of cancer (17.8%) were 
identified. The AMORIS study conformed to the declaration of Helsinki and was 
approved by the ethics board of the Karolinska Institute (167).  
The following table presents the characteristics of the AMORIS population in 




















Table 1. Sociodemographic characteristics of subjects in the AMORIS cohort at time of inclusion (1985-
1999) compared to the general population of Stockholm County in 1990. 
 AMORIS  
at baseline 
Stockholm county (1990) 
Number of subjects 812,073 1,654,766 
Female 51% 52%  
Mean age (years) 42.6  38.4  
Age distribution   
  ≤20 years 8% 24% 
  20-39 years 39% 31% 
  40-59 years 38% 26% 
  60-79 years 13% 16% 
  ≥80 years 2% 3% 
Country of birth   
    Sweden 85% 84% 
    Finland 5% 5% 
    RoW 10% 11% 
=< 9 years education 28.3% 24.3% 
Married 43.3%  36.5% 
Gainfully employed (20-64 years) 89.8% 85.1% 
Socioeconomic group   
  Unskilled worker 90,680 (20%) 177,362 (22%) 
  Skilled worker 58,598 (13%) 117,969 (15%) 
  Lower employee 108,315 (22%) 165,185 (20%) 
  Intermediate employee 110,329 (23%) 174,235 (22%) 
  Higher employee 89,918 (18%) 135,042 (17%) 
  Self employed 15,446 (3%) 35,691 (4%) 








Figure 19A & 19B. Different databases linked to AMORIS. Figure taken from Cohort Profile: The 








Currently, 104 scientific manuscript have been published based on the AMORIS 
cohort, mainly in the area of cancer and cardiovascular disease. Some of the 
publications investigating the association between serum biomarkers and cancer 
are described in Table 2 (169-184). 
 
Table 2. Different studies exploring association between serum markers and cancer in the Swedish 
cohort AMORIS. 
 
Author Cohort Biomarkers Outcome Results 
Van 
Hemelrijck, 
M et al.(169) 
24,820 Immunoglobulin E All cancer types No clear association. 
Van 
Hemelrijck, 
M et al.(170) 
102,749 
C-reactive protein & 
Leukocytes 
All cancer types 
Positive association between 
inflammatory markers and cancer 
risk using repeated measurements. 
Van 
Hemelrijck, 
M et al.(171) 
200,660 
Cholesterol, 
Triglycerides & Glucose 
Prostate Cancer 
Negative association between 
glucose and prostate cancer risk. 
Positive association between 
hypertriglyceridemia and prostate 
cancer risk, in combination with 









Glucose & Triglycerides 
All cancer types 
A positive association was found 
between GGT and overall cancer 
risk. Glucose increased the 
association for certain cancers. No 
effects of ALT or triglyceride levels 
on risk were found. 
Van 
Hemelrijck, 






LDL & HDL 
Prostate Cancer 
ApoA-I and HDL were inversely 
associated with PCa risk. 
Melvin, J et 
al.(174) 
234,494 Lipid profile & Glucose 
Breast and 
Ovarian Cancer 
A weak protective association was 
found between levels of 









& Total Cholesterol 
Endometrial 
Cancer 
Total cholesterol, triglycerides and 
TG/HDL ratio were positively 
associated with EC risk. 
Van 
Hemelrijck, 
M et al.(176) 
542,924 
Lipid profile, Glucose & 
BMI 
Kidney Cancer 
Triglycerides was positively 
associated with kidney cancer risk. 
Van 
Hemelrijck, 
M et al.(177) 
196,022 Calcium & Albumin Prostate cancer 
The weak negative association 
between Calcium and PCa risk is 
likely to be explained by the 
relation between Calcium and 
death. 
Wulaningsih, 
W et al.(178) 
540,309 Lipid profile 
Gastrointestinal 
cancers 
TC is associated with rectal cancer 
risk as well as TG with oesophageal 
and colon cancer risk. 
Gaur, A et 
al.(179) 
220,642 
Serum Iron, Total-Iron 
Binding Capacity & C-
Reactive Protein 
All cancer types 
An inverse relation between TIBC 
and cancer risk was found. 
Wulaningsih, 
W et al.(180) 
397,292 Inorganic phosphate All cancer types 
A higher overall cancer risk with 
increasing Pi levels in men and a 
negative association in women 
was found. 
Wulaningsih, 
W et al.(181) 
492,044 Calcium & Albumin 
Gastrointestinal 
cancer 
A positive relation between serum 
calcium and oesophageal and 
colorectal cancer was found. 
Wulaningsih, 
W et al.(182) 
11,998 
Serum Glucose & 
Fructosamine 
All cancer types 
A positive trend was observed 
between standardized log overall 
mean glucose and overall cancer 
risk. Including standardized log 
fructosamine resulted in a 
stronger association and an 
inverse association between 
fructosamine and cancer. 




Triglycerides & Total 
Cholesterol 
Prostate Cancer 
High serum levels of glucose and 
triglycerides were associated with 









No association found between the 
markers and Testicular and penile 
cancer. 
 
*The following abbreviations have been used in the table: Total Cholesterol (TC), High-density lipoproteins 
(HDL), Low-density lipoproteins (LDL), Triglycerides (TG), Apoliprotein A-1 (Apo A-1), Alanine Amino Transferase 
(ALT), Gamma-Glutamyl Transferase (GGT), Total Iron Binding Capacity (TIBC), Body Mass Index (BMI), 




II. Exposures: Blood metabolites from AMORIS 
The laboratory analyses included in the AMORIS study were performed on fresh 
blood and urine samples by CALAB. The CALAB sample set includes 35,815,102 
laboratory values recorded for 595 biomarkers, including mainly chemistry and 
haematology viral serology biomarkers, but also immunology, allergy and 
bacteriology markers are available in smaller numbers. Most of the markers 
measured are standard of care markers, however there are some novel markers 
such as Apolipoproteins (A-1 and B) and Fructosamine (168). All serum biomarkers 
were analysed using fully automated multichannel analyser Technicon DAXTM 96 
Multichannel Analyzer (Bayer Diagnostics, Tarrytown, USA), using the 
methodologies described in Table 3 for some of the markers studied in this thesis. 
More detailed on the laboratory techniques performed in CALAB can be found 
elsewhere (185-188). 
 
The serum markers studied to investigate population susceptibility in this chapter, 
were selected to represent the main metabolic pathways, at cellular and organ level. 
These markers are not necessarily related to cancer outcome, as illustrated in Figure 
20, but allow for an exploratory approach based on a set of routinely collected 
















Table 3. Fully automated laboratory methods with automatic calibration were performed at one 






GOD-PAP method: Enzymatic colorimetric test in which glucose 
in serum reacts with oxygen to give gluconate and hydrogen 
peroxide in the presence of glucose oxidase. 
<2.2% CV 
Fructosamine 
This technique is based on the reducing ability of fructosamine in 
an alkaline solution. 
≤5.0% CV 
Total cholesterol 
CHOD-PAP: Enzymatic cholesterol assay based on cholesterol 
esterase and cholesterol oxidase conversion followed by a 
Trinder-type sequence of reactions. 
≤2.7% CV 
Triglycerides 
GPO-PAP: Enzymatic determination of glycerol with glycerol-















LD (EC 1.1.1.27) in serum catalyses the reaction in which 
pyruvate is reduced to L-Lactate by dihydronicotinamide adenine 
dinucleotide (NADH2 causes a decrease in absorbance at 340nm 
with resepect to time. Within the range of the method, the rate 
of decrease of absorbance, measure at 340nm, is directly 




Enzymatic UV-test according to International Federation for 





Enzymatic UV-test according to International Federation for 





Enzymatic colorimetric test using reagents from Randox 
Laboratories Ltd, Crumlin, UK. 
≤6.0% CV 
Alkaline Phosphatase 
AP (EC 3.1.31) in serum dissociates parnitrophenyl phosphate 
into paranitrophenol and phosphate. The formation of para-
nitrophenol causes an increase in absorbance with respect to 
time. Within the range of the method, the rate of increase of 
absorbance, measured at 405nm, is directly proportional to the 
ALP activity. 









Jaffe method (kinetics) with deproteinization.  
Creatinine in serum reacts with alkaline picrate to form a colour 
complex. The formation of this complex causes an increase in 
absorbance with respect to time. Within the range of the 
method, the difference in absorbance at 490nm is directly 
proportional to the creatinine concentration. 
<3% CV 
Albumin Bromocresol green method. ≤2.0% CV 
Leukocytes 
The STKS is a haematology flow cytometer that automatically 










Immunotubidemetric determination of haptoglobin. Reagents 
from DAKO A/S, Glostrub, Denmark. 
≤5.0% CV 
Iron 
Acidification with citric acid in order to dissociate the Fe3 
transferring complex. 
<5% CV 
Total Iron binding 
capacity  
Fe3+ is added to the serum, in excess of that capable of being 
bound by the protein transferrin. By the addition of 2, 4, 6 –tri(2-
pyridyl) – 1, 3, 5 -triazine, a coloured complex is formed with the 
iron which is not bound. The absorbance of the complex is 
measured. The difference between the quantity of iron added to 
serum and that found to be in excess is equal to the unsaturated 
iron-binding capacity of the serum. 
≤5.0% CV 
Phosphate Formation of the phosphomolybdic acid complex. <4% CV 
Calcium 








Figure 20.  Panel of biomarkers studied in this chapter. The biomarkers are displayed characterising different biological processes involved which represent main 
metabolic pathways in which the set of routinely collected serum biomarkers may play a role. These metabolic pathways are fundamental for the body homeostasis and 
as a consequence they might also be relevant in carcinogenesis. 
 
*The following abbreviations have been used in the illustration: Fructosamine (FAMN), Lactate dehydrogenase (LDH), Total Cholesterol (TC), High-density lipoproteins (HDL), Low-
density lipoproteins (LDL), Triglycerides (TG), Apoliprotein A-1 (Apo A-1), Apoliprotein B (ApoB), Alanine  Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma-




A brief description of each of the pathways included in the projects, explaining the 
specific markers and their clinical application is explained below: 
 
Energy metabolism 
The generation of energy in human cells is mainly driven by the glycolysis cycle, a 
metabolic cycle that transforms glucose into pyruvate to generate the fuel 
molecules of the body, adenosine triphosphate (ATP) and reduced nicotinamide 
adenine dinucleotide (NADH) (189). The pyruvate resulted from the glycolysis is 
then used to synthesize fatty acids. Fatty acids produce the higher fraction of ATP 
of all molecules when oxidized by beta oxidation and citric acid cycle, so therefore 
fatty acids are the main storage form of fuel in humans. Fatty acids also are key parts 
of the cell membranes on the form of phospholipids (190). Glycolysis is an oxygen 
independent pathway, named as one of the hallmarks of cancer given that cancer 
cells reprogram the energy metabolism limiting their energy metabolism largely to 
glycolysis (3, 4). These two main energy metabolism cycles have also been targeted 
by Pavlova as hallmark of cancer pathways: the deregulated uptake of glucose and 
amino acids, the use of opportunistic modes of nutrient acquisition as lipids and the 
use of glycolysis/TCA cycle intermediates for biosynthesis and NADPH production 
(29). 
 
From these two main energy producer cycles of the body, eight different established 
screening markers have been considered in my analysis: Glucose, Fructosamine 
(FAMN), Total Cholesterol (TC), High-density lipoproteins (HDL), Low-density 
lipoproteins (LDL), Triglycerides (TG), Apoliprotein A-1 (Apo A-1) and Apoliprotein B 
(ApoB).  Lactate dehydrogenase (LDH) is another marker involved in the energy cycle 
and consequently, it was also considered in this section.  
 
The following section explains the utility of these screening markers from the 
current clinical perspective. The fasting glucose blood test measures current glucose 
levels in blood and it is performed for diagnosis of a pre-diabetes condition. 




levels in the body after fasting, are individuals that are not able to process glucose 
efficiently and consequently at higher risk of type 2 diabetes, cardiovascular 
conditions or metabolic syndrome (191). Fructosamine (FAMN), a compound result 
of the combination of sugar and an amine, is also employed in diabetes diagnosis. 
Fructosamine blood test determines the amount of total serum proteins that have 
undergone glycation which reflects the average of 1-3 weeks glucose levels in blood. 
For diabetes management, the use of the haemoglobin A1c test, which measure the 
glycation haemoglobin levels, is preferred to FAMN, because it reflects the glucose 
levels in blood over a  three months period, however this biomarker was not 
available in CALAB sample set (192). 
 
Cholesterol is a fatty acid, essential component of cell membranes and a precursor 
of hormones. Cholesterol is transported through the blood stream in lipoproteins 
and when there is an excess of cholesterol in the blood stream, it can be deposited 
in plaques in the blood vessels which can cause future block of the vessels, which 
increases the risk of cardiovascular events. Total cholesterol blood test determines 
all the lipid components in the blood stream and is used alone or combine with the 
other lipids, in a lipid panel to establish the cardiovascular and heart health status 
of an individual. High-density lipoproteins (HDL) and low-density lipoproteins (LDL) 
are part of the lipid profile blood test. HDL is one type of lipoproteins that carries 
cholesterol and its function is to remove excess of cholesterol from the blood and 
carry it to the liver for disposal. In contrast, LDL, another type of lipoprotein that 
carries cholesterol, tends to deposit the excess of cholesterol in the wall of the blood 
vessels.  
 
Triglycerides (TG), also a major component of the lipid profile, are normally storage 
in adipose tissue, but between meals are released to blood as an energy source for 
the body (193). The standard lipid profile will include all the above-mentioned 





Apoliprotein A-1 (Apo A-1), is the major component of the HDL molecules in plasma, 
accept for fats from within cells for transport, while Apoliprotein B (Apo B) is a 
component mainly found in LDL. These molecules are not standard health 
biomarkers, however the ratio apo B/apo A-1 has been found to have a stronger 
correlation with cardiovascular disease than the conventional lipid profile (186, 187, 
194). Consequently, these two biomarkers have also been included in project B. 
 
Lactate dehydrogenase (LHD) is an enzyme that catalyses the reaction from lactate 
to pyruvate, the last step in the anaerobic glycolysis. The enzyme appears 
extensively in body tissues, as blood, muscles, brain or kidney, and it is released into 
the blood stream when a tissue damage exits. Consequently, it is used as a marker 
of tissue damage events such as heart failure, anaemia, pancreatitis, liver or lung 
disease (195). Given its key role in the glycolysis, and the increase of glycolysis cycle 
in cancer cells, raised LHD levels in blood can be used as an unspecific tumour 
marker (196). 
 
Protein, lipid synthesis and detoxification in liver 
The liver has a key role in maintaining the internal body homeostasis. It is 
responsible for the synthesis of multiple proteins such as clotting factors and 
albumin, assembles carbohydrates, cholesterol and triglycerides, and synthesises 
glycogen to be stored in muscle and liver, together with bile production for food 
digestion. Moreover, the liver stores vitamins and iron. It filters the blood coming 
from the digestive system and detoxifies chemicals and metabolises drugs as 
alcohol, transforming ammonia into urea that is excreted to urine by the kidneys 
(197). 
 
Four different established screening markers for liver function have been 
considered in my analysis: Alanine Amino Transferase (ALT), Aspartate Amino 
Transferase (AST), Gamma-Glutamyl Transferase (GGT) and Alkaline Phosphatase 
(ALP). ALT is an aminotransferase enzyme commonly found in most tissues, mainly 




amino group from glutamate to pyruvate to form ketoglutarate and alanine, it is an 
important enzyme in the gluconeogenesis cycle. The ALT blood test is a sensitive 
marker for the diagnostic evaluation of liver health status.  It has also been 
appointed as a good marker of health specifically for cardiovascular disease and 
metabolic syndrome. The ALT test measures levels of the enzyme in plasma that will 
be elevated if the liver is damaged or inflamed (198).  
 
Aspartate Amino Transferase (AST), another aminotransferase, is always measured 
in conjunction with ALT for liver disease diagnosis, given its faster but shorter 
release into the blood stream when the liver is damaged. AST catalyses the transfer 
of an amino group between aspartate and glutamate to form oxaloacetate and 
glutamate, being key on the amino acid metabolism. AST is found in multiple organs 
as liver, heart, muscle, red blood cells because of this AST test considered less 
specific that ALT (199). 
 
Gamma-Glutamyl Transferase (GGT) is a transferase enzyme that catalyses transfer 
of gamma-glutamyl groups, being an important part of the drug and xenobiotic 
detoxification pathway. GGT is found in the cell membrane of many tissues, mainly 
in liver. GGT blood test is performed predominantly as a marker of liver disease, but 
also of the biliary system and pancreas (200). Recently  is  also been used for CDV 
diagnosis (201).  
 
Alkaline Phosphatase (ALP) is a phosphatase enzyme that dephosphorylates 
compounds. This enzyme plays a main role in liver function and skeleton and hence 
the ALP blood test is mainly used for diagnosis of liver diseases such as hepatitis and 
bone disorders, but also biliary system and kidney (202). 
 
Acid-Base balance, osmosis and detoxification in kidney 
The kidneys have a major role maintaining the homeostasis in the human body by 
preserving main functions such as the acid-base balance, extracellular fluid volume, 




These functions are processed by filtering, reabsorbing, secreting and excreting the 
blood plasma components received through the renal arteries. Some substances 
such as glucose, amino acids are reabsorbed, while other substances such as 
ammonium and uric acid are excreted to the urine via the bladder (203). 
 
Three different established screening markers for kidney health status have been 
considered in my analysis: Creatinine, Urea and Uric acid (Urat). 
 
Creatinine, is an excreted product from the muscle metabolism. It is produced in the 
liver and then transported to other organs to be transformed in a high-energy 
compound. When it is excreted to kidneys it can hardly be reabsorbed, making an 
ideal candidate to assess kidney function. Serum creatine levels are correlated with 
the glomerular filtration rate which is used to diagnose kidney disease, 
consequently high levels of serum creatinine may suggest a kidney  malfunction 
(204). 
 
Urea nitrogen is an excreted product from protein catabolism in the liver. Urea is 
excreted to the blood stream and it is mainly filtered by the kidneys to the urine. 
High levels of urea nitrogen in the blood stream may suggest abnormal kidney 
function (205).  
 
Uric acid (Urat) is a product of the catabolism of the nucleotides, which is normally 
released to blood, filtered by the kidneys and excreted to urine (206). High or low 
levels of uric acid in blood can be associated with health conditions such as cancer, 
cardiovascular disease or gout (high uric acid levels) and kidney or liver disease (low 
uric acid levels) (207, 208). 
 
Defence and inflammation in the immune system 
The immune system is a body system that protects the organism against disease 
through sophisticated mechanisms. The immune system in a simple definition is 




external organisms and neutralise them. The different mechanisms that allow the 
human body to defend infections can be classified into two main categories: the 
innate or humoral immunity and the adaptive or cell-mediated immunity.  
 
Processes part of the innate immune system are the surface barriers, such as 
mechanical, chemical and biological barriers against invasion of external agents, the 
inflammatory processes that are the first response to infection as for example the 
raise of body temperature, the leukocytes (WBC) that recognise pathogens and 
neutralise them, and finally the complement system that works as a biochemical 
reaction that attacks the surface of the exogenous cells. The adaptive immune 
system consists of the development of an immune memory that remembers and 
recognises pathogens. This mechanism is performed by the memory cells or 
lymphocytes, a special type of leukocytes (209). 
 
If there is a malfunction of the immune system, it can result in autoimmune disease, 
inflammatory disease, immunodeficiency disease and cancer. Due to the major role 
of the immune system, evading immune response and inflammation have been 
considered main hallmarks of cancer (3, 4). 
 
Four different established screening markers for the immune health status have 
been considered in my analysis: Albumin, White Blood Cells (WBC), C reactive 
protein (CRP) and Haptoglobin. 
 
Serum albumin is the main plasma protein produced by the liver and its main 
function is to maintain fluid within the circulation system. It also carries low density 
proteins in blood. Abnormal serum albumin levels can be associated with liver or 
kidney disease (210). Moreover, due to capacity of binding with polysaccharides and 
other bacterial products, it can modulated the inflammatory reaction (211). 
 
Leukocytes or white blood cells (WBC) are the main body immune cells that protect 




macrophages, neutrophils, dendritic cells, innate lymphoid cells, mast cells, 
eosinophils, basophils, and natural killer cells. WBC can be found in blood and 
lymphatic system and throughout the body.  The WBC count in blood is a standard 
clinical marker of the body health status, indicating disease when numbers are 
higher or lower that the normal range. 
 
C - reactive protein (CRP) is a plasma protein synthesised in the liver that is released 
into the blood in response to inflammation.  CRP blood tests are usually performed 
to diagnose inflammation, but it has also been associated with cancer, CVD and 
metabolic syndrome (212, 213). 
 
Haptoglobin is a plasma protein synthesised in the liver that binds free 
haemoglobin, the complex is soon degraded and the iron is recycled. Haemoglobin 
is carried by red blood cells so when these cells are damaged, haemoglobin is 
released in blood and captured by haptoglobin. In conditions as haemolytic 
anaemia, haptoglobin serum levels decrease. Haptoglobin serum levels are also 
associated with liver disease, inflammatory diseases, including infections, 
atherosclerosis, and autoimmune disorders (214). 
 
Oxygen, energy & enzymes production in the iron metabolism 
Iron metabolism is responsible for essential body functions such as haematopoiesis 
to produce haemoglobin which transports oxygen in red blood cells, it generates 
energy at the mitochondria through the cellular respiration, produces enzymes and 
hormones and promotes the immune system by depriving of iron load to bacteria 
which results in bacteria growth decrease. Control of iron homeostasis is essential 
for the body given that both iron overload and iron deficiency are causes of 
important human diseases, such as hemochromatosis or anaemia leading to tissue 
hypoxia; body iron unbalance has been associated with major diseases as CVD and 
cancer (215-220). Moreover, free iron is extremely cytotoxic, therefore iron is 
always found bound to proteins and cofactors, as the heme group in haemoglobin. 




released into plasma as an iron-transferrin complex which can be transferred to the 
liver or spleen to be stored as iron-ferritin complex or to the bone narrow to create 
a heme group part of haemoglobin carried by the red blood cells (221, 222).  
 
Three different established screening markers for the iron body balance have been 
considered in my analysis: Serum Iron, Total Iron Binding Capacity (TIBC) and 
Transferrin Saturations (Fe-PCT).  
 
These three biomarkers are closely interrelated to comprehend the amount of iron 
in plasma and are usually combined to report iron deficiency in the body. Serum 
Iron blood test measures the iron that is in circulation bound to transferrin protein 
and to assesses the extent (%) of iron transport by transferrin the Transferrin 
Saturations (Fe-PCT) marker is used. Total Iron Binding Capacity (TIBC) determines 
the capacity of blood to bind iron with transferrin  (223).  
 
Electricity transmission with electrolytes 
Electrolytes are chemicals that have the capacity to conduct electricity when 
dissolved in water, such as phosphate, calcium, potassium, sodium or magnesium, 
and are essential for multiple body functions. Electrolytes regulate the muscle and 
nerve function, regulate body acidity and body hydration and help to heal damage 
tissue. Therefore, electrolytes homeostasis needs to be tightly balanced in the body. 
Excess or deficiency of electrolytes can cause deficiency in muscle function and 
nerve transmission and it has been associated with different diseases as cancer 
(224). Only a small percent of the electrolytes is normally present in blood.  
 
Three different electrolytes have been considered in my analysis: Phosphate, 
Calcium and Potassium. 
 
Phosphate is a chemical closely related to bone growth, muscle and nerve function 




performed in conjunction with calcium to detect kidney or gastrointestinal 
alterations (225). 
 
Calcium is a chemical mainly stored in the bone and together with phosphorous 
builds and maintains bone. It has other important functions such as transmission of 
the cell signalling for the correct functioning of muscles, nerves, and the heart. Total 
calcium is normally measured to diagnose alterations related to bones, heart, 
nerves and kidneys (226).  
 
Potassium is a chemical essential to maintain the muscle function transmitting signal 
between muscles and nerves, especially important for heart function. It also 
transports nutrients to cells and helps to eliminate toxins from cells. Serum 
potassium  is usually assessed to diagnose kidney and heart disease (227). 
 
All the above-mentioned biomarkers have been investigated in the two projects 
discussed in this chapter. It would have been desirable to include more markers 
covering other pathways in the analyses, however the study was limited by the 
availability of markers in the CALAB database and the number of blood results 
available simultaneously at baseline. However, all markers were carefully chosen to 















III. Project A: The blood exposome in AMORIS 
The findings of this project are currently under review with Plos One journal. 
 
a. Rationale 
Chronic diseases present a multi-factorial aetiology with an intricate gene-
environment interplay (228). However, classical observational epidemiological 
studies have mainly studied single factors in relations with health outcomes, 
including complex diseases such as cancer or cardiovascular disease (229, 230). 
From a mechanistic point of view, this approach has been fundamental to 
understand the role of those factors in specific biological pathways and their efficacy 
as diagnostic markers in different diseases (231, 232). However, given the 
multifactorial nature of complex diseases, where multiple pathways at multiple 
levels of complexity are dysregulated during pathogenesis, a systemic approach is 
necessary to decode the biological mechanisms that drive disease (3, 4, 29). 
 
With the advent of genomics, there has been increasing interest in trying to unravel 
the environmental component of disease, especially since the introduction of the 
theoretical concept of the exposome by Professor Christopher Wild in 2005 (106). 
Multiple efforts towards the practical implementation of the exposome have been 
made since (87, 107, 109, 114, 233-240). 
 
Based on a set of routinely collected blood biomarkers available in the Swedish 
AMORIS database, the current project is set out to use an exposome-based 
approach. More specifically, given the top down approach presented by Rappaport 
in 2014 to explore blood metabolites, carriers of both internal and external 
exposure components (117), I aimed to investigate the reciprocity between clinically 
meaningful blood biomarkers and their association with external factors in an 
attempt to evaluate a subset of the internal-external exposome components in a 
given population. The project is not a full application of the exposome, but uses a 
similar framework and aims to evaluate associations between internal and external 




Thus, to explore the synergy in 21 clinically meaningful blood biomarkers and 
external factors, this study aimed to (1) evaluate interactions in commonly assessed 
health biomarkers via their interplay into novel groups and (2) assess how the 
external socio-demographic factors influence these biomarkers. 
 
b. Methods 
i. Study population 
This study utilises individuals from the Apolipoprotein Mortality-related Risk 
(AMORIS) database, as described above.  For this project, I included all individuals 
aged 20 or above with baseline measurements of 21 standard of care metabolites 
(n=154,207), who did not develop a cancer diagnosis within the next three years. 
From the CALAB database, information on age, sex and fasting status was obtained. 
Information on socio-economic status and education levels was obtained from 
national census data (241). In the database, socio-economic status was coded as 
blue or white collar. The panel of biomarkers included in the analysis were:  Glucose, 
Fructosamine (FAMN), Total Cholesterol (TC), Triglycerides (TG), Lactate 
Dehydrogenase (LDH), Alanine Amino Transferase (ALT), Aspartate Amino 
Transferase (AST), Gamma-Glutamyl Transferase (GGT), Alkaline Phosphatase (ALP), 
Creatinine, Urea, Uric acid (Urat), Albumin, C-Reactive Protein (CRP), Haptoglobin, 
Iron, Total Iron Binding Capacity (TIBC), Transferrin Saturations (Fe-PCT), Phosphate, 
Calcium and Potassium. All measurements were measured on the same day and the 
biomarkers were selected to represent the main metabolic pathways (see above). 
During the time of laboratory measurements, high-sensitivity CRP was not available. 
Therefore, CRP levels <10mg/L were not measurable. 
No specific outcome was defined in this analysis as the project aimed to understand 
the interrelations between all the different markers (internal and external). 
 
ii. Statistical Analysis 
The statistical pipeline in this project is divided into four main exploratory analyses 
to understand the interactions between the different serum markers and potential 




between the markers, (2) hierarchical clustering to assess whether there are 
homogeneous subgroups in the dataset, (3) principal component analysis (PCA) to 
summarise if there is a set with a smaller number of representative variables that 
collectively explain most of the variability in the original set, and (4) multivariate 
analysis of variance (MANOVA) to assess the interaction between internal and 
external markers in the dataset. This approach has been used previously to 
investigate metabolic markers of exposure in the study by Chadeau-Hyam et al. (11, 
129, 242-244). 
 
The normal distribution was explored for all the markers included in the analysis and 
given the fact that many variables were not normally distributed, a normalisation 
was applied to all variables prior to analysis, by transforming all the values to 
logarithmic values. Age was categorised into four groups: <40, 40<50, 50<=65 and 
>65. The 50-65 group was included to consider menopausal status in females. The 
last category, included all the individuals that were retired and therefore may be 
different to the rest of the population strata studied. 
 
The four explanatory analyses are explained in more detail below: 
(1) Correlations between all markers were calculated using Spearman’s rank 
order correlations to produce a default 21 x 21 data frame matrix between 
all pairs of variables that explores the interplay between variables. This same 
matrix was calculated for each category of the external markers, sex, age, 
SES and education. 
R package corrplot (245) was employed to visualise the matrixes and using 
iGraph R package (246), a network analysis (cut-off >0.35 for branches) was 
performed as a sensitivity analysis to check the interaction between 
markers. 
 
(2) Hierarchical clustering was performed in standardised data using Z 
transformation (mean =0, standard deviation = 1) applying the function 




data. Hierarchical clustering, network analysis and correlations studied the 
internal interactions between the markers, consequently no further analysis 
exploring interactions were conducted. 
 
(3) Prior to the analysis, a Z transformation of the dataset was required for 
Principal component analysis. R package principal was applied to perform 
the PCA to reduce the dimension of the data into few components that 
explain maximum variation of the dataset (247). A scree-plot graph was 
produced to visualise the variance of the first 10 components (default 
number of components displayed by principal), moreover the proportion of 
variance explained (PVE) in each component and the cumulative proportion 
were performed to investigate the loadings (weight on the total dataset) of 
these components.  
 
(4) Multivariate analysis of variance was calculated to assess the statistical 
difference in mean values for each blood marker and each of the external 
socio-demographic factors in SAS. Levene’s t-test was used to assess the 
homogeneity of the variance of the markers. Welch’s t-test was then used in 
case of equal means but unequal variances, while Tukey’s test was applied 
to assess pairwise comparison of means when there were more than two 
categories (p<0.05). 
 
Data management was performed using SAS version 9.4 (SAS Institute, Cary, NC, 
USA) and data analysis was conducted with R version 2.13.2 and R studio 3.3.2 (R 
Foundation for Statistical Computing, Wien, Austria) (248, 249). 
 
c. Results 
The tables and figures resulted from the analyses are displayed at the end of this 





Descriptive statistics of the baseline characteristics of study population is displayed 
in Table 4.  A total of 154,207 participants were included in the study (53% male, 
47% female). More than 90% of the population were “gainfully employed” and 
consequently, in the strata between the 40 to the 65-age group. More people had 
“white collar jobs” (47.54%) as compared to “blue collar jobs” (42.69%). 45% of the 
population had middle level of education status. 
 
Spearman correlation’s results are displayed in Figure 21, which presents a 21 by 21 
scatter plot matrix in which the biomarkers are plotted against each other.  The 
pairwise correlations were considered significant at a p-value < 0.01. The stronger 
correlations found in the dataset were: Serum Iron and Fe-pct. (r=0.93), part of the 
iron metabolism and the liver enzymes ALT and AST (r=0.68) and ALT and GGT (r= 
0.58). Other correlations were present within markers of similar pathways with r 
values around 0.4. Moreover, a positive association was observed between AST and 
LHD (r=0.44) and between Calcium and Albumin (r=0.42).  Furthermore, I explored 
the correlations between the internal markers by categories of external factors 
(Figures 22 to 25). A strong correlation was observed within markers of related 
pathways for the employed or missing category of the socio-economics status. 
Interestingly, for increasing categories of education (low, medium, high), significant 
levels of correlations were observed for Albumin vs Calcium: r=0.39, r=0.43, r=0.45, 
respectively and Creatinine vs Uric Acid: r=0.43, r=0.46, r=0.48. The magnitude of 
correlation between Glucose and Fructosamine decreased with higher education 
(r=0.50, r= 0.42, r=0.37, respectively) (Figure 23). Trends were observed with 
increasing age from 21 years up to 60 years of age (figure 24). Stronger positive 
correlations between markers were observed with females compared to males (e.g., 
between liver and lipid markers and ALT, LDH and Urat) (figure 25). 
 
The hierarchal clustering dendrogram is displayed in Figure 26.  A cut-off at a height 
of 580 points that produced three clusters was selected to facilitate the visualisation 
of the clusters, presenting markers with similar interactions and metabolic 




is explained below. The first cluster contained only Iron and FE-pct, which is was 
consistent with the strongest correlation observed in the dataset. The second group 
contained TIBC, Albumin, Calcium, Phosphate and Potassium. The third included the 
rest of the markers in subgroups representing connected pathways, LDH, ALP, GT, 
ALT and AST clustered together, one subgroup contains Urea, Creatinine and Uric 
Acid, another one includes Glucose, Fructosamine, TC and Triglycerides and finally 
CRP and Haptoglobin grouping together. Therefore, the results were consistent with 
the output of the correlation analysis. 
 
The principal component analysis identified 21 components that explained the 
variance in the dataset. Figure 27 displays the scree plot of the PCA analysis for the 
variances of the first 10 out of 21 principal components, a default-plot of the R 
package principal, with its associated proportion of variance explained and 
cumulative proportions. Out of 21 principal components, the first 12 had Eigen 
values greater than 1. The first component had an Eigen value > 3 and accounted 
for 18% of the variance in the data. The proportion of the first 10 components 
accounted for 74% of the variance data. The first 12 principal components 
accounted for 80% of the data. The contents of these components were sparse and 
did not showed any specific pattern. The first component was enriched on markers 
of liver metabolism, lipid, glucose and kidney functioning, while the second 
component showed few markers including iron and liver markers with negative and 
positive values. The third component presented the same markers as the first 
component, with half of them with negative values (Figure 28). Because the 
proportions of variance were distributed throughout all 21 components, with the 
first four components explaining 43% of the data, no further analysis was carried 
out using principal component analysis.  
 
The results of the multivariable analysis of variance are illustrated in Table 5. 
Statistical differences in mean were observed for all variables between “blue collar” 
vs “white collar”. A similar trend occurred for males vs females, except for TC where 




were higher in the lower education group, males and older age, respectively. For 
the class variable education, no differences between means were observed 
between medium levels of education and high levels of educations for markers CRP, 
Phosphate and Iron. Age categories showed statistical differences in mean for most 
of the variables between the 4 categories, except from Creatinine and ALP for ages 








Table 4. Descriptive statistics of the baseline characteristics of the study population. 
 
Total    N = 154,207   
(100%) 
Age (years)   
 Mean (SD) 47.31 (13.77) 
 Median (q1, q2) 47.07 (37.76, 58.27) 
<40 (%) 46661 (30.26) 
40-50 (%) 42986 (27.88) 
50-65 (%) 34588 (22.43) 
>65 (%) 29972 (19.44) 
Sex   
Male (%) 81796 (53.04) 
Female (%) 72411 (46.96) 
Socio Economic Status 
 White Collar (%) 67763 (43.94) 
 Blue Collar (%) 75747 (49.12) 
 Not gainfully employed or missing (%) 10697 (6.94) 
Education Status 
Low (%) 42630 (27.64) 
Middle (%) 68580 (44.47) 
High (%) 42997 (27.88) 
Biomarkers  Mean (q1, q2) 
C-Reactive protein (mg/L) 5.33 (1.00, 6.00) 
Albumin (g/L) 42.80 (41.00, 45.00) 
Haptoglobin (g/L) 1.05 (0.90, 1.20) 
Cholesterol (mmol/L) 5.63 (4.80, 6.30) 
Triglycerides (mmol/L) 1.35 (0.70, 1.60) 
Alanine amino transferase (IU/L) 0.44 (0.24, 0.50) 
Aspartate amino transferase (IU/L) 0.39 (0.28, 0.42) 
Gamma-glutamyl transferase (IU/L) 0.48 (0.23, 0.50) 
Glucose (mmol/L) 4.99 (4.40, 5.20) 
Fructosamine (mmol/L) 2.10 (1.95, 2.21) 
Creatinine (µmol/L) 80.80 (72.00, 89.00) 
Urea (mmol/l) 5.05 (4.10, 5.80) 
Calcium (mmol/L) 2.39 (2.32, 2.45) 
Alkaline phosphatase (IU/L) 2.64 (2.00, 3.10) 
Phosphate (mmol/L) 1.05 (0.90, 1.10) 
Iron (µmol/L) 17.70 (14.00, 21.00) 
Total iron binding capacity (µmol/L) 59.60 (54.00, 64.00) 
Transferrin Saturations (µmol/L) 0.30 (0.23, 0.36) 




Lactate dehydrogenase (µmol/L) 5.86 (5.10, 6.40) 
Uric acid (µmol/L) 289.00 (236.00, 334.00) 
 
 
Figure 21.  Spearman’s rank-order Correlation matrix between all 21 blood markers is displayed in 
the 21 by 21 scatter plot matrix in which the biomarkers are plotted against each other. The strength 
of the correlation is represented by the size of the circles (bigger higher r value) and the sign of the correlation is 
displayed using the red and blue palette (red means positive correlation while blue represents negative 
correlations). The actual r values are also displayed in the plot.  
 
 
*The following abbreviations have been used: crp = c-reactive protein, alb = albumin, hp = haptoglobin, tc = 
total cholesterol, tg = triglycerides, glu = glucose, fru = fructosamine, alt = alanine amino transferase, ast = 
aspartame amino transferase, gt = gamma glutamyl transferase, creat = creatinine, ca = calcium, alp = alkaline 
phosphatase, phos = phosphate, tibc = total iron binding capacity, fe-ptc = transferrin saturations, pot = 




Figure 22. Scatter plot matrix’s using spearman’s rank correlations for markers:  21 by 21 scatter plot matrix in which the biomarkers are plotted against each 
other by categories of socio-economics status. The strength of the correlation is represented by the size of the circles (bigger = higher r value) and the sign of the correlation is 
displayed using the red and blue colours (red means positive correlation while blue represents negative correlations). The actual r values are also displayed in the plot. 
 
 
*The following abbreviations have been used: crp = c-reactive protein, alb = albumin, hp = haptoglobin, tc = total cholesterol, tg = triglycerides, glu = glucose, fru = fructosamine, 
alt = alanine amino transferase, ast = aspartame amino transferase, gt = gamma glutamyl transferase, creat = creatinine, ca = calcium, alp = alkaline phosphatase, phos = phosphate, 






Figure 23. Scatter plot matrix’s using spearman’s rank correlations for markers: the 21 by 21 scatter plot matrix in which the biomarkers are plotted against each 
other by categories of education status. The strength of the correlation is represented by the size of the circles (bigger higher = r value) and the sign of the correlation is displayed 




*The following abbreviations have been used: crp = c-reactive protein, alb = albumin, hp = haptoglobin, tc = total cholesterol, tg = triglycerides, glu = glucose, fru = fructosamine, 
alt = alanine amino transferase, ast = aspartame amino transferase, gt = gamma glutamyl transferase, creat = creatinine, ca = calcium, alp = alkaline phosphatase, phos = phosphate, 




Figure 24. Scatter plot matrix’s using spearman’s rank correlations for markers: 21 by 21 scatter plot 
matrix in which the biomarkers are plotted against each other by categories of age. The strength of the 
correlation is represented by the size of the circles (bigger higher =  r value) and the sign of the correlation is 
displayed using the red and blue colours (red means positive correlation while blue represents negative 
correlations). The actual r values are also displayed in the plot.  
 
*The following abbreviations have been used: crp = c-reactive protein, alb = albumin, hp = haptoglobin, tc = 
total cholesterol, tg = triglycerides, glu = glucose, fru = fructosamine, alt = alanine amino transferase, ast = 
aspartame amino transferase, gt = gamma glutamyl transferase, creat = creatinine, ca = calcium, alp = alkaline 
phosphatase, phos = phosphate, tibc = total iron binding capacity, fe-ptc = transferrin saturations, pot = 






Figure 25.  Scatter plot matrix’s using spearman’s rank correlations for markers: 21 by 21 scatter plot 
matrix in which the biomarkers are plotted against each other by categories of gender. The strength of 
the correlation is represented by the size of the circles (bigger higher =  r value) and the sign of the correlation is 
displayed using the red and blue colours (red means positive correlation while blue represents negative 
correlations). The actual r values are also displayed in the plot.  
 
*The following abbreviations have been used: crp = c-reactive protein, alb = albumin, hp = haptoglobin, tc = 
total cholesterol, tg = triglycerides, glu = glucose, fru = fructosamine, alt = alanine amino transferase, ast = 
aspartame amino transferase, gt = gamma glutamyl transferase, creat = creatinine, ca = calcium, alp = alkaline 
phosphatase, phos = phosphate, tibc = total iron binding capacity, fe-ptc = transferrin saturations, pot = 
potassium ldh = lactate dehydrogenase and urat = uric acid. 
 
 
Figure 26.  Hierarchical clustering - Dendrogram displaying results of hierarchical clustering of all 21 
variables. Same abbreviations as in previous figures have been used. A cut-off of 580 in height was 







Figure 27.  Principal component analysis Scree plot displaying variances of first 10 components versus 
the eigenvectors values with associated proportion of variance and cumulative proportions of the first 
10 components with eigenvectors values > 1. The PCA analysis presented 12 components with 










Table 5.  Multivariate analysis of variance: mean values in each category of the given factors Sex, Education status, SES and Age. Same colour = no statistical difference 
between groups (tukey’s range test). * Pr <0.0001, ** P<0.001, ***P>0.05. 
  CRP Alb Hp TC  TG ALT AST GGT Glu Fru Crea Urea Ca ALP Phos Iron TIBC Fe LDH Uric Pot 
Sex * * * *** * * * * * * * * * * * * * * * * * 
M 0.99 3.77 0.01 1.71 0.24 -0.84 -0.95 -0.87 1.61 0.75 4.46 1.65 0.87 0.97 0.01 2.87 4.07 -1.20 1.76 5.76 1.44 
F 1.00 3.74 0.02 1.71 -0.02 -1.23 -1.14 -1.23 1.56 0.72 4.29 1.51 0.87 0.86 0.06 2.78 4.09 -1.31 1.75 5.49 1.43 
                                            
Edu * * * * * * * * * * * * * * * * * * * * * 
Low 1.02 3.74 0.07 1.75 0.21 -1.01 -1.02 -0.98 1.61 0.73 4.36 1.60 0.87 0.97 0.03 2.81 4.08 -1.27 1.78 5.64 1.44 
Med 0.99 3.75 0.02 1.70 0.11 -1.03 -1.05 -1.05 1.58 0.73 4.37 1.57 0.87 0.91 0.04 2.83 4.08 -1.25 1.75 5.62 1.44 
High 0.97 3.76 -0.03 1.68 0.02 -1.04 -1.05 -1.08 1.57 0.74 4.40 1.58 0.87 0.88 0.04 2.83 4.07 -1.24 1.73 5.63 0.08 
                                            
SES * * * * * * * * * * * * * * * * * * * * * 
Blue 1.00 3.75 0.03 1.70 0.12 -1.05 -1.05 -1.07 1.58 0.73 4.35 1.56 0.87 0.92 0.04 2.82 4.09 -1.27 1.76 5.60 1.44 
Whit
e 
0.98 3.76 0.00 1.71 0.11 -1.00 -1.03 -1.00 1.59 0.74 4.40 1.60 0.87 0.90 0.03 2.84 4.07 -1.23 1.74 5.66 1.44 
U/M 1.05 3.74 0.05 1.71 0.14 -1.05 -1.02 -1.04 1.61 0.74 4.37 1.63 0.87 1.01 0.06 2.78 4.08 -1.30 1.80 5.66 1.43 
                                            
Age * * * * * * * * * * * * * * * * * * * * * 
<40 0.98 3.78 -0.05 1.59 -0.04 -1.10 -1.09 -1.24 1.52 0.72 4.37 1.51 0.87 0.85 0.07 2.45 4.09 -1.24 1.70 5.59 1.42 
40-
50 
0.96 3.75 0.02 1.71 0.11 -1.01 -1.06 -1.01 1.58 0.73 4.37 1.55 0.87 0.86 0.03 2.82 4.09 -1.26 1.73 5.61 1.44 
50-
65 
1.00 3.74 0.06 1.78 0.22 -0.95 -1.00 -0.90 1.62 0.75 4.38 1.62 0.87 0.97 0.02 2.83 4.08 -1.25 1.79 5.67 1.44 
>65 1.05 3.72 0.08 1.80 0.24 -1.04 -0.98 -0.91 1.65 0.76 4.40 1.70 0.87 1.04 0.02 2.80 4.06 -1.26 1.82 5.69 1.45 
                      
 
*The following abbreviations have been used: crp = c-reactive protein, alb = albumin, hp = haptoglobin, tc = total cholesterol, tg = triglycerides, glu = glucose, fru = fructosamine, 
alt = alanine amino transferase, ast = aspartame amino transferase, gt = gamma glutamyl transferase, creat = creatinine, ca = calcium, alp = alkaline phosphatase, phos = phosphate, 





To explore the reciprocities between clinically meaningful blood biomarkers, I aimed 
to identify commonly measured biomarker groups into novel groups via their 
interplay with each other and the external environment. The statistical approach 
showed that these markers strongly correlate and cluster with other markers in 
similar and related body functions and metabolic pathways. Evaluation of the 
impact the external environment had on the internal environment indicated that 
lower level of education, older age and male sex were associated with higher 
biomarker levels that might indicated poorer health outcomes. There was a 
significant difference observed in the internal environment of individuals with 
different education levels, sex and age based on different strengths of correlations 
observed between the markers.   
 
Internal environment 
Serum biomarkers which are related to similar pathways and indicate adjacent body 
functions, such as the pairwise AST and ALT, Iron and FE-PCT, fructosamine and 
glucose and TC and TG, correlated and clustered strongly together. This was 
expected and in line with current understanding (250, 251). AST correlated with 
LDH, both enzymes are expressed in muscles and other body tissues and are 
released to blood stream where there is tissue damage. Specifically, the AST and 
LDH biomarkers, together with creatinine kinase and cardiac Troponin, are 
considered cardiac enzymes utilised for diagnosis of myocardial infarction (252-
254).  Albumin and Calcium markers showed a positive correlation and clustered 
together. The association observed between albumin and calcium may illustrate the 
interaction between those markers given that calcium in serum is bound to proteins, 
principally albumin. Total calcium measurement is usually corrected for by albumin 
(255). Finally, uric acid (Urate) correlated strongly with AST, ALT, GT, creatinine and 
triglycerides. Current literature suggests that elevated uric acid is an independent 
risk factor for non-alcoholic fatty liver disease and metabolic syndrome, even after 





For visualisation and interpretation purposes, hierarchical clustering separated the 
data into three main groups based on the selected height cut-off. One differentiated 
group contained only iron and its measure of saturation (Fe_pct), consistent with 
the strong correlations result for those markers.  The second medium sized group 
contained TIBC, phosphate, potassium, albumin and calcium. The latter two were 
also found to correlate strongly and are related given that albumin carries calcium 
in blood. This association was further strengthened, as these two serum markers 
also produced their own cluster at the height of 490 on the dendrogram (Figure 26). 
Serum calcium levels are influenced by the parathyroid hormone, of which 
phosphate is also part, providing some explanation to the weak clustering observed 
between the two variables (258). Albumin has also been associated with TIBC as an 
indicator of inflammation in a malnutrition inflammation score (259). The largest 
cluster contained many of the commonly assessed metabolic and organ specific 
function markers (energy metabolic, inflammation, liver functions and kidney 
functions screening markers). Within this group, markers were most closely 
associated to similar metabolic pathways or body functions, hence indicating a 
complex interwoven internal environment, in which changes in one 
metabolic/organ pathway suggest consequence on another. Current literature also 
states that high circulating lipids may lead to insulin resistance, non-alcoholic fatty 
liver disease and poorer renal functions (260, 261). The results of the hierarchical 
clustering give a statistical basis to this understanding.  The principal component 
analysis presented 12 components that accounted for 80 % of the variability of the 
data which did not indicate a variable or group of variables that accounted for the 
large variance in the dataset. The loadings of the components showed components 
enriched for most of the markers and components presenting few markers. Thus, 
this further strengthens the idea of an intertwined complex internal environment. 
Therefore, it is suggested that the classical epidemiological approach of study single 
markers has been useful to tackle specific biological question interrogating specific 
metabolism pathways, but it may not be sufficient to understand fully the different 






The results from the MANOVA analyses pointed out that males from lower 
education have higher serum biomarker levels that suggested associations with 
worse health outcomes. These findings are in line with large epidemiological and 
public health studies over the years (61, 62, 262-265). These studies suggest that 
healthy risk behaviours differ between levels of education, despite the public 
awareness of the implications about smoking, alcohol and exercise (263, 265).  
Therefore, individuals with lower education and lower SES are thought to be more 
likely to take part in risky health behaviours. Moreover, cohort studies presented 
worse health outcomes for individuals with lower SES, even after adjusting the 
analysis for health behaviours as confounders. This suggests that the interaction 
between SES and health is multifactorial, affect by life-style behaviours, education, 
environment (rural – urban) or access to exercise (264). Similar results were seen in 
the correlation analysis by education. In Figure 23, the correlation between glucose 
and fructosamine, a measure of glycaemic control, decreased as the level of 
education increased. Consequently, suggesting that other external, including 
behavioural factors, influence the fundamental internal environment of the body. 
This suggests the tight interaction between the different components of the 
exposome (external, general external and internal), even though the current study 
only investigated a small subset of the full exposome. When exploring the 
biomarkers by gender, ALP showed stronger correlations between some biomarkers 
in females, but not in males. ALP, as explained previously, is non- specific marker 
used as marker of liver function and bone turn over (197, 266). After menopause, 
oestrogens levels decrease whilst increasing women’s cardiovascular risk , along 
with a decrease in bone mineral density increasing risk of osteoporosis (267, 268). 
This has been associated with raised levels of ALP (266). The results of the 
correlation analysis support this observation, a stratification of women pre-and 
post-menopausal could have helped to confirm this finding, however information 







Even though the principal component analysis did now show any remarkable 
results, future studies should aim to explore novel strategies to reveal clusters of 
markers that contain all the variability inherent to biological data by removing the 
noise and uninformative data, this in turn could allow better accuracy in the 
assessment of the impact of the external environment on the internal environment. 
However, it needs to be noted that there may be a strong interplay between the 
routinely collected markers shown in the current analyses. The internal biomarkers 
showed strong interconnections, beyond their established clinical utility, suggesting 
potential a reductionist approach in the current clinical use of the health 
biomarkers.   
 
The findings of these exploratory analyses of a subset of the exposome confirmed 
tight synergy between the internal and external factors, which suggests the 
importance of exploring the complete exposome in the context of healthy ageing. 
Exposome studies should aim to assess exposures in different SES and education 
population strata and longitudinally along pertinent periods of human 
development.  
 
Strengths and limitations 
The major strength of this study lies with the large cohort and its external and 
internal validity. All participants were from the greater Stockholm area. All 
biomarker analyses were performed in the same laboratory. All individuals at the 
time were generally healthy and referred to the laboratory for a health check-up or 
were outpatients. However, any healthy cohort effect would not influence the 
internal validity of the study. Moreover, this study used a wide range of biomarkers 
and assessed them as individuals, not placing them in presumptuous groups. The 
AMORIS cohort is representative of the Swedish population (Table 1) and the subset 
of individuals studied in this project is comparable to the overall AMORIS 
population, however there is a slightly higher representation of the male population 




AMORIS, in comparison to the general population can be considered generalizable 
to another healthy western populations. During the study period, the all-cause 
mortality was about 14% lower in the AMORIS population than in the general 
population of Stockholm County when taking age, gender, and calendar year into 
account. Nevertheless, this healthy cohort effect would not affect the internal 
validity of our study and it is also likely to be minor since it has been shown that the 
AMORIS population is similar to the general working population of Stockholm 
County in terms of SES and ethnicity (167, 168). The main limitation of the study is 
the partial availability of information on life-style and environmental factors; the 
lack of these external exposures compromised the characterisation of the full 
exposome, however the results are relevant as an exploratory approach of a subset 
of the blood exposome.  
 
Other limitation of this study is that the markers were measured at one point in 
time, a single measurement will not consider temporal variation. Exposome studies 
argue that if limited measurements are to be taken then they should be taken during 
sensitive periods of human development; such as during antenatal development, 
infant and puberty years  (240).  
 
Conclusion 
I observed a complex synergy between the biomarkers and could not identify a 
single/group of markers that had a higher weighting over another that could 
account for the variance of the data. Lower education, older age and male sex were 
found to be markers associated with poorer health outcomes apart from ALP, which 
was more prominent in the female environment. The findings of this study indicate 
that using single markers to assess the internal environment may not represent the 
current underlying biological mechanisms, and may be susceptible to bias results.  
 
Therefore, this exploratory study on a subset of the internal-external exposome (21 
internal and 4 external markers) illustrates the importance of the further 




health outcomes. Future studies should shift from single internal marker 
assessment to multiple markers at different time points, including multiple 
metabolites and external and specific external markers, when assessing an outcome 
such as cancer, which would capture a higher percentage of the heterogeneity 
studied allowing for a better characterisation of the disease. This would in theory 
contribute to better disease prediction of complex, multifactorial diseases – which 




























IV. Project B: Metabolic profiles in AMORIS  
The findings of this project were presented as a poster at the NCRI Conference in 
2015, where it was shortlisted for the BACR Hamilton Fairley poster prize (Appendix 
I). It was also presented as an oral presentation at the Big Data in Biology and Health 
conference in 2017 (Appendix II). The findings of this project are currently under 
review with British Journal of Cancer. 
 
a. Rationale 
The characterisation of the subset of the blood exposome in AMORIS in project A, 
exploring some internal established health markers, external demographics and 
socio-economics factors, confirmed a tight synergy between the internal and 
external factors, which supports the importance of using an exposome approach in 
the context of health. 
 
Moreover, in 2013, Professor Christopher Wild proposed the assessment of the 
exposome in relation to cancer to elucidate putative risk factors associated with 
carcinogenesis for early disease detection (108). Blood metabolites, molecules 
capable of discovering causes of disease whilst channelling the internal exposome 
(117), have been widely explored as markers of exposure and susceptibility. For 
example, in cancer, increasingly seen as a metabolic disease, blood metabolites 
have contributed to identify groups in the population at greater risk of disease (118, 
269-271). Furthermore, with the implementation of the “meet-in-the-middle 
approach”, meaning that metabolites could be used as markers of exposure but also 
as markers of effect, the blood exposure has also been proven useful as a marker of 
effect or preclinical response to exposure (95). This was demonstrated in three pilot 
studies from the European Prospective Investigation into Cancer and Nutrition 
cohort (EPIC) on colon, breast and hepatocellular cancer outcome (244, 272). These 
studies established the role of blood exposome as a powerful tool to unravel cancer 






However, is still uncertain how precisely metabolites can classify individuals 
according to cancer risk, given the heterogeneity, confounding factors and noise 
inherent to the biological data (120, 273). Therefore, novel statistical strategies, to 
explore multiple serum markers in relation to cancer and mortality, are needed to 
build efficient stratification models that reduce the phenotype space to its 
predictive components, which could potentially improve the diagnostic protocols in 
clinical practice (274). Recent studies have investigated different approaches for risk 
stratification For example, Assi et al. performed a partial least squares analysis to 
investigate metabolic profiles in relation to hepatocellular carcinoma (272). Shann 
et al. explored PCA stratification of individuals for CVD risk based on metabolic 
profiles (275), whilst  Lacey at al. applied latent class analysis to cluster multiple 
external and general external exposures for pain scoring (276). In some of the 
studies, the association of the blood markers and the outcome of study was not 
strong enough to allow for disease stratification, however those markers could be 
still be used as markers of disease susceptibility. 
 
Therefore, with the overall goal of investigate statistical methods to classify 
individuals based on their underlying risk of developing cancer and risk of increasing 
mortality, I conducted an exploratory data driven approach utilising routinely 
collected standard of care serum markers  to study susceptibility to cancer and 
death in a well-defined cohort from the AMORIS study. More specifically, the study 
was designed to explore population heterogeneity and cancer susceptibility to 
investigate the capabilities of the LCA latent class serum metabolic profiles as 
possible risk stratification tools for cancer and mortality. .   
 
b. Methods 
i. Study population 
This study utilises individuals from the Apolipoprotein Mortality-related Risk 
(AMORIS) database, as described above.  For this project, I included all individuals 
aged 20 or above with baseline measurements of the following 19 standard of care 




Cholesterol (TC) (mmol/L), High Density Lipoprotein (HDL) (mmol/L), Low Density 
Lipoprotein (LDL) (mmol/L), Triglycerides (TG) (mmol/L), Apolipoprotein A-1 (ApoA-
I)  (g/L), Apolipoprotein B (ApoB) (g/L), Alanine Amino Transferase (ALT) (IU/L), 
Aspartate Amino Transferase (AST) (IU/L), Gamma-glutamyl transferase (GGT) 
(IU/L), Creatinine (µmol/L), Albumin (g/L), Leukocytes (WBC) (109 cells/L), C-reactive 
protein (CRP) (mg/L), Serum Iron (FE) (µmol/L), Total Iron Binding Capacity (TIBC) 
(mg/dL), Phosphate (mmol/L) and Calcium (mmol/L). All measurements were 
measured on the same day, using fully automated methods with automatic 
calibration performed on fresh blood samples. The blood metabolites included in 
the analysis were all the standard serum markers available from routine health 
check-ups, selected to represent main metabolic pathways in an exploratory 
exercise (Figure 20). The panel of biomarkers includes a high representation of 
markers of the energy metabolism with the aim of establishing the optimal markers 
to represent that specific pathway, given the abundance of these markers in the 
CALAB database. 
 
Most of the markers comprised in the analysis have been previously studied 
individually in AMORIS, however no systemic integrative approach to examine the 
metabolic markers interactions and susceptibility to cancer has been conducted to 
date (Table 1) (169-184). All participants were free from cancer at time of study 
entry and none were diagnosed with cancer within the first three years of follow-up 
to avoid reverse causation.  
 
The main outcomes were first cancer diagnosis, as registered in the National Cancer 
Register using ICD-9 for the years 1987-1992, ICD-O/2 for years 1993-2004 and for 
year 2005 onwards has been coded in ICD-O/3, and mortality. As secondary 
outcomes, I explored those cancer types for which there were more than 30 events 
during follow-up. Likewise, cancer mortality and overall mortality were explored. 
Follow-up time was assessed specifically for each of the outcomes studied. For 
cancer diagnosis, follow-up time was defined as time from blood drawn until date 




2012), whichever occurred first. The follow-up time for death was described as time 
from blood drawn until date of death, emigration or study closing date (31st of 
December 2012), whichever occurred first. 
 
Information on the following potential confounders was also incorporated: age, sex, 
education status and comorbidities. The latter was quantified using the Charlson 
Comorbidity Index (CCI) calculated based on data from the National Patient 
Register. The CCI comprises 17 disease categories, all assigned a weight. The sum of 
an individual’s weights was used to create the CCI ranging from no comorbidity to 
severe comorbidity (0, 1, 2, and ≥3) (277). 
 
ii. Statistical Analysis 
The statistical pipeline in this project is divided into three main analyses to explore 
the capabilities of multiple markers of the blood exposome, when reduced to 
informative metabolic profiles, to stratify a population by cancer risk and mortality 
risk. The analyses comprising the statistical pipeline were the following: (1) 
descriptive statistics of the study population, including data distribution and 
correlations, to explore the dataset and observe potential collinearity of the serum 
markers, (2) latent class analysis to characterise different classes of individuals 
based on their biomarker profiles, also evaluating intrinsic associations between 
those biomarkers and (3)  multivariable cox regression analysis to examine whether 
the LCA classes, based on the panel of serum biomarkers, are associated with long-
term risk of cancer and risk of all-cause and cancer-specific death (13, 128, 156). 











Figure 29. Methodological approach.  Innovative avenue to explore cancer susceptibility in a well-
defined cohort. This represents a shift from the classical targeted hypothesis driven approach to an 
exploratory data driven approach. 
 




Furthermore, to perform the above-described LCA analysis, I determined the 
optimal number of LCA-derived classes by executing step-wise models with different 
numbers of classes, starting with the null model and allowing for one extra class in 
each model until reaching the total number of biomarkers in the data whilst the 
model kept converging into a local maximum of the likelihood function. The 
criterions used for model selection (Akaike information criterion (AIC), Bayesian 
information criterion (BIC) and Chi-squared (X2)) were evaluated to estimate the 
best goodness of fit model and to define the optimal number of LCA-derived 
metabolic classes that characterised the dataset. Once the number of latent classes 
was established, I obtained the values of the parameters for the selected model. To 
identify which sets of biomarkers predominantly explained each latent class, how 
the classes were distributed across the study population and which individuals were 
allocated to each class, I assessed the conditional probabilities, mixed proportions 





For the LCA categorical packages, proc LCA and poLCA, the number of latent classes 
was defined by the minimum value for BIC, AIC and X2. For MCLUST, the LCA package 
for continuous data, BIC and AIC provided the best fitting model and best number 
of clusters for the dataset using maximum criteria (160, 162-164). 
 
Once each subject was assigned to its LCA-derived metabolic class, I then conducted 
the final step of analytical pipeline, the multivariate Cox proportional hazards 
regression analysis to examine whether the LCA-derived metabolic classes were 
associated with long term risk of overall cancer as well as specific cancer types. In 
addition, I evaluated how the classes were associated with all cause-death and 
cancer-specific death. All models were adjusted for age, sex, and CCI. Education 
status was excluded of the analysis because of missing values. I performed a 
sensitivity analysis using age as a time-scale, as age is potentially a strong 
confounder in cancer. Moreover, Schoenfeld residuals were tested to ensure the 
proportional hazard assumption of the Cox regression analysis. 
 
Finally, to assess the prediction capabilities of the LCA-derived metabolic classes for 
cancer, cancer death and overall death in comparison with standard health single 
biomarkers, c statistics were calculated for the LCA metabolic profiles compared to 
Total Cholesterol, Glucose and Gamma Glutamyl Transferase as single biomarkers.  
 
The above explained statistical pipeline followed a multistage approach, which was 
developed using different analytical strategies. The analyses leading to this final 
statistical pipeline are described in more detail below.  
  
First, the distribution of all biomarkers and demographic variables was evaluated 
using descriptive statistics including the mean, standard deviation and frequencies. 
Furthermore, histograms were plotted to identify the crude distribution of each 
biomarker. Pearson correlation coefficients were calculated to measure the 
strength of association between the biomarkers in the total study population as well 





Second, latent class analysis was performed using different formats of the values of 
the biomarkers to establish the optimal format of the data to utilise LCA: 
 Model A- Categorisation of the values, based on standard clinical cut-offs  
 Model B- Z-transformation of quartiles values 
 Model C- Z-transformation of continuous values 
Model A and B were performed using the proc LCA package (162) in SAS and the 
poLCA package (163) in R. To allow for analysis of biomarkers as continuous variable, 
the MCLUST package (164) in R was used. As a validation exercise, the study cohort 
was randomly split into a training (2/3) and test (1/3) datasets and LCA was executed 
for model A in both sets. 
 
Finally, after selecting the best input format for the biomarkers in the LCA, a 
sensitivity analysis was conducted following the statistical pipeline, running LCA 
followed by COX regression analysis to assess cancer risk in time scale, by exploring 
different panels of serum markers: 
 Model D- All markers including four established lipids ratios (23) 
 Model E- All markers except the lipid related markers (13) 
 Model F- All markers including TC and TG, but excluding the rest of lipids 
markers (15) 
 Model G- All markers including the established ratios log(TG/HDL) and ratio 
ApoB/ApoA ratios, but excluding the rest of lipids markers (15) 
 
After the sensitivity analysis, a final Model H was obtained which guaranteed the 
optimal performance of the statistical pipeline proposed for this particular project. 
 
This exploratory multistep approach was employed to ensure an effective 
characterisation of individuals for cancer risk and mortality, whilst allowing for an 
easy biological/clinical interpretation of the results, given the novel implementation 




this project will cover all the different models studied. However, detailed 
interpretation is only provided for the final Model H.  
 
Data management was performed using SAS version 9.4 (SAS Institute, Cary, NC, 
USA) and data analysis was conducted in SAS and R version 2.13.2 and R studio 3.3.2 
(R Foundation for Statistical Computing, Wien, Austria) (248, 249). 
 
c. Results 
The tables and figures resulted from the analyses are displayed at the end of this 
section to facilitate the flow of information. 
 
i. Characteristics of the study population 
A total of 1,956 individuals (14.37%) developed cancer after at least 3 years of 
follow-up, including 655 breast and genito-urinary cancers, 330 cases of digestive 
cancer, 133 cases of respiratory cancers and 129 lymphatic and hematopoietic 
cancers, during a mean follow-up time of 16.6 years. 3,158 participants (23.20%) 
died during a mean follow-up of 17.3 years, comprising 706 cancer-specific deaths. 
About 50% of the individuals were in the 40-60 age strata, with high representation 
of participants older than 60 years of age, and there was a significant difference in 
age between individuals with and without cancer. The majority of participants were 
in the high SES status and middle to high educational status and presented no 
comorbidities at baseline. In general, the cancer subgroup showed slightly higher 
values for most of the biomarkers compared with the cancer-free group. For 
instance, high values of TC appeared in 32.5% of the cancer population versus 27.5% 
of cancer free population. Overall, 30% of the total population has high values for 
TC, TG and LDL biomarkers. Study population characteristics by cancer status are 
illustrated in Table 6. The descriptive statistics including clinical cut-offs and 
quartiles values for these biomarkers are listed in Table 7. 
 
To evaluate the distribution of the data, histograms were created to identify the 




normal distribution of the data (Figures 30 – 32) and few markers showed a skewed 
distribution as illustrated in Figure 33. For some of the markers, a third of the 
population showed clinically abnormal values, as observed in table 6 (Figures 30 and 
33). Pearson’s correlation coefficients presented strong correlation between the 
different biomarkers in the lipid metabolism (TC, LDL and ApoB (r>0.7); HDL and 
ApoA-I (r>0.8)). The liver enzymes ALT and AST (r>0.8) also identified a strong 
correlation, as already observed in project A. The correlations by cancer status 
produced similar results. The properties of the total dataset remained in the training 
and test dataset.  
 
ii. Assessment of the different formats of the biomarkers to perform 
LCA 
I explored three different models to determine which input format of the 
biomarkers would produce a better performance of the LCA. In parallel, I 
investigated if the poLCA and proc LCA packages implemented for LCA in the 
statistical languages R and SAS showed the same behaviour when running LCA. 
Moreover, a small validation exercise to assess the LCA outcome when splitting the 
dataset was also conducted for the model A. 
 
MODEL A 
Latent class cluster analysis was executed using the dichotomised values of the 
biomarkers based on the clinical cut-offs (defined in table 6 and 7) in proc LAC for 
SAS and poLCA for R. The null model was run for 1 to 12 classes. The likelihood 
function did not converge into a local maximum for classes 9 to 12. Using R, the BIC 
and AIC, the goodness fit estimators, indicated a need for three or four classes 
(Figure 34a). After four classes both predictors stabilised, which indicated that 
adding more classes would not result in more information. Also in R, X2 presented a 
minimum of three classes (Figure 35).  Similar results were obtained for both the 
training and testing set (Figure 34c, Figure 34d). Using SAS, the BIC and AIC showed 
a slow decrease on their values without reaching a minimum for any of the classes; 




classes (Figure 34b). Consequently, two, three and four latent classes were 
considered as possible models for the dataset. For all three models, the class 
allocation of the observations, the class conditional probability for each biomarker 
and the latent mixing proportions were identical when running R or SAS.  
 
The results for each model are presented in Tables 8-10. Each table displays the 
number of latent class with the correspondence mixing proportion and the class 
conditional probabilities of belonging to each latent class for each of the abnormal 
clinical values of the biomarkers. The results of every model are explained below. 
 
LCA for two latent classes separated the study population into two groups (Table 8) 
with the following latent class mixing proportion: class 2 represented 64% of the 
data and the other 36% belonged to class 1. Considering the biomarker distribution 
within the classes, the probability for abnormal values of TC, TG, LDL and ApoB was 
enriched in class 1, while class 2 clustered individuals with normal values for all the 
biomarkers.  
 
LCA for three latent classes (Table 9) showed that class 3 contained 55% of the data 
and the other two classes held the rest of the population. Class 3 classified normal 
values for all the biomarkers, while the probability of abnormal values for TC, TG, 
LDL and ApoB all clustered in class 2, similarly to the previous model. Class 1 had a 
high probability of abnormal values of TG, HDL, glucose and creatinine. 
 
The LCA four class model separated the study population into three groups (class 1, 
class 2 and class 3) with abnormal lipids measurements and one group (class 4) most 
likely resembling the normal population (Table 10). The training and validation 
dataset showed similar results, using both SAS and R.  
 
MODEL B 
To reduce possible confounding effects of units or dimensions and to ensure normal 




biomarkers into standardised quartiles in the latter poLCA package in R. The null 
model was run for 1 to 16 classes for the standardised quartiles. BIC and AIC 
estimators were less informative in this analysis (Figure 36a). The predictors declined 
smoothly without reaching a minimum. The higher decrease was between two to 
three, then both predictors stabilized after four classes, consistent with the previous 
analyses using clinical cut-offs.  X2 did not reach a minimum, but just increased the 
values with the number of classes (Figure 36b).  Therefore, I also examined the 
results for two and three latent classes using the standardised quartiles (Table 11, 
Table 12); in this case the tables explore only the conditional probabilities for the 
lipid profile and glucose biomarkers given their significance in previous analysis. 
Moreover, the remaining markers in the analysis did not show any trend within the 
classes. 
 
LCA for two latent classes indicated that the mixing proportions of the latent classes 
were balanced (Table 11). One of the groups had abnormal high values for TC, TG, 
LDL and ApoB, while the other class presented low values for those lipids and high 
for HDL and ApoA. Moreover, LCA for three classes revealed a much more uniform 
distribution of the classes (Table 12). Hence, the information appeared diluted 
between the standardized quartiles. In this case, one of the clusters had high values 
of TC, TG and LDL and low HDL while other cluster showed lower values for TC, TG, 
LDL and high HDL and the last class had normal values.  
 
MODEL C 
Finally, to allow for analysis of biomarkers as continuous variables, I ran LCA on a 
continuous dataset and a standardised continuous dataset using the MCLUST 
package in R. This package does not require a null model to estimate the optimal 
number of classes. The package prints the BIC graph with all the possible models and 
number of classes. The class specific probabilities and latent mixing proportions for 
the best BIC value can therefore be retrieved. The analysis for the continuous values 




Moreover, the continuous standardised data showed a model with nine clusters 
(Figure 36a).  
 
After performing three different analyses using Latent Class Cluster Analysis using 
19 biomarkers in different data formats, the analyses were consistent irrespective 
of the software used to conduct LCA. The results of each of the model can be 
interpreted as follows: 
 
MODEL A 
LCA for clinical cut-offs for two classes showed class 2 representing the normal 
population and class 1 corresponding to individuals with dyslipidaemia, defined as 
a disorder of lipoprotein metabolism, including lipoprotein overproduction or 
deficiency (high serum TC, TG, LDL and low HDL) (278, 279). LCA for three classes 
clustered individuals with dyslipidaemia in class 2, class 1 individuals indicated 
presence of components of the metabolic syndrome (high serum TG and glucose)  
(280). Cluster 3 presented individuals with normal values (55%of the dataset).  
The LCA with four classes was less informative, because it separated the study 
population into three groups (class1, class 2 and class 3) illustrating abnormal lipids 
and class 4 with normal values. Thus, using clinical cut-offs three classes was the 
optimal number of clusters in the population based on the BIC, AIC and X2 goodness 




Using LCA for the standardised quartiles LCA models, the three classes model 
presented one class with dyslipidaemia, another one with low lipid profile and a 
third one as the normal population. The 2-class model divided the population in 
those with abnormal values for TC, TG and LDL and those with a low lipid profile. 
Latent Class analysis with standardised quartiles thus resulted in a dilution of the 




within the study population and a polarised characterisation of individuals into low 
and high lipid profiles. 
 
MODEL C 
LCA with continuous and standardised continuous data was difficult to interpret and 
it was not possible to extract any information from the population when used. 
Continuous data analysis showed all the markers in one unique cluster, which did 
not reduce the dimension of the data or provided information about heterogeneity 
in the population. Moreover, standardised continuous data analysis presented 9 
classes as the best model for the data, which similarly did not reduce the dimension 
of the data sufficiently. 
 
The above results thus indicated that the LCA using clinical cut-offs characterised the 
population into biologically meaningful groups, while the standardised quartiles 
seem to stratify the population between high and low values for biomarkers. This 
may be because only a small proportion of the population had abnormal values for 
the biomarkers used according to the clinical cut-offs, whereas there was a more 
homogenous distribution of the population when using quartiles of the biomarkers 
(Figure 31, Figure 32).  Also from a clinical point of view, keeping cancer risk as an 
outcome in mind, it seems reasonable to use the medical cut-offs. Furthermore, it 
has been suggested previously that scaling and normalising is not required for this 
method in comparison to other data reduction methods (281). Moreover, LCA was 
developed originally for categorical data analysis, and the implementation for 
continuous data was performed using a different R package mclust which might 
explain why the results for continuous data were very different to the results of 
clinical cut-off and quartiles. For both quartiles and clinical cut-off analyses, the 
models with number of classes estimated best for the data were similar, which 
confirms that this method is not affected by the scaling of the data. The difference 
between the results of the clinical cut-offs and quartiles analyses lies in the 
description or content of the different classes, which was based on the method used 




by the interpretability of the results in a given context, so there will always be a 
subjective component in the selection of the best model for the data, which will be 
based on previous knowledge and expertise in the area of research. Therefore, given 
the clinical and biological context of the study, clinical cut-offs presented the results 
that were most informative for this particular area of research. 
 
This assessment confirms that clinical cut-offs values seem the best input format to 
perform LCA in a biomedical context. The results from Model A are clinically and 
biologically meaningful. Moreover, the goodness fit indicators of the model were 
more precise in model A, especially for the model fit indicator X2. 
 
iii. Sensitivity analysis of the panel of biomarkers for LCA and COX  
After identifying that the clinical cut-offs were the best input format of the 
biomarkers for LCA, a sensitivity analysis was conducted by exploring different 
panels of serum markers. 
 
The following analyses were conducted in the statistical analysis program R, given 
its faster performance in comparison with SAS and the consistent results for LCA in 
both platforms. As mentioned previously, the biomarker panel contained a high 
proportion of lipid markers (TC, HDL, LDL, TG, ApoA-1 and ApoB) with the intention 
of establishing those markers most representative of that pathway. In standard 
medical practice, TC and TG biomarkers are commonly measured in blood samples 
to assess the lipid metabolism, however recent publications present the ratios 
ApoB/ApoA-I and log (TG/HDL) as superior markers characterising the internal and 
external axis of the lipid component (genomic/environment) (187, 194, 282-284). 
Moreover, LCA requires  the principle of local independence between the covariates 
analysed (159). The correlation analysis showed collinearity for these markers, 
which might explain the strong lipid burden seen in the previous results. Therefore, 
the panel of biomarkers was further investigated to include only the best possible 
markers to stratify the population for cancer risk, specifically concentrating on lipids, 




sex, education status and CCI using calendar-time as a time scale. Four different 
models were investigated: MODEL D which includes the full panel of biomarkers 
adding four established lipid ratios: ApoB/ApoA-I, Total cholesterol/HDL, 
LDL/HDL and Log (triglycerides/HDL) (23), MODEL E containing all markers excluding 
the lipid factors (13), MODEL F based on all markers but only TC and TG of the lipid 
pathway (15) and finally MODEL G which contained all markers including the 
log(TG/HDL) and ApoB/ApoA-1 ratios, but excluded the rest of lipids markers (15).  




LCA was executed using dichotomised values of the full biomarker panel and four 
lipid markers (ratios (ApoB/ApoA-I, Total cholesterol/HDL, LDL/HDL and Log 
(triglycerides/HDL))) based on clinical cut-offs in poLCA in R. The null model was run 
for 1 to 12 classes. The likelihood function did not converge into a local maximum 
for classes 11 and 12. The BIC and AIC, the goodness fit estimators, indicated a need 
for three or four classes and X2 presented a minimum of four classes (Figure 38a). 
Consequently, four classes were considered the best model for the dataset. Table 
13 presents the results for four classes. The LCA separated the data into four groups: 
the largest represented the normal values for the markers (52%), class 3 was 
enriched with TC, LDL, ratio ApoB/apoA-1 (20%), class 2 was largely enriched in the 
lipid markers, glucose (16%) and class 1 (12%) with abnormal values for liver 
enzymes, ALT and elevated GGT. Once each subject was assigned to its LCA-derived 
metabolic class, a multivariate COX regression analysis to assess whether the 
metabolic profiles were associated with long term cancer risk was performed. Class 
1 represented by the altered liver enzymes showed a significance increase of over 
all cancer risk (HR: 1.19 (95%CI: 1.02 - 1.37)) for the individuals allocated in that 








To explore the biomarker panel whilst excluding the extensive lipid component, LCA 
was performed on the remaining 13 markers. The null model was run for one to 12 
classes. The likelihood function did not converge into a local maximum for classes 9 
to 12. The BIC and AIC, the goodness fit estimators, did not presented a clear 
minimum and X2 presented a total minimum of three classes (Figure 38b). 
Consequently, three classes were considered the best model for the dataset. Table 
15 presents the results for three classes. The LCA separated the data in three groups: 
the largest represented the normal values for the markers (78%), class 3 showed 
high Glucose and high liver enzymes ALT, AST and GGT (15%) and class 1 (7%) 
clustered individuals with abnormal values for iron markers.  The multivariate 
regression analysis did not present any statistical significant association with long 




Following the exploratory analysis of the non-lipid related markers, LCA was 
executed for all the markers including only TC and TG from the lipid component (15). 
The null model was run for one to 12 classes. The likelihood function did not 
converge into a local maximum for classes 8 to 12. The BIC and AIC, the goodness fit 
estimators, did not presented a clear minimum and X2 presented a minimum of 
three classes (Figure 38c). Consequently, three classes were considered the best 
model for the dataset (Table 16). Class 1 included individual with normal values for 
the markers (68%), while class 2 clustered 25% of the population presented with 
abnormal values for TC, TG and ALT, GGT from the liver metabolism. Class 3 showed 
low levels for iron and TIBC (7%). Class 2, represented by lipids and the altered liver 
enzymes, showed a significant increase of over all cancer risk (HR: 1.16 (95%CI: 1.04 








LCA was performed on all the markers including only the ratio log (TG/HDL) and ratio 
ApoB/ApoA-1 for the lipid pathway (15). The null model was run for one to 12 
classes. The likelihood function did not converge into a local maximum for classes 8 
to 12. The BIC and AIC, the goodness fit estimators, indicated a need for three or 
four classes and X2 presented a minimum of four classes (Figure 38d). Consequently, 
four classes were considered the best model for the dataset. LCA clustered 
individuals with normal values for all the markers in class 1, representing the largest 
population (63%). Participants allocated in class 2 manifested high values for the 
lipid ratios log (TG/HDL) and ApoB/ApoA-1 being 23% of the population. Class 3 
classified individuals with high values for the enzymes ALT, AST and GGT (9%), and 
class 4 clustered individuals with low values for iron and TIBC (6%) (Table 17). 
Multivariate cox regression analysis showed that individuals with high abnormal 
values for liver enzyme class 3 had a higher risk of overall cancer in comparison with 
the normal class 1 (HR: 1.29 (95%CI: 1.10 - 1.52)) (Table 14). 
 
After conducting LCA followed by Multivariate Cox regression analysis to assess 
cancer risk in the four models that included diverse panels of biomarkers, the results 
showed that metabolic profiles classification based on MODEL D was mainly driven 
by the lipid biomarkers, which was expected given the large number of biomarkers 
from that metabolic pathway included in the analysis. Moreover, MODEL E, which 
represented the rest of the markers after removing the lipid panel, indicated the 
importance of the enzymes ALT, AST and GGT, common markers of liver disease, 
glucose and iron metabolites when classifying individuals to assess hidden 
heterogeneity based on blood metabolites. Furthermore, more interesting 
scenarios including all the markers and a small subset of the lipids (TC and TG for 
MODEL F and ratio log (TG/HDL) and ratio ApoB/ApoA-1 for MODEL G) indicated 
that lipid markers, liver enzymes and iron metabolites carried the main variability 
within the population. MODEL F allocated the individuals in three independent 




more precisely allocated four subgroups of individuals with diverse metabolic 
profiles each driven by markers related to similar pathways.  
 
For all the models examined, the X2 goodness fit indicator reached a minimum 
facilitating the estimation of the number of classes inherent to each model. 
Multivariate COX regression analysis indicated that the individuals classified within 
the class with abnormal values for the enzymes ALT, AST and GGT presented higher 
risk of overall cancer in comparison with the normal class for three of the models 
studied (Table 14). Figure 39 summarizes the sensitivity analyses results for the four 
models investigated. 
 
Therefore, the sensitivity analyses confirmed that the panel of markers included in 
Model F and Model G were more appropriate to study the population heterogeneity 
hidden in blood metabolites in the AMORIS subcohort, given that markers 
representing the main metabolites were included whilst avoiding an excessive 
burden of the lipids on the analysis. LCA for MODEL G presented a clearer cluster of 
the individuals and the ratios seemed to represent more accurately the internal and 
external component of the lipid pathway (187, 194, 285). 
This model was also supported by a small subanalysis where I characterised the 
study population based on the definition of abnormal clinical values for each of the 
two lipid panels: 
 For definition of clinically abnormal TC & TG: The study population was 
constituted by individuals with high lipids n=5704 (42%) and individuals with 
normal lipids n=7911 (58%)  
 For definition of clinically abnormal ratio log (TG/HDL) and ratio ApoB/ApoA-
1: The study population was defined by individuals with high lipids n=4723 
(35%) and individuals with normal lipids n=8892 (65%) 
 
The AMORIS cohort is characterised by individuals with high lipids representing 32% 
of the population with lipid measurements available and individuals with normal 





Thus, this exploratory multistep approach helped identify an effective risk 
stratification of individuals for cancer whilst allowing for an easy biological/clinical 
interpretation of the results. The following biomarkers, when dichotomised based 
on clinical cut-offs, were found to be the most effective input for the statistical 
pipeline performed in this project: Glucose (mmol/L), Fructosamine (FAMN) 
(mmol/L), ratio log(TG/HDL) and ratio ApoB/ApoA-1, Alanine Amino Transferase 
(ALT) (IU/L), Aspartate Amino Transferase (AST) (IU/L), Gamma-glutamyl transferase 
(GGT) (IU/L), Creatinine (µmol/L), Albumin (g/L), Leukocytes (WBC) (109 cells/L), C-
reactive protein (CRP) (mg/L), Serum Iron (FE) (µmol/L), Total Iron Binding Capacity 
(TIBC) (mg/dL), Phosphate (mmol/L) and Calcium (mmol/L). This definitive scenario, 
MODEL H guarantees the optimal performance of the statistical pipeline proposed 
in this particular setting. 
 
iv. Definitive input model for the statistical pipeline: MODEL H 
Latent Class Analysis characterizes the study population into four metabolic profiles 
based on the above-mentioned Model H (Figure 40A, Figure 40B) (43). The class 
allocation of the observations (individuals), the class conditional probability of each 
biomarker and the latent mixing proportions were obtained when running poLCA 
package in R statistical language. 
 
Table 18 and Figure 41 outline the LCA-derived classes with the estimated class 
population proportions, the class conditional probabilities of belonging to each 
latent class for each of the biomarkers and the biological interpretation of the LCA-
derived classes. Figure 41 was included to allow easier visualisation of the LCA-
derived classes. The four mutually exclusive classes characterised the population 
into metabolic profiles based on class conditional probabilities: (1) those with 
probabilities for all abnormal values of the markers under 0.3; therefore, considered 
the normal class (63% of population); (2) those with abnormal values for lipid 
markers (22%); (3) those with abnormal values for liver function markers (9%); (4) 




illustrates each of the different profiles based on all the abnormal values for the 
markers. 
 
A validation of the characterisation of the population performed with the Latent 
class methodology is outlined in Table 19. The baseline clinical characteristics of the 
individuals by LCA-derived metabolic classes (Table 19) replicate the results 
displayed in Table 18 for the class conditional probabilities. 
 
LCA derived metabolic profiles in relation with cancer and mortality  
I then investigated the capabilities of the four LCA-derived metabolic profiles as 
cancer susceptibility metabolic profiles in relation to overall cancer risk, specific 
cancer types risk, cancer mortality and overall mortality, assigning the reference 
level to the healthy metabolic profile Class 1 (Tables 20 - 21). 
 
All metabolic profiles increased risk of cancer and mortality compared to Class 1. 
For instance, individuals in Class 3 (abnormal liver function profile) had a higher risk 
of overall cancer (HR: 1.28 (95%CI: 1.10- 1.50)), but also a worse cancer-specific 
survival and overall survival as compared to those in Class 1 (Tables 20 – 21). Class 
2 (abnormal lipid profile) and Class 4 (abnormal iron markers and inflammatory) 
were positively associated with overall death, while Class 2 was also associated with 
cancer–specific death. The results were consistent for both time-scales (Tables 20 – 
21). 
 
When assessing the risk of specific cancer types, several patterns occurred (Table 
20).  Individuals in Class 2 (abnormal lipid markers) presented a higher risk of 
lymphatic and hematopoietic tissue cancer (HR: 1.72 (95%CI: 1.15 - 2.56)). There 
was a greater risk of digestive cancers in individuals in Class 3 (abnormal values of 
liver enzymes) (HR: 2.12 (95%CI: 1.54 - 2.91)), while individuals in Class 4 (abnormal 
iron markers and inflammation) were exposed to a higher risk of buccal and oral 
system cancers in comparison with the individuals in Class 1 (HR: 3.94 (95%CI: 1.38 




Moreover, the connective tissue and endocrine glands cancer risk was higher in 
individuals grouped in liver metabolic profile (HR: 2.65 (95%CI: 1.00 - 7.02) and in 
participants belonging to the iron markers and inflammation (HR: 3.00 (95%CI: 1.11 
- 8.11)). Similar associations were observed when using the age scale for the Cox 
regression model (Tables 20 – 21).  
All the Cox analyses were adjusted for age, sex and comorbidities (CCI) using 
calendar-time as a time scale. Models with age as a time scale were adjusted for sex 
and CCI. Education status was excluded in these analyses because of the missing 
values. The test for Schoenfeld residuals showed that the hazard ratios were 
proportional for all the outcomes studied. 
 
C statistics test were conducted for LCA-derived metabolic classes as well as Total 
Cholesterol, Glucose and Gamma Glutamyl Transferase as single biomarkers. These 
models were performed for cancer, cancer death and overall death as an outcome 
using calendar-time as a time scale whilst adjusting for age, sex and CCI. LCA 
metabolic profiles presented very similar, but slightly better prediction capabilities 
than standard health single biomarkers for the three outcomes, especially for cancer 

















Table 6. Characteristics of the study population by cancer status. All the serum markers are 




Total No Cancer Cancer 
N=13,615 (100%) N=11,659 (85.63%) N=1,956 (14.37%) 
Age (years)       
Mean (SD) 51.91 (14.80) 50.86 (15.00) 58.14 (11.75) 
Under 40 2951 (21.67) 2841 (24.37) 110 (5.62) 
40-50 3550 (26.07) 3148 (27.00) 402 (20.55) 
50-60 3065 (22.51) 2491 (21.37) 574 (29.35) 
Above 60 4049 (29.74) 3179 (27.27) 870 (44.48) 
Sex       
Female 7588 (55.73) 6636 (56.92) 952 (48.67) 
Male 6027 (44.27) 5023 (43.08) 1004 (51.33) 
Socio-economics Status       
High 6493 (47.69) 5416 (46.45) 1077 (55.06) 
Low 5007 (36.78) 4368 (37.46) 639 (32.67) 
Not employed or missing 2115 (15.53) 1875 (16.08) 240 (12.27) 
Educational Status       
High 4313 (33.42) 3688 (33.40) 625 (33.57) 
Middle 5495 (42.58) 4725 (42.79) 770 (41.35) 
Low 3097 (24.00) 2630 (23.82) 467 (25.08) 
Missing a 710 (5.21) 616 (5.28) 94 (4.80) 
CCI       
0 12258 (90.03) 10520 (90.23) 1738 (88.85) 
1 963 (7.07) 807 (6.92) 156 (7.98) 
2 221 (1.62) 188 (1.61) 33 (1.69) 
3+ 173 (1.27) 144 (1.24) 29 (1.48) 
Glucose (mmol/L)       
Mean(SD) 5.22 (1.53) 5.21 (1.53) 5.30 (1.53) 
< 6.11 12223 (89.78) 10488 (89.96) 1735 (88.70) 
≥ 6.11 1392 (10.22) 1171 (10.04) 221 (11.30) 
Fructosamine (mmol/L)       
Mean(SD) 2.09 (0.27) 2.08 (0.27) 2.10 (0.25) 
< 2.6 13184 (96.83) 11291 (96.84) 1893 (96.78) 
≥ 2.6 431 (3.17) 368 (3.16) 63 (3.22) 
Total Cholesterol (mmol/L)     
Mean(SD) 5.82 (1.17) 5.79 (1.18) 6.00 (1.13) 
< 6.50 9774 (71.79) 8453 (72.50) 1321 (67.54) 
≥ 6.50 3841 (28.21) 3206 (27.50) 635 (32.46) 
HDL Cholesterol (mmol/L)     




< 1.03 1457 (10.70) 1231 (10.56) 226 (11.55) 
≥ 1.03 12158 (89.30) 10428 (89.44) 1730 (88.45) 
LDL Cholesterol (mmol/L)       
Mean(SD) 3.64 (1.06) 3.61 (1.06) 3.82 (1.04) 
< 4.10 9345 (68.64) 8128 (69.71) 1217 (62.22) 
≥ 4.10 4270 (31.36) 3531 (30.29) 739 (37.78) 
Triglycerides (mmol/L)       
Mean(SD) 1.44 (1.00) 1.43 (1.00) 1.48 (0.93) 
< 1.71 10128 (74.39) 8716 (74.76) 1412 (72.19) 
≥ 1.71 3487 (25.61) 2943 (25.24) 544 (27.81) 
Apolipoprotein A-1 (g/L)       
Mean(SD) 1.44 (0.23) 1.44 (0.23) 1.43 (0.23) 
< 1.05 328 (2.41) 278 (2.38) 50 (2.56) 
≥ 1.05 13287 (97.59) 11381 (97.62) 1906 (97.44) 
Apolipoprotein B (g/L)       
Mean(SD) 1.22 (0.35) 1.22 (0.35) 1.29 (0.34) 
< 1.50 10902 (80.07) 9431 (80.89) 1471 (75.20) 
≥ 1.50 2713 (19.93) 2228 (19.11) 485 (24.80) 
ALT (IU/L)       
Mean(SD) 29.02 (34.35) 28.95 (35.73) 29.41 (24.54) 
< 50 12296 (90.31) 10546 (90.45) 1750 (89.47) 
≥ 50 1319 (9.69) 1113 (9.55) 206 (10.53) 
AST (IU/L)       
Mean(SD) 22.84 (19.23) 22.70 (19.60) 23.64 (16.88) 
< 45 13155 (96.62) 11271 (96.67) 1884 (96.32) 
≥ 45 460 (3.38) 388 (3.33) 72 (3.68) 
GGT (IU/L) *       
Mean(SD) 33.21 (48.12) 32.74 (48.09) 36.03 (48.21) 
Normal (<18) 5511 (40.48) 4827 (41.40) 684 (34.97) 
Normal high (18-36) 4983 (36.60) 4236 (36.33) 747 (38.19) 
Elevated (36-72) 2098 (15.41) 1750 (15.01) 348 (17.79) 
Highly elevated (>72) 1023 (7.51) 846 (7.26) 177 (9.05) 
Creatinine (µmol/L) *       
Mean(SD) 79.65 (16.16) 79.38 (16.37) 81.26 (14.74) 
Low 40 (0.29) 31 (0.27) 9 (0.46) 
Normal 12088 (88.78) 10392 (89.13) 1696 (86.71) 
High 1487 (10.92) 1236 (10.60) 251 (12.83) 
Albumin (g/L)       
Mean(SD) 43.05 (2.82) 43.13 (2.83) 42.58 (2.72) 
<35 28 (0.21) 23 (0.20) 5 (0.26) 
>35 13587 (99.79) 11636 (99.80) 1951 (99.74) 
Leukocytes (109 cells/L)       




<10 12956 (95.16) 11106 (95.26) 1850 (94.58) 
≥ 10 659 (4.84) 553 (4.74) 106 (5.42) 
C-Reactive Protein (mg/L)       
Mean(SD) 5.86 (15.14) 5.82 (14.25) 6.16 (19.58) 
<10 11858 (87.1) 10193 (87.43) 1665 (85.12) 
10- 15 1196 (8.78) 993 (8.52) 203 (10.38) 
15-25 265 (1.95) 223 (1.91) 42 (2.15) 
25-50 200 (1.47) 167 (1.43) 33 (1.69) 
>50 96 (0.71) 223 (0.71) 13 (0.66) 
Iron (µmol/L) *       
Mean(SD) 18.13 (5.80) 18.13 (5.83) 18.11 (5.59) 
Low 636 (4.67) 540 (4.63) 96 (4.91) 
Normal 12512 (91.90) 10715 (91.90) 1797 (91.87) 
High 467 (3.43) 404 (3.47) 63 (3.22) 
TIBC (mg/dL) *       
Mean(SD) 0.39 (0.11) 0.31 (0.11) 0.31 (0.10) 
Low 4067 (29.87) 3494 (29.97) 573 (29.29) 
Normal 6650 (48.84) 5683 (48.74) 967 (49.44) 
High 2898 (21.29) 2482 (21.29) 416 (21.27) 
Phosphate (mmol/L) *       
Mean(SD) 1.07 (0.17) 1.07 (0.17) 1.05 (0.17) 
Low 95 (0.70) 76 (0.65) 19 (0.97) 
Normal 12796 (93.98) 10948 (93.90) 1848 (94.48) 
High 724 (5.32) 635 (5.45) 89 (4.55) 
Calcium (mmol/L) *       
Mean(SD) 2.38 (0.09) 2.38 (0.09) 2.38 (0.10) 
Low 191 (1.40) 167 (1.43) 24 (1.23) 
Normal 13195 (96.92) 11300 (96.92) 1895 (96.88) 
High 229 (1.68) 192 (1.65) 37 (1.89) 
Log (triglycerides/HDL) b       
mean(SD) (-)0.19 (0.81) (-)0.20 (0.82) (-)0.14 (0.80) 
< 0.5 11197 (82.24) 9618 (82.49) 1579 (80.73) 
≥ 0.5 2418 (17.76) 2041 (17.51) 377 (19.27) 
ApoB/ApoA-I b       
mean(SD) 0.87 (0.29) 0.87 (0.29) 0.92 (0.30) 
< 1.00 9584 (70.39) 8347 (71.59) 1237 (63.24) 
≥ 1.00 4031 (29.61) 3312 (28.41) 719 (36.76) 
Life Status       
Alive 10457 (76.80) 9385 (80.50) 1072 (54.81) 
Death 3158 (23.20) 2274 (19.50) 884 (45.19) 
Cancer 1956 (14.90) 11659 (0.00) 1956 (100.00) 
Follow up time (years)       




Death Mean(SD) 17.26 (4.29) 17.40 (4.16) 16.39 (4.89) 
 
The following abbreviations have been used in Table 5: High Density Lipoprotein (HDL), Low Density Lipoprotein 
(LDL), Apolipoprotein A-1 (ApoA), Apolipoprotein B (ApoB), Alanine aminotransferase (ALT), Aspartate 
aminotransferase (AST), Gamma-Glutamyl transferase (GGT) and Total iron binding capacity (TIBC). 
a The missing values are not included in the percentage of the Educational Status categories 
b Ratios are dimensionless 
*Clinical cut-offs 
The following cut-offs criteria was applied: 
GGT reference interval: 
Low [GGT < 36 IU/L] 
Normal [36 IU/L ≥ GGT <72 IU/L] 
High [GGT ≥ 72 IU/L] 
Creatinine reference interval: 
Men [Low ≤ 60, Normal = 60-100, High ≥ 100] 
Women [Low ≤ 45, Norma l= 45-90, High ≥ 90] 
Iron reference interval: 
Men [Low ≤ 11, Normal = 11-31, High ≥ 31] 
Women [Low ≤ 9, Normal = 9-30, High≥ 30] 
TIBC reference interval: 
Men [Low ≤ 0.257, Normal = 0.257-0.379, High ≥ 0.379] 
Women [Low ≤ 0.246, Normal = 0.246- 0.391, High ≥ 0.391] 
Phosphate reference interval: 
Men [Low ≤ 0.7, Normal = 0.7-1.4, High ≥ 1.4] 
Women [Low ≤ 0.8, Normal = 0.8-1.4, High ≥1.4] 
Calcium reference interval per gender by age: 
Men 
[Age < 40, Low ≤ 2.22, Normal = 2.22-2.60, High ≥2.60] 
[Age 40-60, Low ≤ 2.20, Normal = 2.20 -2.59, High ≥2.59] 
[Age > 60, Low ≤ 2.19, Normal= 2.19 -2.58, High ≥ 2.58] 
Women 
[Age < 40, Low ≤ 2.17, Normal = 2.17-2.56, High ≥2.56] 
[Age 40-60, Low ≤2.19, Normal = 2.19-2.60, High ≥2.60] 









Table 7. Descriptive statistics of the data including clinical cut-offs and quartiles. 
Biomarkers Min. 1st Qu. Median Mean 3rd Qu. Max. Cut-off low Cut-off high Units 
Glucose 0.30 4.50 5.00 5.22 5.40 39.90 - 6.10 mmol/L 
Fructosamine 1.22 1.94 2.06 2.09 2.19 6.10 - 2.60 mmol/L 
Total Cholesterol 2.10 5.00 5.80 5.82 6.60 13.20 - 6.50 mmol/L 
HDL 0.02 1.26 1.53 1.54 1.80 6.35 1.30 - mmol/L 
LDL 0.58 2.88 3.58 3.64 4.31 12.50 - 4.10 mmol/L 
Triglycerides 0.20 0.80 1.20 1.44 1.80 17.10 - 1.71 mmol/L 
ApoA 0.42 1.29 1.42 1.44 1.57 2.97 1.05 - mmol/L 
ApoB 0.23 0.96 1.19 1.22 1.43 5.05 - 1.50 mmol/L 
ALT 2.40 16.80 22.80 29.02 32.99 2616.08 - 50.00 IU/L 
AST 3.60 16.20 20.40 22.84 25.19 1238.15 - 45.00 IU/L 
GGT 3.00 14.40 21.00 33.21 34.19 1546.49 - 36 -72 IU/L 
Creatinine 34.00 70.00 78.00 79.65 88.00 656.00 45.00 - 60.00 90.00 - 100.00 µmol/L 
Albumin 25.00 41.00 43.00 43.05 45.00 54.00 35.00 - g/L 
WBC 1.40 5.20 6.20 6.51 7.50 42.50 - 10.00 109cells/L 
CRP 1.00 3.00 4.00 5.87 6.00 720.00 - 10.00 mg/L 
Iron 3.00 14.00 18.00 18.13 21.00 62.00 9.00 - 11.00 30.00 -31.00 µmol/L 
TIBC 0.04 0.24 0.30 0.31 0.37 0.98 0.246 - 0.257 0.379-0.391 mg/dL 
Phosphate 0.40 1.00 1.10 1.07 1.20 3.20 0.70 - 0.80 1.40 mmol/L 
Calcium 2.00 2.31 2.37 2.38 2.44 3.44 2.17- 2.22 2.56-2.60 mmol/L 
*The following abbreviations have been used in Table 6: High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), Apolipoprotein A-1 (ApoA), Apolipoprotein B (ApoB), Alanine 




Figure 30. Histograms of the data distribution for TC. TC presents a normal distribution of the data. 
A) Blue line is the cut-off value, while green lines are the quartiles values. Approximate 30 % of the 





















Figure 31. Histogram of the data distribution for ApoA. ApoA presents a normal distribution. A) The 
clinical cut-offs (blue line) represent less population than the quartiles (green lines). B) Histograms 





















Figure 32. Histogram of the data distribution for Calcium. Calcium presents a normal distribution. A) 
The clinical cut-offs (blue lines) represent less population than the quartiles (green lines). B) 





















Figure 33. Histogram of the data distribution for TG. TG presents a skewed distribution. A) The blue 
line is the cut-off value, while green lines are the quartiles values. Approximately 30 % of the 





















Figure 34. MODEL A. Line-graph depicting the goodness of fit indicators (AIC and BIC) for different 
LCA analysis. Figures A and B show the total population based on biomarkers based on clinical cut-
offs run on R and run on SAS.  Figures C and D show the training and the testing set based on 
biomarkers categorised based on clinical cut-offs run on R. The fit indicators decreased rapidly and 






Figure 35.  MODEL A. Line-graph depicting the goodness of fit indicators (X2) for total population 
based on biomarkers based on clinical cut-offs run on R (same analysis as figure 33a). A minimum is 






Table 8. MODEL A. Class membership probabilities for abnormal clinical values of serum markers for 
LCA two latent class model in the dataset. The numbers represent the probability of having an 
abnormal value for a biomarker in each class. * The clinical cut-offs used are identical to those 
defined in Table 5. 
 
LCA-derived Classes Class 1 Class 2 
% on the population 36% 64% 
Biological interpretation Dyslipidaemia Normal 
Glucose ≥6.11 mmol/L 0.16 0.07 
Fructosamine ≥ 2.60 mmol/L 0.06 0.02 
Total Cholesterol ≥6.50 mmol/L 0.67 0.07 
HDL < 1.03 mmol/L 0.24 0.03 
LDL ≥4.10 mmol/L 0.75 0.07 
Triglycerides ≥1.71 mmol/L 0.50 0.12 
ApoA < 1.05 mmol/L 0.05 0.01 
ApoB ≥ 1.50 mmol/L 0.56 0.00 
ALT ≥ 50 IU/L 0.15 0.07 
AST ≥ 45 IU/L 0.05 0.03 
GGT 18-36 IU/L 0.40 0.35 
GGT 36-72 IU/L 0.23 0.11 
GGT ≥72 IU/L 0.12 0.05 
Creatinine low µmol/L* 0.03 0.07 
Creatinine high µmol/L* 0.27 0.15 
Albumin <35 g/L  0.00 0.00 
WBC ≥109 cells/L  0.07 0.04 
CRP ≥10 mg/L 0.07 0.06 
Iron low µmol/L* 0.04 0.07 
Iron high µmol/L* 0.02 0.04 
TIBC low mg/dL* 0.30 0.31 
TIBC high mg/dL* 0.17 0.23 
Phosphate low mmol/L* 0.02 0.01 
Phosphate high mmol/L* 0.05 0.05 
Calcium low mmol/L* 0.01 0.02 
Calcium high mmol/L* 0.03 0.01 
 
The following abbreviations have been used in Table 7: High Density Lipoprotein (HDL), Low Density Lipoprotein 
(LDL), Apolipoprotein A-1 (ApoA), Apolipoprotein B (ApoB), Alanine aminotransferase (ALT), Aspartate 
aminotransferase (AST), Gamma-Glutamyl transferase (GGT), Leukocytes (WBC), C-Reactive Protein (CRP) and 





Table 9.  MODEL A. Class membership probabilities for abnormal clinical values of serum markers for 
LCA three latent class model in the dataset. The numbers represent the probability of having an 
abnormal value for a biomarker in each class.  * The clinical cut-offs used are identical to those 
defined in Table 5. 
 
LCA-derived Classes Class 1 Class2 Class3 
% on the population 16% 29% 55% 
Biological interpretation Metabolic syndrome Dyslipidaemia Normal 
Glucose ≥6.11 mmol/L 0.25 0.12 0.04 
Fructosamine ≥ 2.60 mmol/L 0.08 0.04 0.01 
Total Cholesterol ≥6.50 mmol/L 0.08 0.86 0.06 
HDL < 1.03 mmol/L 0.39 0.13 0.00 
LDL ≥4.10 mmol/L 0.08 0.96 0.07 
Triglycerides ≥1.71 mmol/L 0.56 0.42 0.08 
ApoA < 1.05 mmol/L 0.11 0.02 0.00 
ApoB ≥ 1.50 mmol/L 0.15 0.62 0.00 
ALT ≥ 50 IU/L 0.34 0.11 0.01 
AST ≥ 45 IU/L 0.13 0.03 0.01 
GGT 18-36 IU/L 0.37 0.40 0.35 
GGT 36-72 IU/L 0.29 0.20 0.09 
GGT ≥72 IU/L 0.21 0.10 0.02 
Creatinine low µmol/L* 0.02 0.04 0.07 
Creatinine high µmol/L* 0.34 0.23 0.13 
Albumin <35 g/L  0.00 0.00 0.00 
WBC ≥109 cells/L  0.07 0.06 0.04 
CRP ≥10 mg/L 0.10 0.06 0.05 
Iron low µmol/L* 0.05 0.03 0.08 
Iron high µmol/L* 0.05 0.02 0.04 
TIBC low mg/dL* 0.30 0.29 0.31 
TIBC high mg/dL* 0.21 0.17 0.23 
Phosphate low mmol/L* 0.02 0.01 0.01 
Phosphate high mmol/L* 0.07 0.05 0.05 
Calcium low mmol/L* 0.02 0.01 0.02 
Calcium high mmol/L* 0.02 0.03 0.01 
 
The following abbreviations have been used in Table 8: High Density Lipoprotein (HDL), Low Density Lipoprotein 
(LDL), Apolipoprotein A-1 (ApoA), Apolipoprotein B (ApoB), Alanine aminotransferase (ALT), Aspartate 
aminotransferase (AST), Gamma-Glutamyl transferase (GGT), Leukocytes (WBC), C-Reactive Protein (CRP) and 






Table 10. MODEL A.  Class membership probabilities for abnormal clinical values of serum markers 
for LCA four latent class model in the dataset. The numbers represent the probability of having an 
abnormal value for a biomarker in each class. * The clinical cut-offs used are identical to those 
defined in Table 5.  
 
LCA-derived Classes Class 1 Class2 Class3 Class 4 
% on the population 12% 19% 19% 50% 
Biological interpretation Dyslipidaemia Dyslipidaemia Dyslipidaemia Normal 
Glucose ≥6.11 mmol/L 0.23 0.06 0.23 0.04 
Fructosamine ≥ 2.60 mmol/L 0.09 0.01 0.07 0.01 
Total Cholesterol ≥6.50 mmol/L 0.74 0.83 0.08 0.04 
HDL < 1.03 mmol/L 0.39 0.00 0.29 0.00 
LDL ≥4.10 mmol/L 0.77 0.97 0.09 0.03 
Triglycerides ≥1.71 mmol/L 0.82 0.17 0.45 0.07 
ApoA < 1.05 mmol/L 0.04 0.00 0.10 0.00 
ApoB ≥ 1.50 mmol/L 0.92 0.42 0.02 0.00 
ALT ≥ 50 IU/L 0.23 0.03 0.32 0.00 
AST ≥ 45 IU/L 0.06 0.00 0.12 0.00 
GGT 18-36 IU/L 0.39 0.40 0.38 0.34 
GGT 36-72 IU/L 0.30 0.14 0.28 0.07 
GGT ≥72 IU/L 0.19 0.04 0.19 0.01 
Creatinine low µmol/L* 0.03 0.04 0.02 0.07 
Creatinine high µmol/L* 0.32 0.17 0.33 0.12 
Albumin <35 g/L  0.00 0.00 0.00 0.00 
WBC ≥109 cells/L  0.08 0.05 0.07 0.03 
CRP ≥10 mg/L 0.07 0.05 0.11 0.05 
Iron low µmol/L* 0.03 0.04 0.05 0.08 
Iron high µmol/L* 0.02 0.02 0.05 0.04 
TIBC low mg/dL* 0.32 0.29 0.29 0.32 
TIBC high mg/dL* 0.14 0.20 0.22 0.23 
Phosphate low mmol/L* 0.02 0.01 0.02 0.01 
Phosphate high mmol/L* 0.06 0.03 0.07 0.05 
Calcium low mmol/L* 0.01 0.01 0.02 0.02 
Calcium high mmol/L* 0.04 0.02 0.02 0.01 
 
The following abbreviations have been used in Table 9: High Density Lipoprotein (HDL), Low Density Lipoprotein 
(LDL), Apolipoprotein A-1 (ApoA), Apolipoprotein B (ApoB), Alanine aminotransferase (ALT), Aspartate 
aminotransferase (AST), Gamma-Glutamyl transferase (GGT), Leukocytes (WBC), C-Reactive Protein (CRP) and 





Figure 36.  MODEL B. Line-graph depicting the goodness of fit indicators (AIC, BIC (A) and X2 (B)) for 
LCA of the total population based on biomarkers categorised based on standardised quartiles run on 























Table 11. MODEL B. Class membership probabilities of the serum markers in a LCA for 2 latent classes 
for standardised quartiles values of the biomarkers run in R.  The numbers represent the probability 
of having an abnormal value for a biomarker in each class. Marked quartiles in red represent clinical 
abnormal values. 
 
LCA-derived Classes Class 1 Class 2 
% on the population 51% 49% 
Biological interpretation High lipids profile Low lipids profile 
Glucose 1st quartile 0.18 0.33 
Glucose 2nd quartile 0.28 0.34 
Glucose 3rd quartile 0.21 0.17 
Glucose 4th quartile 0.33 0.16 
Total Cholesterol 1st quartile 0.07 0.47 
Total Cholesterol 2nd quartile 0.14 0.25 
Total Cholesterol 3rd quartile 0.34 0.22 
Total Cholesterol 4th quartile 0.45 0.06 
HDL  1st quartile 0.42 0.07 
HDL 2nd quartile 0.3 0.2 
HDL 3rd quartile 0.19 0.32 
HDL 4th quartile 0.1 0.41 
LDL  1st quartile 0.05 0.46 
LDL 2nd quartile 0.16 0.34 
LDL 3rd quartile 0.32 0.18 
LDL  4th quartile 0.46 0.03 
Triglycerides 1st quartile 0.09 0.5 
Triglycerides 2nd quartile 0.21 0.29 
Triglycerides 3rd quartile 0.26 0.14 
Triglycerides 4th quartile 0.44 0.06 
ApoA 1st quartile 0.36 0.15 
ApoA 2nd quartile 0.28 0.22 
ApoA 3rd quartile 0.21 0.25 
ApoA 4th quartile 0.14 0.37 
ApoB 1st quartile 0.01 0.5 
ApoB 2nd quartile 0.15 0.36 
ApoB 3rd quartile 0.34 0.13 
ApoB 4th quartile 0.49 0.01 
 
The following abbreviations have been used in Table 10: High Density Lipoprotein (HDL), Low Density 




Table 12. MODEL B.   Class membership probabilities of the serum markers in a LCA for 3 latent classes 
for standardised quartiles values of the biomarkers run in R. The numbers represent the probability 
of having an abnormal value for a biomarker in each class.  Marked quartiles in red represent clinical 
abnormal values. 
 
LCA-derived Classes Class 1 Class2 Class3 
% on the population 34% 37% 28% 
Biological 
interpretation 
High lipids profile Low lipids profile Normal 
Glucose 1st quartile 0.17 0.34 0.23 
Glucose 2nd quartile 0.28 0.34 0.3 
Glucose 3rd quartile 0.21 0.17 0.19 
Glucose 4th quartile 0.33 0.15 0.28 
TC 1st quartile 0.01 0.49 0.3 
TC 2nd quartile 0.05 0.22 0.35 
TC 3rd quartile 0.29 0.23 0.34 
TC 4th quartile 0.66 0.07 0.01 
HDL 1st quartile 0.39 0.02 0.38 
HDL 2nd quartile 0.25 0.14 0.4 
HDL 3rd quartile 0.21 0.31 0.22 
HDL 4th quartile 0.15 0.52 0 
LDL 1st quartile 0.01 0.51 0.19 
LDL 2nd quartile 0.05 0.31 0.41 
LDL 3rd quartile 0.26 0.16 0.36 
LDL 4th quartile 0.67 0.03 0.03 
TG 1st quartile 0.08 0.55 0.2 
TG 2nd quartile 0.19 0.28 0.28 
TG 3rd quartile 0.25 0.12 0.26 
TG 4th quartile 0.49 0.05 0.25 
ApoA 1st quartile 0.29 0.09 0.46 
ApoA 2nd quartile 0.26 0.19 0.34 
ApoA 3rd quartile 0.23 0.25 0.19 
ApoA 4th quartile 0.22 0.47 0.01 
ApoB 1st quartile 0 0.56 0.14 
ApoB 2nd quartile 0.02 0.33 0.45 
ApoB 3rd quartile 0.25 0.11 0.4 
ApoB 4th quartile 0.73 0.01 0.01 
The following abbreviations have been used in Table 11: Total Cholesterol (TC), High Density Lipoprotein (HDL), 




Figure 37. MODEL C. Line-graph depicting the goodness of fit indicator BIC for LCA of the total 
population based on standardised continuous data (A) and continuous data (B) on MCLUST R. 9 
classes indicated the best model for standardised continuous data (red arrow) while continuous 
show a BIC maximum with only one class (red arrow). This LCA implementation on MCLUST allowed 
for testing of multiple different data distribution models represented by the letters in the box on the 













Figure 38. Line-graph depicting the goodness of fit indicator X2 for LCA of the total population using 
biomarkers dichotomised based on clinical cut-offs run on R for MODEL D (A), MODEL E (B), MODEL 
F (C) and MODEL G (D). A minimum is indicated with a red arrow. 
                                                                      
 
 























Table 13. MODEL D.  Class membership probabilities of the serum markers in a LCA for 4 latent classes. 
The numbers represent the probability of having an abnormal value for a biomarker in each class.              
* The clinical cut-offs used are identical to those defined in Table 5.   
 
LCA-derived Classes class 1 class 2 class 3 Class 4 
% on the population 12% 16% 20% 52% 
Biological interpretation Liver Dyslipidaemia Dyslipidaemia Normal 
Glucose ≥6.11 mmol/L 0.2272 0.2089 0.0735 0.0467 
Fructosamine ≥ 2.60 mmol/L 0.0644 0.0799 0.0184 0.0128 
TC ≥6.50 mmol/L 0.1238 0.5482 0.8235 0.038 
HDL < 1.03 mmol/L 0.1039 0.5498 0 0.0075 
LDL ≥4.10 mmol/L 0.0607 0.6104 0.9711 0.0412 
Triglycerides ≥1.71 mmol/L 0.5569 0.7996 0.1625 0.0409 
ApoA-I < 1.05 mmol/L 0.0221 0.1101 0 0.0064 
ApoB ≥ 1.50 mmol/L 0.0715 0.6088 0.4719 0.0016 
ApoB/ApoA-I ≥ 1.00 0.1636 0.9231 0.5375 0.0424 
Total cholesterol/HDL ≥ 5.00 0.1122 0.9844 0.1732 0.001 
LDL/HDL ≥ 3.50 0.0056 0.8853 0.2013 0.0005 
Log (triglycerides/HDL) ≥ 0.5 0.3553 0.7832 0.0158 0 
ALT ≥ 50 IU/L 0.3836 0.1865 0.055 0.0097 
AST ≥ 45 IU/L 0.1614 0.0474 0.0128 0.0042 
GGT Elevated36-72 IU/L 0.285 0.2616 0.1611 0.0835 
GGT Highly elevated ≥72 IU/L 0.2391 0.1447 0.0573 0.0172 
Creatinine low µmol/L* 0.0062 0.0023 0 0.0034 
Creatinine high µmol/L* 0.1262 0.1721 0.1224 0.08 
Albumin <35 g/L  0.0025 0.0049 0.0016 0.0012 
WBC ≥109 cells/L  0.062 0.0832 0.0481 0.034 
CRP ≥10 mg/L  0.1167 0.0878 0.043 0.0461 
Iron low µmol/L* 0.0575 0.0528 0.024 0.0504 
Iron high µmol/L* 0.0635 0.0188 0.0199 0.037 
TIBC low mg/dL* 0.311 0.3388 0.2599 0.2973 




Phosphate low mmol/L* 0.0068 0.0056 0.0053 0.0081 
Phosphate high mmol/L* 0.0845 0.0654 0.0342 0.0482 
Calcium low mmol/L* 0.016 0.0122 0.0076 0.0165 
Calcium high mmol/L* 0.025 0.0254 0.0193 0.0111 
 
The following abbreviations have been used in Table 12: Total Cholesterol (TC), High Density Lipoprotein 
(HDL), Low Density Lipoprotein (LDL), Apolipoprotein A-1 (ApoA), Apolipoprotein B (ApoB), Alanine 
aminotransferase (ALT), Aspartate aminotransferase (AST), Gamma-Glutamyl transferase (GGT), Leukocytes 






Table 14.  Hazard ratios and 95 % confidence interval for the association of LCA-derived metabolic 
classes and overall cancer risk crude and adjusted analysis using calendar-time as a time scale for 




HR (95% CI) crude 
HR (95% CI)  adjusted for Age, 
Sex, CCI and Education Status 
  MODEL D: All Lipids     
Normal (52%) 1.00 (ref) 1.00 (ref) 
Dyslipidaemia (20%) 1.44 (1.27 - 1.63) 1.10 (0.97 -1.26) 
Dyslipidaemia (16%) 1.49 (1.33 - 1.67) 1.02 (0.90 - 1.14) 
Liver (12%) 1.40 (1.25 - 1.61) 1.19 (1.02 - 1.37) 
  MODEL E: No Lipids     
Normal (78%) 1.00 (ref) 1.00 (ref) 
Liver (15%) 1.15 (1.02 - 1.30) 1.06 (0.93 - 1.21) 
Iron (7%) 1.11 (0.93 - 1.32) 1.09 (0.91 - 1.30) 
  MODEL F: TG TC     
Normal (68%) 1.00 (ref) 1.00 (ref) 
Liver & Lipids (25%) 1.32 (1.19 - 1.45) 1.16 (1.04 - 1.28) 
Iron (7%) 1.19 (0.99 - 1.42) 1.17 (0.97 - 1.40) 
MODEL G: Lipid ratios     
Normal (63%) 1.00 (ref) 1.00 (ref) 
Lipids (23%) 1.36 (1.22- 1.51) 1.10 (0.98 - 1.23) 
Liver (9%) 1.26 (1.08 -1.47) 1.29 (1.10 - 1.52) 










Table 15. MODEL E. Class membership probabilities of the serum markers in a LCA for 3 latent classes.  
The numbers represent the probability of having an abnormal value for a biomarker in each class.     
*The clinical cut-offs used are identical to those defined in Table 5.  
 
LCA-derived Classes class 1 class 2 class 3 
% on the population 7% 78% 15% 
Biological interpretation Low iron Normal Liver 
Glucose ≥6.11 mmol/L 0.1221 0.0506 0.2938 
Fructosamine ≥ 2.60 mmol/L 0.0409 0.0112 0.1066 
ALT ≥ 50 IU/L 0.0476 0 0.4989 
AST ≥ 45 IU/L 0.0223 0.0028 0.1603 
GGT Elevated36-72 IU/L 0.193 0.0956 0.3627 
GGT Highly elevated ≥72 IU/L 0.0737 0.0132 0.3171 
Creatinine low µmol/L* 0.005 0.0023 0.0043 
Creatinine high µmol/L* 0.1171 0.1007 0.1386 
Albumin <35 g/L  0.0103 0.0012 0.0015 
WBC ≥109 cells/L  0.1436 0.0349 0.054 
CRP ≥10 mg/L  0.2611 0.0337 0.0724 
Iron low µmol/L* 0.4953 0 0.007 
Iron high µmol/L* 0 0.032 0.0601 
TIBC low mg/dL* 0.9974 0.2271 0.2325 
TIBC high mg/dL* 0.0007 0.2212 0.2852 
Phosphate low mmol/L* 0.008 0.0069 0.0069 
Phosphate high mmol/L* 0.1122 0.0454 0.0541 
Calcium low mmol/L* 0.0418 0.0112 0.0114 
Calcium high mmol/L* 0.0143 0.0138 0.0297 
 
The following abbreviations have been used in Table 14: Alanine aminotransferase (ALT), Aspartate 
aminotransferase (AST), Gamma-Glutamyl transferase (GGT), Leukocytes (WBC), C-Reactive Protein (CRP) and 







Table 16.  MODEL F.  Class membership probabilities of the serum markers in a LCA for 3 latent classes. 
The numbers represent the probability of having an abnormal value for a biomarker in each class.     
*The clinical cut-offs used are identical to those defined in Table 5. 
 
LCA-derived Classes class 1 class 2 class 3 
% on the population 68% 25% 7% 
Biological interpretation Normal Liver and Lipids Iron 
Glucose ≥6.11 mmol/L 0.0344 0.2592 0.1095 
Fructosamine ≥ 2.60 mmol/L 0.007 0.0878 0.0368 
Total cholesterol ≥6.50 mmol/L 0.231 0.4314 0.1862 
Triglycerides ≥1.71 mmol/L 0.1354 0.5477 0.2289 
AST ≥ 45 IU/L 0.0024 0.109 0.0288 
ALT ≥ 50 IU/L 0 0.3348 0.0623 
GGT Elevated36-72 IU/L 0.0677 0.3476 0.1838 
GGT Highly elevated ≥72 IU/L 0.0053 0.2389 0.0751 
Creatinine low µmol/L* 0.0024 0.0035 0.0052 
Creatinine high µmol/L* 0.0935 0.144 0.116 
Albumin <35 g/L  0.001 0.0016 0.0114 
WBC ≥109 cells/L  0.0313 0.0595 0.143 
CRP ≥10 mg/L  0.03 0.0707 0.2749 
Iron low µmol/L* 0.0002 0.0025 0.5467 
Iron high µmol/L* 0.033 0.0479 0 
TIBC low mg/dL* 0.2312 0.2425 0.9982 
TIBC high mg/dL* 0.2242 0.2515 0 
Phosphate low mmol/L* 0.0067 0.0072 0.0086 
Phosphate high mmol/L* 0.0433 0.0585 0.1112 
Calcium low mmol/L* 0.012 0.0089 0.0461 
Calcium high mmol/L* 0.012 0.0293 0.0128 
 
The following abbreviations have been used in Table 15: Alanine aminotransferase (ALT), Aspartate 
aminotransferase (AST), Gamma-Glutamyl transferase (GGT), Leukocytes (WBC), C-Reactive Protein (CRP) and 




Table 17. MODEL G.  Class membership probabilities of the serum markers in a LCA for 4 latent classes. 
The numbers represent the probability of having an abnormal value for a biomarker in each class.     
*The clinical cut-offs used are identical to those defined in Table 5. 
 
LCA-derived Classes Class 1 Class 2 Class 3 Class 4 
% on the population 63% 23% 9% 6% 
Biological interpretation Normal Lipids Liver Iron 
Glucose ≥6.11 mmol/L 0.0342 0.2401 0.2174 0.0919 
Fructosamine ≥ 2.60 mmol/L 0.0039 0.0967 0.0555 0.028 
ApoB/ApoA-I ≥ 1.00 0.132 0.684 0.4519 0.248 
Log (Triglycerides/HDL) ≥ 0.50 0.0126 0.5436 0.3852 0.1421 
AST ≥ 45 IU/L 0.0052 0.0045 0.3168 0.018 
ALT ≥ 50 IU/L 0.0051 0.0107 1 0.0291 
GGT Elevated36-72 IU/L 0.0848 0.2532 0.3521 0.1732 
GGT Highly elevated ≥72 IU/L 0.024 0.0843 0.4098 0.0619 
Creatinine low µmol/L* 0.0022 0.0037 0.0041 0.0051 
Creatinine high µmol/L* 0.0822 0.1765 0.1166 0.1116 
Albumin <35 g/L  0.0007 0.0022 0.0024 0.0114 
WBC ≥109 cells/L  0.0265 0.0786 0.0438 0.1344 
CRP ≥ 10 mg/L  0.0282 0.0715 0.0771 0.274 
Iron low µmol/L* 0.0001 0.004 0.0281 0.5527 
Iron high µmol/L* 0.0404 0.0155 0.0712 0 
TIBC low mg/dL* 0.2201 0.2807 0.2622 1 
TIBC high mg/dL* 0.2438 0.1707 0.2984 0 
Phosphate low mmol/L* 0.0078 0.0041 0.0063 0.0098 
Phosphate high mmol/L* 0.0425 0.0611 0.0544 0.111 
Calcium low mmol/L* 0.0124 0.0092 0.0099 0.0458 
Calcium high mmol/L* 0.0121 0.0253 0.0299 0.0135 
 
The following abbreviations have been used in Table 16: High Density Lipoprotein (HDL), Apolipoprotein A-1 
(ApoA), Apolipoprotein B (ApoB), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Gamma-











Figure 40. Line-graph depicting the goodness of fit indicators AIC, BIC (A) and X2 (B) for LCA of the 
total population using biomarkers dichotomised based on clinical cut-offs run on R for MODEL H. A 






















Table 18.  MODEL H. Predicted class memberships of the clinically abnormal biomarkers cut-off values 
for the estimated class population shares for the four different LCA classes. The numbers represent 
the probability of having an abnormal value for a biomarker in each class. *The clinical cut-offs used 
are identical to those defined in Table 5. 
 
LCA-derived Classes Class 1 Class 2 Class 3 Class 4 
% on the population 63% 22% 9% 6% 
Biological interpretation Normal Lipids Liver Iron/ Inflammation 
Glucose ≥6.11 mmol/L 0.0342 0.2401 0.2174 0.0919 
Fructosamine ≥ 2.60 mmol/L 0.0039 0.0967 0.0555 0.028 
ApoB/ApoA-I ≥ 1.00  0.132 0.684 0.4519 0.248 
Log (Triglycerides/HDL) ≥ 
0.50  
0.0126 0.5436 0.3852 0.1421 
ALT ≥ 50 IU/L 0.0051 0.0107 1 0.0291 
AST ≥ 45 IU/L 0.0052 0.0045 0.3168 0.018 
GGT Elevated36-72 IU/L 0.0848 0.2532 0.3521 0.1732 
GGT Highly elevated ≥72 IU/L 0.024 0.0843 0.4098 0.0619 
Creatinine low µmol/L* 0.0022 0.0037 0.0041 0.0051 
Creatinine high µmol/L* 0.0822 0.1765 0.1166 0.1116 
Albumin <35 g/L 0.0007 0.0022 0.0024 0.0114 
WBC ≥ 109 cells/L 0.0265 0.0786 0.0438 0.1344 
CRP ≥10 mg/L 0.0282 0.0715 0.0771 0.274 
Iron low µmol/L* 0.0001 0.004 0.0281 0.5527 
Iron high µmol/L* 0.0404 0.0155 0.0712 0 
TIBC low mg/dL* 0.2201 0.2807 0.2622 1 
TIBC high mg/dL* 0.2438 0.1707 0.2984 0 
Phosphate low mmol/L* 0.0078 0.0041 0.0063 0.0098 
Phosphate high mmol/L* 0.0425 0.0611 0.0544 0.111 
Calcium low mmol/L* 0.0124 0.0092 0.0099 0.0458 
Calcium high mmol/L* 0.0121 0.0253 0.0299 0.0135 
 
The following abbreviations have been used in Table 16: High Density Lipoprotein (HDL), Apolipoprotein A-1 
(ApoA), Apolipoprotein B (ApoB), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Gamma-




Figure 41. MODEL H. Class Membership Probabilities for abnormal clinical values of the serum markers for the four LCA – derived metabolic classes.  The four 






Table 19. Characteristics of the study population by LCA-derived metabolic classes based on MODEL 
H. All the serum markers are dichotomized using the standardized clinical cut-offs. Clinically abnormal 
cut-off values are highlighted for each biomarker. *The clinical cut-offs used are identical to those 







Class 2 Lipids 
N=2936 
(21.56%) 






Age (years)         
Mean(SD) 51.25 (15.46) 55.17 (13.04) 48.98 (12.34) 51.71 (15.21) 
Under 40  2126 (24.69) 360 (12.26) 295 (23.38) 170 (21.12) 
40-50 2192 (25.45) 699 (23.81) 415 (32.88) 244 (30.31) 
50-60  1779 (20.66) 813 (27.69) 313 (24.80) 160 (19.88) 
Above 60 2515 (29.20) 1064 (36.24) 239 (18.94) 231 (28.70) 
Sex         
Female 5742 (66.67) 1076 (36.65) 320 (25.36) 450 (55.90) 
Male  2870 (33.33) 1860 (63.35) 942 (74.64) 355 (44.10) 
Socio-economics Status       
High 3959 (45.97) 1515 (51.60) 672 (53.25) 347 (43.11) 
Low 3257 (37.82) 972 (33.11) 466 (36.93) 312 (38.76) 
Not employed or missing 1396 (16.21) 449 (15.29) 124 (9.83) 146 (18.14) 
Educational Status         
High 2846 (34.91) 840 (30.26) 388 (32.17) 239 (31.04) 
Middle 3525 (43.24) 1156 (41.64) 498 (41.29) 316 (41.04) 
Low 1782 (21.86) 780 (28.10) 320 (26.53) 215 (27.92) 
Missing +  459 (5.33) 160 (5.45) 56 (4.44) 35(4.35) 
CCI         
0 7959 (92.42) 2497 (85.05) 1113 (88.19) 689 (85.59) 
1 495 (5.75) 294 (10.01) 103 (8.16) 71 (8.82) 
2 101 (1.17) 71 (0.52) 24 (1.90) 25 (3.11) 
3+ 57 (0.66) 74 (0.54) 22 (1.74) 20 (2.48) 
Glucose (mmol/L)         
Mean(SD) 4.89 (0.75) 5.96 (2.29) 5.80 (2.18) 5.26 (1.87) 
< 6.11 8316 (96.56) 2188 (74.52) 989 (78.37) 730 (90.68) 
≥ 6.11 296 (3.44) 748 (25.48) 273 (21.63) 75 (9.32) 
Fructosamine (mmol/L)       
Mean(SD) 2.04 (0.18) 2.22 (0.37) 2.15 (0.34) 2.05 (0.28) 
< 2.6 8597 (99.83) 2619 (89.20) 1191 (94.37) 777 (96.52) 
≥ 2.6 15 (0.17) 317 (10.80) 71 (5.63) 28 (3.48) 
Total Cholesterol (mmol/L)       
Mean(SD) 5.62 (1.10) 6.43 (1.13) 5.99 (1.26) 5.42 (1.14) 
< 6.50 6753 (78.41) 1530 (52.11) 837 (66.32) 654 (81.24) 
≥ 6.50 1859 (21.59) 1406 (47.89) 425 (33.68) 151 (18.76) 
HDL Cholesterol (mmol/L)        
Mean(SD) 1.69 (0.36) 1.18 (0.39) 1.32 (0.42) 1.50 (0.40) 
< 1.03 144 (1.67) 950 (32.36) 272 (21.55) 91 (11.30) 
≥ 1.03 8468 (98.33) 1986 (67.64) 990 (78.45) 714 (88.70) 
LDL Cholesterol (mmol/L)        
Mean(SD) 3.45 (0.98) 4.21 (1.06) 3.79 (1.09) 3.38 (1.05) 




≥ 4.10 2061 (23.93) 1574 (53.61) 457 (36.21) 178 (22.11) 
Triglycerides (mmol/L)       
Mean(SD) 1.06 (0.47) 2.35 (1.25) 1.99 (1.32) 1.33 (0.84) 
< 1.71 7843 (91.07) 993 (33.82) 653 (51.74) 639 (79.38) 
≥ 1.71 769 (8.93) 1943 (66.18) 609 (48.26) 166 (20.62) 
Apolipoprotein A-1 (g/L)       
Mean(SD) 1.48 (0.22) 1.33 (0.20) 1.38 (0.22) 1.40 (0.22) 
< 1.05 88 (1.02) 157 (5.35) 52 (4.12) 31 (3.85) 
≥ 1.05 8524 (98.98) 2779 (94.65) 1210 (95.88) 774 (96.15) 
Apolipoprotein B (g/L)       
Mean(SD) 1.11 (0.29) 1.52 (0.34) 1.34 (0.38) 1.14 (0.33) 
< 1.50 7828 (90.90) 1499 (51.06) 875 (69.33) 700 (86.96) 
≥ 1.50 784 (9.10) 1437 (48.94) 387 (30.67) 105 (13.04) 
Log (triglycerides/HDL) c       
mean(SD) (-)0.54 (0.53) 0.63 (0.79) 0.29 (0.87) (-)0.23 (0.75) 
< 0.5 8576 (99.58) 1166 (39.71) 770 (61.01) 685 (85.09) 
≥ 0.5 36 (0.42) 1770 (60.29) 492 (38.99) 120 (14.91) 
ApoB/ApoA-I c         
mean(SD) 0.76 (0.22) 1.15 (0.28) 0.99 (0.31) 0.83 (0.28) 
< 1.00 7582 (88.04) 699 (23.81) 683 (54.12) 620 (77.02) 
≥ 1.00 1030 (11.96) 2237 (76.19) 579 (45.88) 185 (22.98) 
AST (IU/L)         
Mean(SD) 20.05 (6.55) 21.24 (6.49) 46.41 (52.16) 21.61 (20.46) 
< 45 8565 (99.45) 2925 (99.63) 876 (69.41) 789 (98.01) 
≥ 45 47 (0.55) 11 (0.37) 386 (30.59) 16 (1.99) 
ALT (IU/L)         
Mean(SD) 21.60 (9.35) 28.32 (10.02) 84.71 (91.11) 23.59 (12.90) 
< 50 8578 (99.61) 2936 (100.00) 0 (0.00) 782 (97.14) 
≥ 50 34 (0.39) 0 (0.00) 1262 (100.00) 23 (0.17) 
GGT (IU/L)         
Mean(SD) 22.93 (23.71) 38.18 (31.99) 93.70 (117.85) 30.24 (26.33) 
Normal (<18) 4713 (54.73) 447 (15.22) 33 (2.61) 318 (39.50) 
Normal high (18-36) 2959 (34.36) 1453 (49.49) 284 (22.50) 287 (35.65) 
Elevated (36-72) 731 (8.49) 780 (26.57) 442 (35.02) 145 (18.01) 
Highly elevated (>72) 209 (2.43) 256 (8.72) 503 (39.86) 55 (6.83) 
Creatinine (µmol/L)   
Mean(SD) 77.42 (15.03) 84.80 (17.99) 83.17 (13.92) 79.22 (18.58) 
Low 20 (0.23) 11 (0.37) 5 (0.40) 4 (0.50) 
Normal 7863 (91.30) 2412 (82.15) 1108 (87.80) 705 (87.58) 
High 729 (8.46) 513 (17.47) 149 (11.81) 96 (11.93) 
Albumin (g/L)         
Mean(SD) 42.98 (2.71) 43.14 (2.72) 44.09 (3.01) 41.79 (3.31) 
<35 6 (0.07) 7 (0.24) 3 (0.24) 12 (1.49) 
>35 8606 (99.93) 2929 (99.76) 1259 (99.76) 793 (98.51) 
Leukocytes (109 cells/L)       
Mean(SD) 6.24 (1.79) 6.89 (1.99) 6.55 (2.14) 7.56 (2.64) 
<10 8374 (97.24) 2703 (92.06) 1206 (95.56) 673 (83.60) 
≥ 10  238 (2.76) 233 (7.94) 56 (4.44) 132 (16.40) 
C-Reactive Protein (mg/L)       
Mean(SD) 4.99 (15.41) 5.51 (12.17) 5.78 (7.53) 16.63 (24.12) 
<10 7764 (90.15) 2557 (87.09) 1095 (86.77) 442 (54.91) 
10 15 717 (8.33) 265 (9.03) 106 (8.40) 108 (13.42) 




25-50 48 (0.56) 31 (1.06) 23 (1.82) 98 (12.17) 
>50 21 (0.24) 5 (0.17) 5 (0.40) 65 (8.07) 
Iron (µmol/L)         
Mean(SD) 18.77 (5.43) 17.99 (4.70) 20.00 (6.65) 8.86 (2.79) 
Low 1 (0.01) 4 (0.14) 36 (2.85) 595 (73.91) 
Normal 8276 (96.10) 2888 (98.37) 1138 (90.17) 210 (26.09) 
High 335 (3.89) 44 (1.50) 88 (6.97) 0 (0.00) 
TIBC (mg/dL)         
Mean(SD) 0.32 (0.10) 0.30 (0.09) 0.33 (0.12) 0.15 (0.05) 
Low 2050 (23.80) 877 (29.87) 335 (26.55) 805 (100.00) 
Normal 4490 (52.14) 1603 (54.60) 557 (44.14) 0 (0.00) 
High 2072 (24.06) 456 (15.53) 370 (29.32) 0 (0.00) 
Phosphate (mmol/L)  
Mean(SD) 1.07 (0.16) 1.06 (0.18) 1.07 (0.19) 1.10 (0.19) 
Low 70 (0.81) 7 (0.24) 8 (0.63) 10 (1.24) 
Normal 8160 (94.75) 2750 (93.66) 1185 (93.90) 701 (87.08) 
High 382 (4.44) 179 (6.10) 69 (5.47) 94 (11.68) 
Calcium (mmol/L)         
Mean(SD) 2.37 (0.09) 2.39 (0.10) 2.40 (0.10) 2.35 (0.10) 
Low 110 (1.28) 26 (0.89) 13 (1.03) 42 (5.22) 
Normal 8394 (97.47) 2838 (96.66) 1212 (96.04) 751 (93.29) 
High 108 (1.25) 72 (2.45) 37 (2.93) 12 (1.49) 
Life Status         
Alive 6815 (79.13) 2066 (70.37) 973 (77.10) 603 (74.91) 
Death  1797 (20.87) 870 (29.63) 289 (22.90) 202 (25.09) 
Cancer 1148 (13.33) 490 (16.69) 197 (15.61) 121 (15.03) 
 
The following abbreviations have been used in Table 1: High Density Lipoprotein (HDL), Low Density Lipoprotein 
(LDL), Apolipoprotein A-1 (ApoA), Apolipoprotein B (ApoB), Gamma-Glutamyl transferase (GGT), Alanine 
aminotransferase (ALT), Aspartate aminotransferase (AST) and Total iron binding capacity (TIBC). 





















Table 20. MODDEL H. Hazard ratios and 95 % confidence interval for the association of LCA-derived 
metabolic classes and overall cancer risk and cancer specific risk. 
 
 Hazard Ratios (95% CI) a Hazard Ratios (95% CI) b 
Cancer Risk: All cancer types   
Number of events 1,956 1,956 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 1.09 (0.98 - 1.22) 1.05 (0.94 - 1.17) 
3 - Liver 1.28 (1.10 - 1.50) 1.28 (1.09 - 1.49) 
4 – Inflammation & Iron 1.17 (0.97 - 1.41) 1.17 (0.97 - 1.41) 
Cancer Risk: Buccal cavity and 
pharynx 
  
Number of events 34 34 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 1.79 (0.77 - 4.14) 1.70 (0.73 - 1.17) 
3 - Liver 2.66 (0.96 - 7.35) 2.60 (0.94 - 7.16) 
4 - Inflammation & Iron 3.94 (1.38 - 11.30) 3.77 (1.31 - 10.82) 
Cancer Risk: Digestive organs and peritoneum  
Number of events 330 330 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 0.83 (0.62 - 1.11) 0.83 (0.62 - 1.11) 
3 - Liver 2.12 (1.54 - 2.91) 2.12 (1.54 - 2.91) 
4 - Inflammation & Iron 0.86 (0.51 - 1.46) 0.86 (0.51 - 1.46) 
Cancer Risk: Respiratory system   
Number of events 133 133 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 1.40 (0.94 - 2.08) 1.32 (0.88 -1.96) 
3 - Liver 0.90 (0.44 - 1.82) 0.87 (0.43 - 1.77) 
4 - Inflammation & Iron 1.48 (0.76 - 2.88) 1.46 (0.75 - 2.84) 
Cancer Risk: Skin melanoma   
Number of events 205 205 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 0.78 (0.56 - 1.10) 0.78 (0.56 - 1.11) 
3 - Liver 0.71 (0.40 - 1.26) 0.73 (0.41 - 1.31) 
4 - Inflammation & Iron 0.70 (0.35 - 1.37) 0.70 (0.35 - 1.37) 
Cancer Risk: Breast and genito-
urinary organs 
  
Number of events 655 655 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 1.19 (0.99 - 1.42) 1.12 (0.94 - 1.33) 
3 - Liver 1.04 (0.80 - 1.37) 1.04 (0.80 - 1.37) 




Cancer Risk: Brain & nervous system, Thyroids  
Number of events 34 34 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 1.01 (0.51 - 1.99) 0.96 (0.48 - 1.00) 
3 - Liver 1.01 (0.38 - 2.67) 0.99 (0.38 - 2.59) 
4 - Inflammation & Iron 0.92 (0.28 - 2.99) 0.91 (0.28 - 2.96) 
Cancer Risk: Connective and endocrine tissue  
Number of events 56 56 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 0.65 (0.21 - 1.95) 0.64 (0.21 - 1.94) 
3 - Liver 2.65 (1.00 - 7.02) 2.67 (1.01 - 7.07) 
4 - Inflammation & Iron 3.00 (1.11 - 8.11) 2.96 (1.10 - 8.00) 
Cancer Risk: Lymphatic and hematopoietic tissues: Hodgkin lymphoma, Non-H lymphoma, 
Leukaemia and Myeloma 
Number of events 129 129 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 1.72 (1.15 - 2.56) 1.68 (1.12 - 2.51) 
3 - Liver 1.65 (0.91 - 3.00) 1.68 (0.93 - 3.05) 
4 - Inflammation & Iron 1.23 (0.56 - 2.68) 1.25 (0.57 - 2.73) 
 
a Time scale adjusted for age, sex and CCI 




Table 21. MODEL H. Hazard ratios and 95 % confidence interval for the association of LCA- derived 
metabolic classes and all causes death and cancer death. 
 
 Hazard Ratios (95% CI) a Hazard Ratios (95% CI) b 
All causes death   
Number of events 3158 3158 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 1.26 (1.16 - 1.37) 1.29 (1.19 - 1.40) 
3 - Liver 1.67 (1.47 - 1.90) 1.70 (1.49 - 1.93) 
4 - Inflammation & Iron 1.21 (1.05 - 1.41) 1.20 (1.04 - 1.40) 
Cancer death   
Number of events 706 706 
1 - Normal class 1.00 (ref) 1.00 (ref) 
2 - Lipids 1.22 (1.02 - 1.45) 1.20 (1.01 - 1.42) 
3 - Liver 1.44 (1.11 - 1.86) 1.46 (1.13 - 1.90) 
4 - Inflammation & Iron 0.93 (0.66 -  1.32) 0.93 (0.66 - 1.32) 
 
a Time scale adjusted for age, sex and CCI 





Table 22. C statistics for the MODEL H. LCA metabolic profiles and the standard health markers 
Total Cholesterol, Glucose and Gamma Glutamyl Transferase were assessed for all the outcomes 
studied: cancer, cancer death and overall death using calendar-time as a time scale. 
  
Cancer Risk Cancer Death Risk Overall Death Risk 
 
HR (95% CI) 
adjusted for 




HR (95% CI) 
adjusted for 




HR (95% CI) 
adjusted for 




MODEL H:             
1- Normal 
Class (60%) 
1.00 (ref) 0.70 1.00 (ref) 0.77 1.00 (ref) 0.84 
2- Lipids 
(23%) 
1.09 (0.98 - 1.22) 1.22 (1.02 - 1.45) 1.26 (1.16 - 1.37) 
3- Liver (9%) 1.28 (1.10 - 1.50) 1.44 (1.11 - 1.86) 1.67 (1.47 - 1.90) 
4 - Iron (8%) 1.17 (0.97 - 1.41) 0.93 (0.66 - 1.32) 1.21 (1.05 - 1.41) 
Single 
Biomarkers: 
            
Total 
Cholesterol 
1.00 (0.96 - 1.05) 0.69 1.03 (0.96 - 1.10) 0.76 0.99 (0.96 -1.02) 0.83 










To investigate population heterogeneity and cancer susceptibility in a given 
population, I aimed to identify novel statistical approaches to improve stratification 
of individuals, based on their underlying risk of developing cancer and risk of 
increasing mortality, by exploring the stratification capabilities of multiple markers 
of the blood exposome. The optimised multistage methodology employed in this 
project, indicated that standard of care baseline serum markers when assembled 
into meaningful metabolic profiles by data reduction techniques, can help stratify 
the population for cancer risk, cancer mortality and overall mortality. More 
specifically, I observed that abnormal values for markers of the lipid metabolism, 
liver function and inflammatory and iron metabolism distinguish participants into 
metabolic profiles, which were associated with of long term cancer risk and/or 
mortality and cancer mortality. Moreover, the results suggested that data reduction 
methods, specifically latent class analysis, can slightly improve the stratification 
models for cancer and mortality in comparison with single standard health 




extraction of the population heterogeneity hidden in the biological data. Even 
though the results are quite comparable, to assess improvement in the 
predictions a formal testing of the statistical significance would have been 
required.  
 
The outcome of the statistical pipeline that explored the blood exposome to assess 
population heterogeneity associated with cancer risk and mortality is illustrated in 
Figure 42.  
 
Figure 42.  Study statistical pipeline describing the methodology followed in the project and LCA 
outcome. 
  
   
 
Metabolic profiles 
Among the biological pathways addressed in the LCA for the final model H, 
abnormalities in the lipid metabolism were the most common. Hyperlipidaemia was 
present in about a quarter of the study population explaining the largest abnormal 
metabolic profile. The weight of the lipid profile in the analysis was consistent with 
the reported global prevalence of hypercholesterolemia among adults (37% for 
males and 40% for females) as reported in the Global Health Observatory in 2008 




Swedish population in the WHO MONICA project (286). Dyslipidaemia is associated 
with higher risk of CVD and other chronic diseases such as cancer, as also observed 
in the study (287). Liver dysfunction, iron deficiency and altered inflammatory 
markers profiles also distinguished important subgroups in the study population. 
About 9% of the population had abnormal values for markers of liver functioning 
(GGT, AST and ALT), which is similar to the results obtained in a population-based 
survey in the United States that estimated abnormal alanine aminotransferase (ALT) 
was present in 9% of respondents in absence of viral hepatitis C or excessive alcohol 
consumption (288). Moreover, these enzymes are known to be linked to cancer 
because of their role in preserving the intracellular homeostasis of the oxidative 
stress (201, 289, 290), which is concordant with the results of these analyses. The 
iron profile and inflammatory markers clustered 6% of individuals in the study, 
which was predominantly driven by low levels of serum iron and TIBC, as well as 
high levels of CRP and leukocytes. This could potentially point towards anaemia of 
inflammation, a chronic inflammation presenting low iron values, that occurs 
because the iron deficiency provides the body with infection resistance, which 
demonstrates the tightly connection between the inflammatory response and the 
iron and its homeostasis (291). This condition has been reported in more than 30% 
of cancer patients at time of diagnosis (292-294). 
 
Metabolic profiles as a risk factor for long term cancer and mortality  
The above-described three classes of abnormal metabolic profiles were all 
associated with an increased risk of cancer and worse survival, as compared to the 
healthy class. The findings therefore confirm the key importance of these 
metabolisms and the specific molecules in the maintenance of the intracellular 
homeostasis and how their unbalance can be related with the aetiology of cancer 
disease and mortality (3). The LCA adapted in this study thus illustrates how a 
biomarker-wide approach can help assess markers of the blood exposome in the 





More specifically, individuals presenting abnormal liver function markers carried 
worse outcomes in terms of overall cancer risk and cancer death, and a positive 
association with digestive, connective and endocrine cancers diagnosis. Moreover, 
the participants with this profile had a higher probability of overall death. These 
results are consistent with previous published data. A positive association between 
elevated GGT and overall cancer risk, with no interaction of ALT, was found in the 
AMORIS cohort previously (172), and it was also reported in other large cohort 
studies (295, 296). These studies also found strong associations with elevated levels 
of GGT and digestive and respiratory cancer incidence. Elevated GGT has been 
associated with mortality from all causes, liver disease, cancer and diabetes, while 
ALT only showed associations with liver disease death in a large US cohort (297). 
However, in a study based on an elderly population it was found that GGT was 
associated with increased cardiovascular disease mortality, and ALP and AST with 
increased cancer-related mortality (298). Moreover, a meta-analysis evaluating the 
associations between liver enzymes and all-cause mortality found positive 
independent associations of baseline levels of GGT and ALP with all-cause mortality 
(299). Furthermore, some of the multiple functions of the liver organ include to 
process the nutrients absorbed from the small intestine in the digestive system, to 
produce important hormones of the endocrine system such as Insulin-Like Growth 
Factor 1 and an active role in the maintenance of tolerance to self-molecules which 
pointed it as  target for autoimmune diseases as connective tissue diseases (CTD) 
(300), therefore underlying biological links exists between the altered abnormal 
function and the association with the digestive, connective and endocrine cancers.   
 
In the present study, the liver biomarker profile was positive associated with all the 
outcomes studied, suggesting a key role of this pathway in the development of 
cancer, probably related with its active role maintaining the intracellular redox 
regulation. Moreover, the specific enzymes studied in the project participate in 
relevant body functions, that according to the hallmarks of cancer publication are 
fundamental features in the development of cancer, such as gluconeogenesis cycle 




29). Thus, further investigations are necessary to establish the potential of the 
altered enzymes and the liver profile as a tool for cancer risk stratification. 
 
Individuals allocated to the lipid profile presented positive associations with cancer 
mortality, and overall mortality and higher risk of lymphatic and hematopoietic 
cancers. The link between hyperlipidaemia and mortality has been studied broadly, 
with associations with established links for cancer and all-cause mortality (301-303). 
The association between lipids and lymphatic and hematopoietic cancers is more 
controversial, as some studies found an inverse association for these cancers and 
high levels of serum cholesterol (304, 305) and a  systematic literature review from 
2016 found no association (306). However, the fatty acid metabolism and 
hematopoietic cell biology are connected through the WNT signalling pathway, an 
established dysregulated pathway in cancer(22), and its association has been 
investigated for leukaemia (307). Moreover, recently has been suggested the active 
and intricated lymphatic role in lipid transportation (308).  
 
Participants clustered in the unbalanced iron profile and inflammation had an 
increased risk of endocrine, buccal and oral cancers and were observed to have a 
higher risk of all-causes death. Altered inflammation and iron metabolisms are key 
metabolic ‘hallmarks of cancer’ (3, 179, 309). These markers are tightly connected 
via a body response denominated as anaemia of inflammation that is characterised 
for body iron sequestration in response to an underlying inflammatory disease or 
malignancy (294, 310). Moreover, CRP and leukocytes have been associated with 
cancer risk in AMORIS previously (170) and the observation of an association with 
an increased risk of buccal and oral cancer corroborates previous findings in AMORIS 
(179). Furthermore, a study in oral cancer patients suggested that iron deficiency is 
associated with increased oxidative stress, increasing the risk of oral cavity cancer 
(311). In relation with all-causes death, iron deficiency, an  indicator of malnutrition 
considered to contribute to maternal, perinatal and over-all death, ranked 9 out of 
22 mortality risk on to the Global burden of Disease 2000 publication, accounting 





Population heterogeneity and risk stratification: the need for data reduction 
techniques 
The modulation effect of population heterogeneity on the association between 
potential risks factors and disease is a new avenue to understand the variability of 
risk in the population (314).  Moreover, given the multifactorial nature of chronic 
diseases influenced by diverse exposures and the potential of the blood exposome 
to unravel cancer susceptibility in a population, a new area for innovative 
methodological approaches investigating disease risk stratification to improve 
disease prevention, has emerged.  For instance, in a targeted metabolomics exercise 
Shan et al. performed a principal component analysis and time to event analysis 
identifying metabolic profiles to predict risk of CVD (275). Another study used 
Monte Carlo Cross Validation and Lasso logistic regression to evaluate serum 
biomarkers as an alternative to faecal immunochemical testing to improve 
detection of colorectal cancer (118).  In 2010, the European Prospective 
Investigation on Cancer and Nutrition (EPIC) cohort reported that a specific 
prediagnostic plasma phospholipid fatty acid profile could predict the risk of gastric 
cancer (270). As rationalized in the HELIX project, these multiple profiling 
approaches aim to identify groups of individuals in the population that share a 
similar exposome signatures that might account for differences on the specific risk 
of study (111). Together with these studies, the systematic data integration 
approach based on LCA presents the potential of investigating population 
heterogeneity using metabolic profiling, as a subset of the exposome, as risk factors 
for long term cancer risk and mortality. The LCA metabolic profiles can be further 
explored as markers of cancer and mortality susceptibility, however their prediction 
capabilities were very comparable with established health markers such as total 









This project, as a prospective cohort study, examined the association of the markers 
with cancer disease and mortality. The biomarkers investigated in the project have 
been explored as markers of susceptibility, given that the measurements included 
were taken three years before any outcome event, so these pre-clinical biological 
samples are not influenced by the inherent metabolic changes due to the disease 
itself. In principle, the measurements would not be affected by disease at baseline 
for most of cancer types, given the cancer lack time, however these markers would 
reflect both the exposure and early biological effects of disease (Figure 8). 
 
Markers of susceptibility are valuable and effective instruments for cancer 
stratification on screening and prevention programmes, however in order to 
establish their prediction capabilities (Table 22) further studies to validate the 
results whilst allowing to measure sensitivity and specificity, will need to be 
conducted. Some examples of such studies are the pilot studies conducted in the 
EPIC cohort in relation to colon, breast and hepatocellular cancer outcome (244, 
272). Hence, a nested case-control could be conducted in AMORIS to determine the 
predictive capabilities of the metabolic profiles and markers that defined the 
profiles to estimate cancer risk and mortality. Moreover, a validation exercise in a 
different study population characterised by diverse life-style, demographics and 
genetics, such as the American National Health and Nutrition Examination Survey 
(NHANES), would allow to establish the external validity of the metabolic profiles 
without compromising the validity of the statistical approach (288, 315-318).  To 
establish the external validity of the LCA metabolic derived classes, a validation 
exercise has already been performed using data from NHANES based on the same 
panel of serum markers – with additional adjustments for alcohol and smoking 
consumption. The results showed the same four LCA metabolic derived classes as 
seen in AMORIS: one normal class with normal values for all the markers (66% 
population), one class defined by abnormal values for the lipids ratios (22%), one 
class strongly defined for abnormal values of inflammation markers and low iron 




NHANES database lacks information on date of cancer diagnosis and so therefore 
these analyses were limited to overall death and cancer-specific death as an 
outcome (Note: this work was conducted outside the scope of the PhD; manuscript 
in preparation). In this analysis the iron and inflammation class were strongly 
associated with both outcomes (Overall death HR (95% CI) =1.99 (1.09 - 3.62) and 
Cancer Death HR (95% CI) = 2.93 (1.14 - 7.54)), as compared to the normal class.  
The rest of the classes were not associated with the outcomes. The NHANES findings 
thus implies general validity of the methodology used to explore population 
heterogeneity in the context of metabolic profiles and cancer susceptibility. 
 
Future studies will benefit from longitudinal approaches assessing repeated 
multiple serum marker measurements that will capture the population phenotypic 
variations in relation to disease over long periods of time and will help understand 
the complexity of cancer and be able to stratify population at risk of cancer and 
mortality. 
 
Strengths and limitations 
The present study was conducted in a large and well-defined population, applying a 
multi-faced approach covering main biological pathways to assess biomarker 
profiles that could indicate cancer risk, cancer survival and mortality.  The major 
strength of these analyses lies in the innovative avenue to study population 
heterogeneity and susceptibility to disease and mortality in a large cohort of 
participants with multiple routinely collected blood biomarkers (a sub-set of the 
exposome), all measured on fresh blood samples on the same day at the same 
clinical laboratory. I included all the markers available in the cohort for a large 
population (n>13000) in an exploratory data driven approach, however not every 
marker of the central metabolic pathways was available in the database (i.e. 
Complete Blood Count).  Please see project A for a further discussion about the 
generalisability of the AMORIS cohort. The main limitation of the study is the partial 
availability of information on life-style and environmental factors established as 




these external exposures compromised the extent of the markers utilised to 
characterize the external exposome component and limited the characterisation of 
the metabolic profiles in the population. However, to mitigate the lack of external 
factors, the analyses have been adjusted for Charlson Comorbidity Index which 
includes comorbidities such as obesity and hypertension and other chronic diseases 
such as circulatory or respiratory diseases. Alcohol consumption is also an important 
risk factor for cancer; the lack of information on these variables was mitigated by 
using information on serum biomarkers such as gamma glutamyl transferase and 
other liver enzymes (319, 320). The rather low number of respiratory cancers in this 
population may be explained by a lower prevalence of smoking in Sweden at the 
time (15). Moreover, given the results of the validation study in NHANES, which did 
include adjustment for both alcohol and smoking consumption, it can be suggested 
that lack of adjustment for these confounders has little effect on the actual 




The LCA adapted in this study illustrates how an exploratory biomarker-wide 
approach, can help to assess population susceptibility to disease and provide insight 
into disease aetiology in the context of carcinogenesis and mortality. The analyses 
outlined the importance of the lipid molecules, the enzymes ALT, AST and GGT and 
the iron metabolites when classifying individuals to evaluate hidden heterogeneity 
based on blood metabolites. These findings suggest the relevant function of these 
established biomarkers in the internal body homeostasis, however these molecules’ 
utility is commonly reduced to the specific biological pathways linked to their 
current clinical application (i.e.: standard health assessment). Considering the tight 
interaction of the internal metabolic molecules and the external exposome and 
given the environmental and genetic modulation of metabolic molecules, metabolic 
profiling based on standard of care serum markers could become a useful non-
invasive predictive signature for risk stratification and an important area of research 




markers and life style and environmental factors will be necessary to establish the 
potential role of these methods in stratified medicine.  
 
Therefore, the findings support the recently expressed need for a shift from the 
classical epidemiological approach of assessing one exposure to a systemic 
approach with multiple exposures in order to capture the population and disease 
heterogeneity and better characterise the population cancer susceptibility with the 










Chapter V. Individual susceptibility to Disease.  
 
The findings of this section were published as an abstract in the European Journal of 
Surgical Oncology (EJSO) November 2015 (Appendix III) and published in Biomedical 
Optical Express June 2017 (321) (Appendix IV). 
 
To accomplish personalised medicine in cancer, acquiring a comprehensive 
perspective of the population susceptibility to cancer, in conjunction with insight 
knowledge of the inherent variability of the disease, will be necessary. 
 
In the previous chapter, population heterogeneity was investigated in a subset of 
blood exposome markers which when reduced to meaningful metabolic 
components, using data reduction techniques, presented the capability to stratify 
the population for cancer risk and mortality.  This confirms that efforts towards 
exploring population cancer susceptibility could help us to optimise stratification 
models for prevention and early detection of the disease.  
 
Therefore, this chapter investigates the heterogeneity inherent to cancer in a 
translational imaging setting. Focusing on breast cancer, the project aimed to 
distinguish variability at cellular level by differentiating tissue composition (tumour, 
fibrous and adipose material) using imaging data generated in an ex vivo study (REC 
12-EE-0493). Considering the complexity and multidimensionality of imaging data, 
the data reduction techniques were applied to perform supervised clustering 
allocating each observation to a specific tissue type through a predictive analysis. 
 
To investigate individual susceptibility to cancer in an imaging setting, I explored 
individuals’ heterogeneity in cancer composition in a diagnostic context to improve 
breast cancer tissue discrimination intraoperatively, using material from King’s 





Project C: I evaluated how imaging data produced by a terahertz probe can 
distinguish between different breast tissue samples, with the ultimate aim of 
using this probe intraoperatively in breast-conserving surgery to predict positive 
tumour margins. 
 
I. Project C: Discrimination of breast tumour tissue 
a. Rationale 
Breast cancer (BC) is the leading cause of cancer and cancer death in females 
worldwide, accounting for about 2.4 million cancer BC cases and about 523,000 BC 
deaths in 2015 (15) (Figure 3).  
 
Surgery to remove the primary tumour is one of the main treatment options for BC 
patients, which has evolved from radical surgery options (mastectomy) to more 
conservative approaches, such as breast-conserving surgery (BCS) in the last 
decades. Since 1990, BCS has become a patient’s treatment of choice, because of 
the cosmetic and less invasive implications, estimating that in United Kingdom two-
thirds of newly diagnosed patients undergo BCS as initial treatment (322). Currently, 
BCS is also performed in large or locally advanced tumour cases after pre-surgery 
tumour downstaging and downsizing using neoadjuvant chemotherapy or 
endocrine therapy treatments (323-325). 
 
To determine the surgical outcome of BCS procedures, the assessment of the 
negative tumour margins in the excised material post-surgery, is a common practice 
(324). Moreover, about 20% of the patients that undergo a BCS require a re-
operation due to the positive tumour margins on a postoperative pathological 
assessment, which is considered the gold standard for estimating tumour margins 
(326). The additional surgery to obtain clear margins and/or remove remaining 
lymph nodes in the axilla, causes a significant physical and psychological morbidity 





Hence, in an effort to decrease re-excision rates, different reliable intraoperative 
margin assessment (IMA) tools are being investigated to assess tumour resection 
margins intraoperatively. Some of these techniques are clinically established, such 
as frozen section analysis (330, 331), specimen radiography (332), intraoperative 
ultrasound (333) and touch imprint cytology (331), however these IMAs present 
diverse performance and limitations in terms of accuracy, speed, cost, and 
reliability. Therefore, new IMA tools are currently under development including 
Raman spectroscopy (334), microcomputed CT (335), mass spectroscopy  (336) or 
fluorescence imaging (337, 338).  
 
Terahertz pulsed imaging (TPI) is such a developing IMA tool, that employs terahertz 
(THz) radiation with very low proton energy (0.1 – 4 THz) which does not cause 
harmful ionization in biological tissues (339, 340). Given its the millimetric 
penetration depth and sensitivity of THz radiation to changes in water content and 
tissue composition, it has been applied to image biological tissue in different 
studies, such as in cancer research to distinguish malignant from benign tissue in 
skin, colon, oral, gastric, brain and breast cancer in 2006 (341, 342).  
 
As a consequence of the previous studies, Teraview Ltd. (Cambridge, UK) developed 
a handheld THz Probe to intraoperatively assess tumour margins and sentinel lymph 
nodes in breast cancer patients, eventually aiming to reduce the number of BCS 
reoperations. A collaborative feasibility study was established between Teraview 
Ltd. (Cambridge, UK) and Prof Purushotham’s research team at King’s Health 
Partners (KHP) to test the performance of the probe in ex-vivo fresh breast tissue 
(REC 12-EE-0493). 
 
Thus, to understand each individuals’ susceptibility to cancer driven by disease 
variability, whilst evaluating the application of data reduction methods in an 
imaging setting, I used data generated in this collaborative pilot study of Teraview 
and KHP. The project aimed to distinguish between different breast tissue samples, 




tissue intraoperatively ensuring clear negative tumour margins in BCS. Therefore, a 
supervised clustering method, the Naïve Bayes Classifier algorithm was utilised to 
build a classifier able to distinguish between tumour, fibrous and adipose tissue in 
real – time surgery. 
 
b. Methods 
i. Study population: Data collection 
The data included in the project was obtained from the first-in-human, single centre 
pilot study to evaluate the ability of a handheld TPI probe to discriminate benign 
from malignant breast tissue in an ex vivo setting conducted in KHP. 
 
Technology 
The study utilised a terahertz pulsed imaging (TPI) handheld probe device version 
2.0 (Teraview Ltd. Cambridge, UK). The TPI probe produced THZ pulses of frequency 
0.1-2.0 THz through a scan window that contained 26 pixels, providing a pixel 
resolution of about 0.6 mm. During the tissue scanning, each pixel received residual 
THZ pulses from the tissue that formed TPI waveforms as illustrated in Figure 43. 
 
Figure 43. Schematic description of the raw data acquisition. Images are courtesy of the study (REC 
12-EE-0493). TPI handheld probe measurement of tissue sample positioned in histology cassette. 
Residual THZ pulses are received by each pixel from the tissue producing typical TPI waveforms per 
pixel. Based on the type of tissue present in the breast sample the TPI waveform presented a different 
shape (tumour (blue), fibrous (red), and adipose cells (black)) (image on the right). 
 





Imaging data was generated by scanning, with the TPI handheld probe, 46 freshly 
excised breast cancer samples from 30 BC patients, who underwent BCS or 
mastectomy at Guy’s Hospital (Guys and St Thomas NHS Foundation Trust) between 
August 2013 and August 2014. Written informed consent was obtained for the 
research use of the material (REC 12-EE-0493).  
 
The data acquisition followed the following pathway: (i) while the ex vivo breast 
tissue was scanned with the probe, using air as a reference, (ii) each pixel 
transmitted many THZ pulses to the tissue sample and (iii) each pixel received 
multiple residual THZs  per scan of tissue sample, following (iv) the residual THZs  
were averaged into a TPI waveform with 674 data points of information per pixel 
within the device software, resulting in (v) the final raw data obtained from the 
device that contained one waveform with 674 data points per pixel producing a 
matrix of 26 waveforms (one per pixel) with 674 data points of information per scan 
of a tissue sample. A posterior pre-processing of the data to remove the noise of the 
signals, reduced the number of data points to 301 per waveform (final matrix of 
n=26 waveforms x m=301 data points per scan of tissue sample). 
 
Moreover, detailed histopathology was correlated with the Terahertz time domain 
data (THz) per pixel area by two pathologists blinded for the patient’s details. 
Consequently, each waveform per pixel was labelled with the percentage of tumour, 
fibrous and adipose content (Figure 44). The ex vivo breast tissue samples were 
characterised based on their tissue composition which included different 
proportions of tumour tissue, consisting of tumour cells embedded with normal 
breast cells, adipose tissue, mainly composed by adipocytes cells and fibrous or 
connective tissue containing elastic and collagenous fibres, ground substance and 
cells. The 46 tissue samples included in the project had the following tissue 
composition: (i) 20 samples contained tumour including 16 invasive ductal (IDC)/no 
special type (NST) carcinoma, two NST admixed with ductal carcinoma in situ (DCIS), 




or a mixture of fibrous and adipose tissue (78% characterised by its high-fibrous 
density content), and (iii) four samples contained pure adipose tissue. 
 
Figure 44.  Correlating TPI waveforms with histopathology. (A) Typical impulse function of tumour, 
fibrous, and adipose tissue, and air, respectively. Clear differences are seen between the impulse 
functions from air and from tissue, and between adipose and tumour/fibrous tissue (black arrows). 
(B) TPI image from sample based on the amplitude of the impulse function at t = 7.97ps. (C) Digital 
histopathology slide of the same tissue sample. By using the photograph of the sample in 
combination with the air-tissue interface visible in the TPI image, the TPI 15 x 2 mm scan area can be 
accurately mapped onto the histopathology slide (black rectangle). The pixels are displayed as 
intermittent horizontal lines at 0.6 mm distance in the scan window. Pixel 5 – 17 contain invasive 
ductal/no special type (NST) carcinoma; the percentage of tumour cells in each pixel area ranges 
between 5 – 10%. The tissue immediately surrounding the tumour cells (called background) is 
composed of fibrous tissue, whilst fatty adipose tissue is seen inferiorly. Figure and caption taken 
from Grootendorst et al. 2017 (321). 
 
            
 
Final dataset 
The final dataset contained selected THz data from each tissue sample, given that 
the size and orientation of the tissue samples varied, resulting in a different number 
of pixel scanning the tissue for each sample (Figure 44).  Consequently, the data for 




detailed histopathology results were appended to the Terahertz (THz) data for each 
pixel. The final dataset contained a number of rows (pixels), containing each row of 
the waveform 301 data points and the percentage of each tissue type (tumour, 
fibrous, adipose) present in that particular pixel. A total number of 257 pixels was 
collected resulting in a matrix of n=257 waveforms by m=301 data points. The 
dataset contained 115 tumour pixels, 116 fibrous pixels and 26 pure adipose pixels. 
The tumour pixels predominantly consisted of invasive ductal/no special type 
carcinoma (N = 92) and invasive lobular carcinoma (N = 19). Most of the tumour 
pixels contained a low to moderate percentage of tumour cells ranging between 1 
– 60% (N = 98). Almost all tumour cells had a background of pure fibrous tissue; only 
five had a background containing a mix of fibrous and adipose. Most of the fibrous 
pixels had a high percentage of fibrous cells ranging between 81 – 100% (N = 91). 
Only 26 of the 257 pixels consisted of pure adipose tissue. A detailed description of 
the pixel characteristics of the dataset is illustrated in Table 23. 
 
Table 23.  Pixel characteristics analysis dataset. A total of 257 pixels were included in the TPI dataset: 
115 tumour pixels, 116 fibrous pixels and 26 pure adipose pixels.  Figure taken from Grootendorst et 
al. 2017 (321). 











ILC No. of 
pixels 
BG No. of 
pixels 
BG No. of 
pixels 
81 – 100  3 1  4 F 91 A 261 
 
61 – 80  11 2  13 F 2 A 
 
 
41 – 60  22  6 28 F 7 A 
 
 
21 – 40  33 1 12 46 F: 43 
F/A: 3 
 
3 A  
1 – 20   23  1 24 F: 22 
F/A: 2 
13 A  
No. of pixels 92 4 19 115  116  26 
 
IDC/NST = invasive ductal/no special type carcinoma; DCIS = ductal carcinoma in situ; ILC = invasive lobular 
carcinoma; BG = background tissue. In our dataset, the background consisted of fibrous tissue (F), adipose tissue 
(A), or a mixture of fibrous and adipose tissue (F/A).   




The raw data was therefore highly complex, multidimensional and contained lots of 
noise. There was a lack of standardised procedures for data acquisition, post 
processing, image analysis and interpretation of the data generated with this 
technology. 
 
ii. Statistical Analysis 
The analytical pipeline followed in this project is an innovative approach to process 
TPI THz data, previously analysed using support vector machine, a traditional 
machine learning technique (341, 343). 
 
The statistical pipeline in this project is therefore divided into three main analyses 
performed to understand individuals’ susceptibility to cancer by exploring the 
variability on tissue composition with the ultimate aim of identifying discriminating 
features in imaging data that will allow us to classify breast tissue as malignant or 
healthy tissue in real-time surgery (Figure 45). The analyses comprising the 
statistical pipeline were the following: (1) Gaussian wavelet deconvolution 
algorithm, a signal processing algorithm was first developed to reduce the noise and 
expand the information of the original signals, (2) Naïve Bayes Classifier, was 
applied to find rules or patterns (if any) that were associated with the 
histopathological composition of the tissue samples and the TPI waveforms using 
the prior information on the correlated histopathological composition known for 
each waveform (pixel) and finally (3) Leave one sample out cross validation 
(LOOCV), was applied to predict the histopathological composition of an 
observation (waveform) while leaving all the rest of waveforms from the same scan 
of the tissue sample out of the dataset employed for prediction, to ultimately 
evaluate the prediction accuracy of the Bayesian algorithm on unseen samples. 
Figure 45. Methodological approach using an innovative avenue to explore individual susceptibility 
to cancer using TPI imaging data. The raw sample waveforms are modelled via Gaussian wavelet 
deconvolution generating multidimensional heat-maps of imaging data. The heat-maps are then 
used as an input model for the Bayesian classifier that will predict the different tissue types based 
on the true histopathology values. Finally, the accuracy of the prediction is measured applying leave 





Furthermore, to perform the above-described statistical pipeline, the Gaussian 
wavelet deconvolution was applied to the high dimensional dataset which 
constituted of the TPI waveforms from all 46 breast samples included for analysis 
(matrix of n=257 waveforms by m=301 data points). Gaussian deconvolution was 
considered as an adequate signal processing transformation for this data due to the 
analogy of the TPI impulse function and the derivatives of the Gaussian function. 
The transformation aimed to reduce the noise and to expand the information of the 
TPI signal. 
 
The transformation of the original TPI waveform was based on the calculation of 
Gaussian derivatives of different orders (n = 0, 1, 2, 3, 4) to each of the 301 data 
points which comprised each signal, thereby producing one heat-map per order of 
derivatives per pixel (Figure 46, Figure 47). Higher order Gaussian derivatives were 
not used to avoid potential overfitting.  
 
Figure 46. Gaussian wavelet deconvolution signal transformation applied to the TPI dataset involved 
Gaussian convolutions of derivatives of the original time series. Below the standard formula of 





































Figure 47. Example of the heat-maps generated from one TPI waveform. Gaussian derivatives of 
different orders (n=0, 1,2,3,4). 
 
 
The five heat-maps per waveform were merged together into a multidimensional 
heat-map per waveform which also incorporated as corresponding outcome 
variable the specific tissue content of each of the pixels and was defined as follows: 
percentage of tumour, percentage of fibrous and percentage of adipose tissue in 
the pixel (e.g.: %tumour=35, %fibrous=45 and %adipose=20). 
 
A Naïve Bayes Classifier algorithm was then applied to the multidimensional heat-
maps to discriminate benign from malignant breast tissue (166). The classifier used 
the known classification of the observations to find the rules or patterns (if any) that 
link those observations to their classes. These rules were then applied to predict the 
classes of new observations from a test or validation set. Here, the classifier used 
the pathologically defined tissue content of each of the observed TPI waveforms of 
each of the pixels to establish patterns that linked the specific waveforms to the 
tissue content, so that it could then employ these rules to predict the tissue content 
in a new breast TPI signal. 
 
The classifier algorithm implemented a probabilistic approach, or model-based, 
where it was assumed that the observations in each class were generated by a 
distribution that was specific to that class, given that the distributions were 
multivariate Gaussian. 
This algorithm was preferred among other classification methods given its capacity 
to rapidly analyse multidimensional dataset with bigger number of covariates or 




To simplify the nature of the tissue when training the classifier, the classifier was 
programmed to implement three scenarios that assessed the type of tissue available 
in the sample in a different manner depending on the particular research question 
evaluated. Scenario 1:  pixels were marked as tumour when containing any amount 
of cancer cells (if %tumour>0 TPI waveform was considered as tumour, irrespective 
of the content of fibrous or adipose tissue), otherwise the tissue content of the pixel 
was defined by the highest percentage of fibrous or adipose tissue; Scenario 2: 
pixels were marked as tumour when containing any amount of cancer cells (if 
%tumour>0 pixel TPI waveform was considered as tumour, independently of the 
content of fibrous or adipose tissue), otherwise tissue was considered to be 
“benign”. In this scenario, adipose and fibrous tissues were grouped together; 
Scenario 3: pixels were marked based on their tissue content, so the tissue content 
of each pixel was defined by the highest percentage. Given that the main aim of the 
project was to discriminate malignant tissue from benign breast tissue, and that 
benign breast tissue could be subdivided into fibrous and adipose tissue 
respectively, scenario 1 was the preferred option in the study. The naïve Bayes 
classifier was employed using both the raw waveforms dataset and the 
multidimensional heat-maps dataset for each of the three scenarios to assess the 
best input model for the classifier. 
 
Finally, the performance of the classifier was evaluated using the ‘leave one sample 
out cross validation (LOOCV)’. The Bayesian classifier was trained individually by 
leaving out the pixels of a single sample to be classified, and training each classifier 
with the other samples. The trained classifiers were then applied to the pixels of the 
sample that was left out. This process was repeated for all the samples. The results 
were compiled to estimate accuracy, sensitivity, specificity, positive predictive 
value, and negative predictive value to distinguish malignant from benign tissue.  
Moreover, leave one pixel out cross validation was also explored to assess the 
performance of the classifier when considering each pixel independent of the rest 






A visual examination of the Gaussian derivatives of order 0 to 4, generated with the 
wavelet deconvolution signal processing algorithm when applied to the waveforms, 
presented clear differences between the pixels with a high adipose component and 
the pixels with tumour and fibrous content as illustrated in Figure 48. However, the 
samples with tumour content did not showed any distinct visual difference with the 
samples with high fibrous content. 
 
Figure 48. Examples of heat-maps from a waveform generated from tissue with fibrous and tumour 
content and a heat-map from a waveform from adipose tissue. Clear visual differences exist between 
both heat-maps for all the Gaussian derivative orders. 
 
 
The naïve Bayes classifier was applied on the raw waveforms dataset and on the 
heat-maps multidimensional dataset for the three scenarios, measuring the 
predictive capabilities of the classifier using both the leave one sample out cross 
validation and the leave one pixel out cross validation. The classifier showed a better 
performance when the heat-maps multidimensional dataset was the input model in 
comparison with the raw waveforms dataset (Figure 49). Scenario 1 which aimed to 
predict the presence of tumour in any percentage on the tissue sample, even for the 
lower strata of 1-20 percentage of tumour present, obtained lower sensitivity and 
higher specificity compared to scenario 2 (Figure 50) and lower predictive scores 
compared to scenario 3, given the prevalence of the low tumour content pixels on 
the dataset (Table 23). When applying the leave one pixel out cross validation, the 




This was expected, because the leave one pixel out cross validation did not consider 
any possible correlations between the pixels belonging to the same scanned tissue 
sample (Figure 50). To replicate the real-time surgery context, the final results were 
based on the performance of the naïve Bayes classifier when scenario 1 and LOOCV 
was employed. 
 
Figure 49 presents the final classification results for the 46 breast cancer specimens 
by tissue type, using both the original waveform and the processed heat-map as the 
input model of the Bayesian classified when performed using scenario 1 and leave 
one sample out was applied. The accuracy, sensitivity, specificity, PPV and NPV of 
the Bayesian classifier for tumour tissue discrimination, performed using the 
combined Gaussian derivatives of order 0 (normal Gaussian function), 1, 2, 3 and 4 
applied to the TPI waveforms, were 69%, 89%, 53%, 60%, 86%, respectively. The 
classifier considered tumour pixels when the pixel contained any amount of cancer 
cells. Tumour tissue type scanlines were classified correctly in 89% of the cases using 
the heat-map derivatives from the time domain pulse in the Bayesian classifier with 
an accuracy of 0.7 and sensitivity of 0.9. The adipose tissue scanlines were 
accurately discriminated from tumour/fibrous tissue using the heat-map derivatives 
with an accuracy of 0.95. Fibrous tissue scanlines were incorrectly misclassified as 















Figure 49. Classification results for the 46 breast cancer specimens by tissue type, using both the 
original waveform and the processed heat-map as our input model of the Bayesian classified when 
performed using scenario 1 and leave one sample out was applied. Tumour and Adipose scanlines 




















Figure 50. Tumour tissue classification results when using Bayes classifier on heat-maps dataset 








Figure 51 presents the tissue type content of the waveforms in the dataset. The 
classification by tissue type by waveform (pixel) showed that of the 115 tumour 
pixels, 89% were classified correctly as tumour and 15 were misclassified as fibrous. 
All misclassified pixels contained ≤60% tumour cells and included a high percentage 
of the ILC samples in the dataset (6/19) (Figure 52). Sixty-six of the 142 benign pixels 
were wrongly classified as tumour; 64 of these were 81 – 100% fibrous pixels, only 
two 1 – 80% fibrous pixels were misclassified. The scanlines containing 81-100% of 
fibrous are misclassified as tumour in a 70% of the cases.  All pure adipose pixels 
were correctly classified (Figure 53).  
 





Figure 52. Classification of the tumour content for the pixels on the dataset based on the final results 













Figure 53. Classification of the benign content for the pixels on the dataset based on the final results 





To investigate individuals’ susceptibility to cancer by examining the heterogeneity 
inherent to cancer, I aimed to distinguish variability at cellular level by 
differentiating tissue composition (tumour, fibrous and adipose material) in a 
translational setting, using imaging data generated from ex vivo breast tissue 
samples. The project explored the capability of a naïve Bayes classification algorithm 
to discriminate malignant from benign breast tissue for a real-time surgery 
utilisation with the ultimate aim of improving breast cancer surgical outcomes. The 
innovative statistical approach followed in the project, indicated that wavelet 
deconvolved pre-processed imaging data when analysed with the Bayesian classifier 
can accurately distinguish malignant from benign tissue in an ex vivo setting, 
obtaining high sensitivity and low specificity. More specifically, I observed that 
tumour and adipose tissue were correctly classified in most of the cases (89%), 
however high density fibrous was incorrectly classified as tumour and adipose in 
73% of the cases. 
Moreover, the results suggested that supervised clustering methods can effectively 
classify multidimensional complex biological data extracting the hidden patterns to 
accurately predict new observations in the data. Further optimisation of these new 
approaches could help improving diagnosis in translational and clinical settings. 
 
Malignant and benign tissue 
The raw waveforms and the processed heat-maps visually presented distinct 




the plots produced by tumour and fibrous tissue samples (Figure 44 and Figure 48). 
This confirmed the results by Ashworth et al. observed in a small study where  the 
TPI generated THz impulse functions from fibrous tissue and breast cancer showed 
similar features while the impulse functions from adipose tissue were dissimilar 
(344). The classifier results confirmed these observations being adipose the tissue 
type with higher classification performance presenting values over 90% for 
accuracy, sensitivity and specificity. Tumour tissue was correctly predicted in 89% 
of the cases, which was reflected in a high sensitivity score (89%) and percentage of 
true positive cases identified by the classifier. This suggest the potential clinical 
applicability of this method to identifying tumour cells close to a resection margin 
intraoperatively, with the subsequent possibility to improve the adequate excision 
of the margins reducing re-operation rates, however the potential applicability of 
the classifier is  conditioned on the improvement on the specificity score. Tumour 
specificity showed moderate results (53%) as a consequence of the high number of 
fibrous samples misclassified as tumour (65% of the cases). Exploring the 257 pixels 
generated by scanning the 46 BC samples, the tumour samples contained 
predominantly low-to-moderate tumour cell percentages, which replicates the 
tissue composition of the resection border of breast samples from patients with 
positive margins. Moreover, the benign dataset contained a high representation of 
81-100% high dense fibrous (91/142 pixels), from which 64 pixels were misclassified 
as tumour. This suggests that tumour cells might present similar water content and 
cell density as high dense fibrous material when measured with TPI terahertz 
technology. 
 
Imaging data analysis  
The proposed statistical pipeline to process and analyse the TPI imaging data 
showed good classification capabilities to discriminate tumour samples, however it 
only had moderate capability of discriminating fibrous. The naïve Bayes classifier 
explored the information contained in the raw waveforms given that the Gaussian 
derivative heat-maps were performed based on the similarity of the distribution of 




capability to rapidly analyse multidimensional matrixes, then avoided the evaluation 
of standard heuristic parameters predefined for imaging data such as amplitude or 
peak to peak, commonly used to analyse imaging data, as for example utilised in 
previous analysis of TPI imaging data, obtaining  similar results with a faster 
performance (SVM: sensitivity (86%), specificity (66%)) (321). Moreover, the 
sensitivity and specificity obtained by the classifier (89%, 53%) were comparable to 
the performance of IMAs techniques currently used for intraoperatively assess 
tumour margins during BCS, given that there is broad variability between the 
current IMASs as reported by a meta-analysis such as specimen radiography (53%, 
84%), ultrasound imaging (59%, 81%), radiofrequency spectroscopy (71%, 68%) or 
frozen section analysis (68%, 96%) (337). Most of the techniques explored in the 
meta-analysis presented lower sensitivity than the Bayesian classifier, which 
indicates that these IMAs are not able to classify tumour tissue as tumour with the 
same accuracy as the Bayesian classifier. However, these IMAs presented better 
specificity, which means they are able to detect false negatives more accurately 
than the Bayesian classifier. They will identify fibrous tissue more accurately. 
Moreover, given that frozen section analysis is considered the gold standard, the 
Bayesian classifier needs further development to improve the specificity score. 
 
Future steps 
Based on the results of the present study, the TPI imaging data, when analysed with 
supervised clustering methods, has the ability to assess intraoperatively tumour 
margins quite effectively given the sensitivity obtained in the project. However, the 
performance in terms of specificity needs to improve to meet the needs of this 
specific diagnostic setting.  Therefore, different steps can be followed to improve 
the specificity of the classifier: (i) explore the predictive capability of each of the 
Gaussian derivatives independently, (ii) optimise the Bayesian classifier to improve 
its performance, and (iii) acquire a new dataset increasing the number of BC tissue 
samples including data from diverse pathologically well-defined breast tumour 




intraindividual variability. The latter was not possible in this project given the 
relative small dataset. 
 
Strengths and limitations 
The major strength of these analyses lies in the innovative avenue to study 
individuals’ susceptibility by examining the heterogeneity inherent to cancer tissue 
in a translational imaging setting. The dataset analysed was generated in the first-
in-human, single centre pilot study to evaluate the ability of a handheld TPI probe 
to discriminate benign from malignant breast tissue in an ex vivo setting conducted 
in KHP. Forty-six freshly excised breast samples with low to moderate tumour 
content from various BC types generated 257 THz pixels which were included in the 
analysis. However, a dataset more representative of the different tissue 
composition, including more low density fibrous, more adipose samples and diverse 
BC molecular subtypes, together with multiple measurements per patient would 
better reflect the heterogeneity inherent to the disease and would replicate the 




The results of the Bayesian classifier adapted in this study illustrate how an 
individuals’ susceptibility to disease can be explored examining the heterogeneity 
inherent to cancer by investigating tissue composition (tumour, fibrous and adipose 
material) in a translational setting using imaging data. The naïve Bayes classification 
can effectively discriminate malignant from benign breast tissue using TPI imaging 
data, however presents a low specificity. This suggests the potential clinical 
applicability of this method to improve the adequate excision of the margins in BCS 
surgery if the classifier is optimised to improve the specificity score. 
 
Thus, based on the results of this exploratory exercise, it can be concluded that 
supervised clustering approaches present the capability to classify multidimensional 




observations in the data. In the future, these innovative approaches could help 
































Chapter VI: Conclusion and future directions 
 
Cancer burden continues to increase in an aging population. It has evolved into a 
chronic condition in high income countries, whilst in developing countries early 
detection is still a critical milestone in the cancer pathway (14). Moreover, cancer is 
characterised by a multifactorial aetiology with an intricate gene-environment 
interplay (228), which implies the involvement of diverse biological pathways, 
including distinct genetic, molecular and clinical events between patients (4, 29). 
Biological variability is thus inherent to the disease and population susceptibility 
depends on a tight reciprocity between biological components modulated by 
genetics, life-style behaviour aspects and environmental factors  (39).  Due to this 
complexity, single biomarkers and single clinical symptoms seem insufficient to 
understand the disease and tailor patient treatments. Hence, a new research 
avenue towards the pursuit of personalized medicine has arisen. Novel systematic 
efforts exploring the vast amount of cancer data, acquired with new technologies,  
in combination with the implementation of the exposome concept and advanced 
statistical methods, have the potential to build efficient stratification models for 
predictive health that could be implemented in clinical practice (345). 
 
Hence, this thesis was written with the ultimately aim of acquiring a comprehensive 
perspective of the population susceptibility to cancer and variability of the disease 
whilst investigating new statistical approaches using multidimensional cancer 
datasets, in the pursuit of an accurate and effective stratified medicine for cancer. 
Therefore, three different projects were performed, two of them exploring 
population susceptibility to cancer in a clinical setting and one exploring individuals’ 
susceptibility to cancer in a translational imaging setting. These projects helped to 
investigate and generate hypotheses and new research ideas for future work.  
 
Thus, the next section provides a summary of the conclusions for each project, 





The chapter Population susceptibility to cancer included Project A - the blood 
exposome in AMORIS and Project B - metabolic profiles in AMORIS. The projects 
aimed to explore multiple standard of care serum markers available in AMORIS in 
relation to cancer diagnosis and mortality, firstly by understanding the role of this 
subset of serum markers in the blood exposome and secondly, by characterizing the 
potential of these established markers as markers of cancer susceptibility.  
 
The practical framework established in this thesis to study a subset of markers of 
the blood exposome in AMORIS showed that internal biological markers were 
strongly correlated with markers of related body functions and biological pathways. 
Simultaneously novel networks within markers of a priori unrelated functions, were 
also observed. Thus, this complex synergy between markers, explained the reason 
why the variance of the data was distributed along the different biomarkers, 
without a group of markers that could account for all the variability of the data. This 
exploratory analysis demonstrated the need of systemic approaches involving 
multiple markers capable of evaluating the internal biological environment. 
Moreover, the interactions observed with the panel external (2), specific external 
markers (2) and the internal molecules (21) included in this study illustrate the 
interaction between the environmental, life style factors and the internal biological 
component in human populations for this small subset of the exposome. The results 
of this exploratory analysis of a subset of the exposome highlight the importance of 
the implementation of practical frameworks to characterise the exposome that will 
enable us to unlock the heterogeneity in a given population, which emphasises the 
relevance of the assessment of the exposome when measuring exposure impact and 
health outcomes. 
 
The statistical pipeline developed in this thesis to characterise the potential of blood 
markers as markers of cancer susceptibility in AMORIS demonstrated that routinely 
collected serum markers, when assembled into meaningful metabolic components, 
have the potential to stratify the population for cancer risk, cancer mortality and 




enzymes ALT, AST and GGT and the iron metabolites classified individuals at higher 
risk of cancer and mortality, suggesting a key role of these markers in the internal 
body homeostasis. Moreover, these results suggested the potential use of standard 
serum markers as markers of cancer susceptibility in early detection of cancer. The 
optimised statistical analysis revealed a  promising role of data reduction methods 
in risk stratification modelling for biomedical data, which needs to be established in 
larger datasets including broad panels of markers and lifestyle and environmental 
factors such as the EPIC cohort - given the moderate prediction scores shown by the 
LCA metabolic profiles in comparison to the single established markers (Table 
22)Therefore, the project highlights that data driven efforts using multiple markers 
and statistical advanced technologies are necessary to understand disease and 
population susceptibility to disease, and could help to implement better 
stratification programs for prevention and early detection in cancer.  
 
Given the observed stratification capabilities of the metabolic profiles for cancer risk 
and mortality in AMORIS, a nested case-control study could be conducted in the 
same cohort to establish whether these profiles could be utilised to predict cancer 
risk and mortality in the Swedish population. Moreover, to assess the external 
validity of the metabolic profiles as markers of cancer susceptibility, a validation 
study is currently being conducted in a different population characterised by diverse 
life-style, demographics and genetics, using the American National Health and 
Nutrition Examination Survey (NHANES) cohort data (outside the scope of this PhD 
thesis). This validation study includes the final panel of biomarkers performed in 
AMORIS as the crude model, together with other models including different 
standard serum markers, such as red blood count, diverse types of white blood cells, 
haemoglobin or immunoglobulins available in NHANES. The results of the LCA 
analysis for the crude model have already identified four main metabolic classes in 
the population defined by similar markers as the serum markers identified in the 
AMORIS project, which suggests the external validity of the metabolic profiles to 






Overall, future work should aim to investigate the exposome in relation to disease 
and mortality to improve prediction of complex, multifactorial diseases, such as 
cancer, which in turn could lead to better public health strategies to prevent chronic 
diseases. However, longitudinal studies to account for exposome temporal variation 
with measurements at different relevant life time points will be necessary to 
understand the complex interaction between environment, biology and disease in 
human populations. 
 
Following the findings of this thesis, I have already been involved in the 
development of two new projects in AMORIS to better understand the exposome 
and its association with disease. First, the twin study, a small subcohort of twins 
with monozygotic and dizygotic status available in AMORIS, will be utilised. The aim 
of this project will be to quantify the proportion of the environmental and the 
genetic contribution of the serum markers to cancer. The second project will consist 
on the utilisation of job matrixes available for the Swedish population during the 
same period as the CALAB blood analyses were taken. The link between the job 
matrixes available and the serum markers from the same period will allow to 
identify specific environmental exposures for the participants of the AMORIS 
dataset. The combined information will then favour a better assessment of the 
exposome in relation to cancer. Moreover, there will be a possibility to make use of 
newly developed data reduction techniques of Professor Ton Coolen to further 
explore population heterogeneity (166, 346). 
 
The chapter Individual susceptibility to cancer included Project C - Discrimination of 
breast tumour tissue.  The project aimed to evaluate how imaging data produced by 
a terahertz probe can distinguish between different breast tissue samples, with the 
ultimate aim of using this probe intraoperatively in breast-conserving surgery to 
predict positive tumour margins. The study illustrated how individuals’ susceptibility 
to disease can be explored examining the heterogeneity inherent to cancer present 




cancer samples in an imaging setting. The two-step statistical approach (Gaussian 
wavelet deconvolution of the raw imaging data followed by the naïve Bayes 
classifier) showed that it could accurately discriminate malignant from benign tissue 
in an ex vivo setting, obtaining high sensitivity and moderate specificity, classifying 
correctly tumour and adipose tissue in 89% of the cases. The ultimately aim of the 
classifier was to be implemented in BCS surgery to improve adequate excision of the 
tumour margins avoiding re-operations in patients. This clinical application can be 
achieved in future with an improvement on the specificity score of the classifier. For 
that purpose, a follow up project is currently being conducted exploring the 
predictive capabilities of the different Gaussian derivatives and  utilising an 
optimized Bayesian classifier to improve the sensitivity and specificity of the 
classifier to discriminate malignant breast tissue (346). Thus, supervised clustering 
approaches present the capability to classify multidimensional complex biological 
and accurately predict new observations in the data which could help improving 
diagnosis and prognosis in translational and clinical settings. 
 
Overall, the projects in this thesis highlight the importance of data driven 
approaches in the assessment of multifactorial diseases, such as cancer, when 
supported by robust statistical analysis. Moreover, the results suggest that the 
inherent heterogeneity present in the population plays an important role in the 
susceptibility to cancer, which needs to be taken into consideration to develop 
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